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Abstract 
Reason for performing this study: Granulosa cell tumours (GCT) are the most 
common type of ovarian tumours associated with mare infertility requiring highly 
invasive treatment, yet knowledge of GCT prevalence, pathogenesis and early 
diagnostic options is lacking. Text mining of UK veterinary practice data was 
used to enable the estimation of equine GCT (and ovarian pathology) prevalence 
in the UK. Gene sequencing studies were undertaken to investigate an important 
point mutation found in the coding region of the forkhead transcription factor 
gene FOXL2 (C402G) in adult human GCT biopsies. Antral follicle wave 
development in mares is highly regulated and leads to differing outcomes in 
follicles (differentiation versus atresia) with consequences for cellular 
morphology and function. As rapidly growing GCT must transform from normal 
ovarian follicles, specifically the granulosa cell, but also the theca 
compartment, a detailed histological and functional comparison of normal 
(control) follicle walls to diseased, solid or cystic GCT tissues was also carried 
out. While the influence of the time of year on follicular function has previously 
been studied in mares, the cellular effects of other factors such as disease or 
age of the mare are less clear, yet important for understanding and controlling 
mare reproduction. In addition, the mare is also considered an excellent model 
for ovarian function in women, thus our understanding of both regulated and 
dysregulated follicle growth may benefit from our studies using mare ovaries. 
Objective: The general aims were to determine the prevalence of ovarian 
pathology and particularly GCT in UK equine practice; determine the effects of 
GCT formation in mare ovaries, which may dysregulate follicular granulosa (GC) 
or theca cell (THC) proliferation in very healthy (VH), healthy (H), early atretic 
(EA) and late atretic (LA) antral follicles using morphometric and functional 
histological approaches; determine whether the FOXL2 gene mutation identified 
in human GCT also exists in the equine GCT; and finally determine the FOXL2 
protein localization in GCT samples compared with medium and large healthy 
and atretic antral follicles. 
Materials and Methods: Data mining of clinical records (515,832 records) from 
seven veterinary practices from around the UK was used in this study.  
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Sixty-three follicles H&E sections were dissected from the normal ovaries of 19 
mares classified as healthy (n= 35), or suffering from chronic clinical disease (n= 
4) or severe systemic illness (n= 24) unrelated to the reproductive system. 
Follicle walls were processed for histological categorisation and (granulosa and 
theca layer, and a subset for granulosa cell nuclear circumference) 
measurements using H&E sections. Forty follicle walls recovered from 16 mares 
were functionally examined for hormone (inhibin), enzyme (aromatase, 
CYP17A), receptor (AMHR2) or transcription factor (FOXL2) expression 
parameters (stain intensity, distribution and % area covered) using 
immunohistochemistry. Similarly, ten GCT tissue samples from five mares (each 
mare provided two tissue section samples, one from cystic and one from solid 
areas of the GCT) were histologically categorised using H&E sections, followed 
by measurement of the nuclear circumference of granulosa cells within the GCT 
and the same immunohistochemical evaluations. Data were analysed using non-
parametric statistical analyses, including correlation analyses between protein 
expression (% area covered) and functional follicle parameters (diameter and 
follicular fluid oestradiol concentration). 
In addition, the FOXL2 gene was partially sequenced from a subset of GCT (from 
seven mares) and control follicle wall samples (from five mares) using in house 
molecular approaches followed by next generation sequencing (Illumina NextSeq 
500 at Glasgow Polyomics), to analyse the region spanning the FOXL2 CG 
mutation discovered in human adult GCT. 
Results: Data mining of clinical records from 26,019 mares revealed 115 
potential GCT cases, but with only 11 cases being true GCT positive on further 
reading, resulting in a prevalence estimate of 0.04% (1: 2,365 mares); 143 
potential ovarian pathology cases were found of which 65 cases were truly 
positive resulting in a prevalence estimate of 0.25% (1 in 400 mares). 
Follicles measured on average 21 mm in diameter, which was not associated 
with mare disease status (p>0.05), and were allocated to very healthy (VH), 
healthy (H), early atretic (EA) and late atretic (LA) categories based on the 
histological appearance of the GC and THC layers. Mare disease status was not 
associated with the follicle health category (p>0.05), and was not associated 
with percentages of basal, intermediate or antral GC, or GC layer thickness 
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(p>0.05). However, the THC layer thickness was greater (p=0.01) in follicles from 
mares with severe disease compared with follicles from healthy mares. More 
healthy than diseased mares were in seasonal transition at the time of ovary 
recovery (p= 0.001), and transitional follicles showed reduced THC layer 
thickness and percentages of basal GC and large THC, compared with follicles 
recovered from those in deep anoestrus (all p-values <0.05). Follicle 
categorization into VH, H or EA was correlated with follicular fluid oestradiol 
concentrations, but not associated with follicle diameter or any GC layer 
characteristics (all p-values >0.05); however, H follicles had a thicker THC layer 
than EA follicles (p=0.001). In LA follicles the GC layer was not present, and the 
percentage of large THC was reduced, while the percentage of small THC was 
increased compared to VH and H follicles (p<0.001), reducing the THC layer 
thickness in LA versus H follicles (p=0.001). 
Inhibin expression was detected only in GC of normal follicular walls (FW) and 
GCT categories, not in THC. Similarly, aromatase expression was detected only 
in GC of normal FW; no aromatase stain was detected in any of the GCT samples 
and categories. Conversely, CYP17 expression was only detected in THC of 
normal FW and in interstitial TH like cells in diseased GCT samples. Both 
compartments of GC and THC in normal FW demonstrated the expression of 
AMHR2, which was also highly expressed in GC of cysts and solid areas in GCT 
samples, where it showed only little expression in the interstitial stromal tissue. 
Within normal ovaries the nuclear circumference of GC nuclei decreased from 
basal (62.9±3.1) to intermediate (54.5±1.6) and antral cells (44.7±1.9) (p-0.001), 
with follicle atresia being associated with reduced basal GC nuclear size 
(p=0.04). In GCT1 and GCT2 cysts, basal GC nuclei (73.3±3.9) were also larger 
than antral (53.7±3.1) (p=0.001) and intermediate cell nuclei (63.9±4.7) 
(p=0.03), and antral GC nuclei of GCT1 and 2 (52.8±2.8) were larger than those 
in normal ovaries (44.7±1.9) (p=0.03). The nuclear circumference of solid GC 
nests (74.0±4.1) varied more between tumours and was larger than antral GC 
nuclei within cysts (53.7±3.1) (p=0.001). 
The FOXL2 CG (C402G) human mutation was detected very rarely, and 
considered to be a result of sequencing error. However, a second, proximal CT 
mutation was identified in 25% of all reads (mean ± SEM: GCT 27.2± 4.3, controls 
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25.5± 3.0, P=0.4), even though this was not predicted to change the amino acid 
within the protein. Nuclear expression of FOXL2 was seen in GC and THC of all 
control FW, and expression declined with follicle atresia; FOXL2 was very highly 
expressed in GC of GCT cysts and solid areas, yet showed only a low level of 
expression in interstitial stromal tissue of GCT. 
Conclusion: A very low prevalence of GCT in horses attending UK veterinary 
practices was identified. Differences in histomorphological and functional GC 
and THC measurements in equine large antral follicles appear more associated 
with season and follicle atresia than with disease. Location within normal antral 
follicle and tumour cyst walls, tumour transformation, and GCT compartment 
are associated with GC nuclear size, likely reflecting differing nuclear activity. 
While this study could not link the specific human FOXL2 SNP to equine GCT in 
the samples that were collected, a further frequent mutation in the small region 
amplified was identified. Therefore, further investigation of the complete 
equine FOXL2 gene may identify other mutations with functional significance in 
GCT formation in the horse and thus potentially also in the woman. 
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Chapter 1 Literature Review  
1.1 Introduction 
Most horse breeders are rightly concerned about their mare’s fertility in terms of 
producing foals every season. Some producers therefore categorise infertility in 
a mare by whether or not she cycles normally and by whether or not the mare 
conceives and holds a pregnancy. The mare reproductive function is seasonally 
polyestrous which implies that the reproductive season (oestrus) and non-
reproductive season (anoestrus), followed by transitional period during the 
breeding season are controlled by daylight (Morel et al., 2010). In other words 
the mare does not show heat during winter but starts to cycle just before spring 
and reaches a peak in the spring and early summer (March, April and May). The 
mare’s ovarian cyclicity is seasonal and during the short days of winter they 
come into a period of anoestrus where very small follicles exist in the ovaries 
(Watson and Ai-zi'abi, 2002). During the transitional period, which occurs 
between normal ovarian cyclicity and deep winter anoestrus, in many mares 
large follicles develop and then regress. The granulosa cells from preovulatory 
follicles produce more oestrogen than those originating from anovulatory 
transitional follicles because the latter are thought to be steroidogenically 
inadequate (Watson and Ai-zi'abi, 2002). 
In all characterised species (Young and McNeilly, 2010) follicles have been 
classified into different types as follows:  
Primordial follicles - prior to follicular activation and development and when 
only one flattened granulosa cell layer incubates the oocyte;  
Primary follicles - when the granulosa cells have only one cuboidal layer; 
Secondary follicles - when the number of granulosa cell layers has increased to 
two or four;  
Large pre-antral follicles - when the follicle contains four to six granulosa cell 
layers; 
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Antral follicles - if the number of granulosa cell layers has reached more than 
five. So antrum develops in six granuolsa cell layers. 
Theca cells start to form after formation of the secondary follicle, creating a 
layer all over the granulosa cell structure.  
Equine follicles have been categorised according to developmental stage and to 
normality and abnormality (Haag et al., 2013). Normal if the oocyte is intact and 
it is covered by one or more organised layers of granulosa cells whereas, it is 
‘abnormal’ if the latter descriptive features are deteriorated and cells are 
detached from the basement membrane. According to the stage of development 
classification, the oocyte that is surrounded by one layer of cuboidal granulosa 
cells is defined as a primary follicle, while the primordial follicle is 
characterised by an oocyte surrounded by one layer of flattened granulosa cells. 
Atretic follicles have been classified into three stages according to (Driancourt 
et al., 1982, Kenney et al., 1979) depending on the appearance of pyknotic 
nuclei and granulosa cells: Stage I - more than five pyknotic areas detected; 
stage II - wide distribution of pyknosis and floating of granulosa cells to the 
antrum; and stage III – a lack of granulosa cells apart from in the oocyte area. 
Moreover, healthy follicles were identified by counting the number of granulosa 
cells per follicle or by measuring the density of the cells in the large follicles 
using a circular reticule. 
Common abnormal ovarian functional problems that impact a mares’ fertility are 
haemorrhagic follicles, ovulation failure (anovulatory follicles or cystic follicles), 
persistent corpus lutem, premature luteolysis (endometritis), failure of follicular 
development and ovarian tumours (Troedsson et al., 2003). A granulosa cell 
tumour (GCT) is considered as one of the major causes of horse infertility, 
representing 85% of ovarian tumours (McCue et al., 2006). GCT are most 
frequently successfully treated by way of surgical removal or ovariectomy. 
Frequently, following ovariectomy (Crabtree et al., 2013), mares have a good 
chance of returning to a healthy and normal life with no complications due to 
the fact that the majority of GCT are benign (van der Kolk et al., 1998).  
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Many types of ovarian tumours (granulosa-theca cell tumour, teratoma, 
cystadenoma and dysgerminoma) detrimentally affect a mares’ fertility, the 
impact varying from mild to severe. Tumour is defined as an uncontrollable 
growth of tissue cells and can either be malignant or benign (McCue et al., 2006, 
Crabtree, 2013). GCT, although most frequently benign, might reduce pregnancy 
rates and can cause severe behavioural changes in the mare (Crabtree et al., 
2013). They can also inhibit a mare's reproductive career to some extent by 
damaging the internal organs (McCue et al., 2006)). This thesis will focus on 
various aspects of GCT, describing the prevalence of GCT (and ovarian 
pathology); histological classification of the normal follicular wall using 
haematoxylin and Eosin (H&E) based on health status by measuring the thickness 
of the granulosa and theca cells and their counts; comparing the control follicle 
wall and GCT immunohistochemically and nuclear circumferences of their 
granulosa cells; and finally detecting the occurrence of FOXL2 gene mutation in 
equine GCT. 
1.2 Epidemiology  
1.2.1 Background 
1.2.1.1 Text mining in knowledge discovery in databases 
Text mining is defined as “deriving structured information from text, usually to 
fill some specific information need” (Garten et al., 2010). Text mining enables 
the use of data from the whole body of written records, and permits data from 
multiple sources to be joined and presented to clients. Some authors 
characterize content mining as the detection, by computer, of new obscure 
information, by automatically removing data from diverse written text (Garten 
et al., 2010). Others assert that it is characterized as mining or extracting 
required data from the content, as a way of providing valuable information 
about that text-based content (Garten et al., 2010). Moreover, the authors 
separate text mining into two principle steps: Identification of archives that may 
contain the required data followed by the extraction of the data itself. The 
identification process or computerized reading can be divided into four general 
subtasks: text arrangement, named substance labelling, reality extraction, and 
accumulation wide analysis (de Bruijn and Martin, 2002). 
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1.2.1.2 Electronic patient records in medical practice, companion animal 
and equine veterinary practice 
There has been a dramatic increase in the use of computer databases in general 
practice for public health auditing and commissioning (Pringle et al., 1995). 
Although applying computer databases in general practice has been widely 
noticeable, some problems still exist such as patient data transmission and the 
use of or agreement regarding the common coding structure(s) for diseases.  
Although the majority of veterinary practices in UK use modern electronic 
practice management systems (PMS), its utilisation remains a challenge for 
epidemiologists. This is largely because there is no central hub in veterinary 
practices as in the NHS, from which validated data can be collected.  
In the veterinary field, the VetCompassTM project delivers significant 
management assistance to particular practices such as facilitating clinical audit 
and accelerated reviews of patient history (O'Neill, 2012). Currently 
VetCompassTM includes nearly 10 million animals from 1,100 UK participating 
veterinary practices (over 20% of all UK practices) and now contains 55 million 
clinical notes and 181 million treatment records. Mattin et al. (2014) noted that 
there were a few limitations to their present studies, for example the 
information analysed were not recorded for research purposes, and therefore it 
will contain irregularities and mistakes. Nevertheless, the authors contend that 
continued data gathering within the VetCompassTM project will enable larger 
analyses of affected animals in the future to produce more useful 
epidemiological analyses which, in time, will include temporal and spatial 
disease pattern recognition.   
1.2.1.3 Free text mining in the veterinary literature 
The number of projects that have been performed in recent years to gather 
information from veterinary clinical records or large Electronic Medical Record 
(EMR) datasets, both retrospectively and also prospectively, has grown (Jones-
Diette et al., 2014, Lam et al., 2007, Mattin et al., 2014, O'Neill, 2012, O'Neill et 
al., 2012, O'Neill et al., 2013, Oswald et al., 2010, Radford et al., 2011). In 
addition to some regulated databases, various bespoke and specially designed 
recording systems have been produced in therapeutic and veterinary practice in 
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the previous 20 years (Lam et al., 2007). Moreover, they conducted an analysis 
of a large electronic database in use at the Hong Kong Jockey Club since 1970. 
These data included health records of more than 6000 Thoroughbred racehorses 
and their racing performance.  The authors condensed a large number of text 
words that were extracted from the data based on reasons for retirement from 
racing for the racing seasons 1992/93 to 2003/04 using Wordstat and Simstat 
content analysis software. They found that more than 95% of 3,727 horse records 
were extracted from the database and 21 defined dictionaries of retirement 
categories were established in Wordstat. All these categories were filtered using 
Simstat and this complete process was done in approximately 2-weeks (Lam et 
al., 2007). 
This widespread use of EMR enables epidemiological research by facilitating 
access to large quantities of clinical records without the preparatory work 
required to translate conventional paper records into electronic formats. 
Content mining is a part of Natural Language Processing (NLP) and aims to 
discover or create a structure of free text to make it useful for further 
automated analytic procedures (Anholt et al., 2014a). These authors reported 
that text mining works by two fundamental systems: The first, untrained or 
linguistic approach, distinguishes client-characterized terms included within the 
free text and gives an account of their position within dataset. The second, 
trained or rule based approach, applies statistical algorithms to separate 
predetermined sorts of data. Both these systems aim to provide structure to an 
essentially unstructured group of sentences. This is accomplished by the 
classification of sentences by the words or phrases that comprise those 
sentences, as indicated by pre-defined categories. The classification of these 
free content EMR also permits the assessments of the existence and importance 
of connections between those pre-defined classes. The conduct of content 
mining in clinical studies are different and have different aims and objectives 
including, retrospective investigation of data to illustrate disease prevalence 
(Chapman et al., 2005, Chapman et al., 2004), identification of symptoms and 
side effects (Chapman et al., 2004), treatment outcomes (Penz et al., 2007) and 
prognostication and survival examination (Penz et al., 2007, Bradley et al., 
2005).  
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1.3 Anatomical aspects in the mare 
1.3.1 Gross anatomy and topography of the ovary  
The anatomy of the mare’s ovary is inverted which is different than in other 
species. The outer layer of the ovary is what would otherwise be the medulla, 
which contains blood vessels and nerves, and the inner layer, which would 
normally be the cortex that contains the follicles. The ovulation fossa is on the 
concave surface where the oocyte is expelled (Carnevale et al., 1988). The 
cranial aspect of this kidney bean shaped ovary is smooth and attached to the 
mesovarium of the broad ligament that suspends the ovary and supplies the 
blood through the ovarian branch of the ovarian artery (Davis Morel, 2015). As 
the cortex consists of follicles and oocytes, the follicle needs to migrate through 
ovarian stroma to the ovulation fossa in order to ovulate. The thick protective 
layer (tunica albuginea) that covers the whole ovary, is absent at this fossa 
(Davis Morel, 2015).  
The ovulation fossa is attached to the funnel shaped infundibulum of the 
oviduct. This fossa is coated with germinal epithelium whereas the bulk of the 
ovary is coated with visceral peritoneum or serosa (McCue, 1998, Watson, 1994, 
Gastal et al., 2007). The size and weight of the mare’s ovary generally ranges 
from 35-120 cm3 in volume and 40-80 g, respectively (Aurich, 2011). The size of 
the ovaries depends on the season, varying from 2-4cm during anoestrus to 6-
8cm during sexual activity (Davis Morel, 2015). Mare reproductive organs are 
similar to other mammals’ organs in term of their position in the pelvis, their 
anatomy and physiology. The anatomical location, as presented in Figure 1-1, 
facilitates rectal palpation of the mare as presented in Figure 1-2 and enables 
the examination of the mare’s reproductive stages ultrasonographically.   
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Figure 1-1: Mare reproductive tract. (Ab. AL Ibrahim, Thesis Image) 
 
 
Figure 1-2: Demonstration of mare rectal palpation on a dummy mare illustrating the 
topography of the mare’s tract. The images were acquired by Ab. AL Ibrahim.  
The follicle develops a double ring of blood vessels. The outer ring is composed 
of venules and arterioles in the theca externa and the inner ring is composed of 
a prominent capillary plexus in the theca interna (Ginther et al., 2006). In the 
histological study conducted by (Ginther et al., 2006), it was identified that both 
vascular capillaries and terminal lymphatics contain the fluid between cells in 
the follicle wall and appear as a partially anechoic band. A rich capillary plexus 
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develops in the theca cells encapsulating the avascular granulosa cells during 
follicle growth (Watson and Ai-zi'abi, 2002).  
1.3.2 Histology of the ovary 
Stroma constitutes the body of the ovary, and is composed of spindle shaped 
cells and fine collagen fibres. Stromal cells simulate fibroblasts, however, some 
contain lipid droplets. The cortex is composed of follicles, which contain 
oocytes, in various stages of development, atretic follicles and corpora lutea. 
The tunica albuginea is the superficial surface of the cortex and is more fibrotic 
than the deep surface. The germinal epithelium covers the surface of the ovary 
but only where the cortex is. The medulla is highly vascular and contains hilus 
cells that are analogous to Leydig cells of the testes (Watson and Ai-zi'abi, 
2002).  
In the antral follicle the vascular theca interna and the avascular granulosa are 
divided by a basement membrane (Ginther et al., 2006). The granulosa cells, 
which attach to the basement membrane, constitute the upper layers of 
anovulatory and preovulatory follicles. Both transitional and preovulatory 
follicles can have mitotic nuclei (Watson and Ai-zi'abi, 2002). The theca interna 
in preovulatory follicles consists of a thick layer of plump polyhedral cells with 
large cytoplasm and a pale nucleus.  
Developmental stages of the follicle are: germ cell, primordial, primary, 
secondary, antral, preovulatory, ovulation and corpus luteum (CL). It has been 
noted that the approximate numbers of primordial follicles and growing follicles 
in adult mares’ ovaries is 40,000 and 100, respectively (Raz and Aharonson-Raz, 
2012, Donadeu and Pedersen, 2008, Haag et al., 2013, Pedersen et al., 2003). 
Antral follicle formation in horses and ponies starts when the follicular diameter 
reaches 0.2 to 0.4 mm. Follicle regression or atresia is uncommon until their 
diameter reaches 1mm. There are three classified stages of the atresia based on 
the counting of granulosa cells pyknosis on the section: Stage I (early atresia), 
when five pyknotic nuclei were counted, Stage II (advanced atresia), when 
pyknosis is noticed to be significantly distributed and huge numbers of granulosa 
cell are detected in the antrum, and Stage III (late atresia), when the 
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appearance of the granulosa cell layer is significantly reduced except around the 
oocyte (Driancourt et al., 1982).  
1.4 Physiology 
1.4.1 Oestrous cycle and seasonality  
The oestrous cycle of the mare during the normal breeding season in the 
Northern Hemisphere begins in late April or early May and continues through to 
August and September (Satué and Gardón, 2013). The duration of the oestrous 
cycle is 21 days ± 3 days and it consists of two periods, oestrous (heat) and 
dioestrous (between heat) as presented in Figure 1-3. Oestrus usually lasts six 
days but it can be from 4-10 days especially in ponies (Aurich, 2011). Dioestrus 
lasts 15 days but it might be from 12-18 days. During oestrus ovulation could 
occur at any time but normally 24-48 hours before the end of the period. First 
oestrous cycle of the mare is usually prolonged and irregular, and might last 
from 20-30 days or more. The mare cycles normally under the effect of 
increasing daylight in spring. According to (Heidler et al., 2004), the length of 
oestrous cycle is influenced by reproductive stage, for instance in a lactating 
mare the length is 21.2 ± 1.8 days but is 22.8 ± 1.4 days in non-lactating mares. 
In young and middle aged mares the interovulatory interval is shorter than in old 
mares due to the delay of the growth rate of the dominant follicle in the old 
mares (Ginther et al., 2008). Transitional stages from winter anoestrus to the 
ovulatory season and once again into the anovulatory season are characterised 
by irregular oestrous behaviour that may last from a few days to weeks (Aurich, 
2011).  
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Figure 1-3: Mare oestrous cycle. DF (dominant follicle), CL (corpus luteum) 
 
1.5 Ovarian pathology in the mare 
1.5.1 Differential diagnosis of ovarian enlargements  
1.5.1.1 Anovulatory follicle (follicular cyst)  
The anovulatory follicle is also often referred to as a haemorrhagic anovulatory 
follicle or follicular cyst as presented in Figure 1-4 and it occurs due to ovulation 
failure from a non-ruptured dominant follicle (Cuervo-Arango and Newcombe, 
2010). In a study conducted by McCue and Squires (2002), the diameter of an 
anovulatory follicle was approximately 50.9 ± 11.2 mm and the occurrence of 
persistent anovulatory follicles increased with age of the mare. The main cause 
of this condition is unclear, however it might be due to low follicular oestrogen 
(Pierson, 1993), low FSH and LH levels (Mckinnon, 1997), or follicular internal 
haemorrhage inside the lumen of the follicle (McCue and Squires, 2002). In 
addition, the majority of mares that had developed an anovulatory follicle have 
elevated progesterone concentrations due to luteinisation. Anovulatory follicles 
might persist for many months and their lumen is filled with echogenic particles 
on ultrasound investigation.  
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Figure 1-4: Follicular cavity filled with blood: Anovulatory haemorrhagic follicle, 49.1x38.2 
mm. (Ab. AL Ibrahim, Thesis Image). 
1.5.1.2 Haematomas   
Haematomas are always non pathological, not affecting the mare breeding 
capability and do not have external clinical signs (Beachler et al., 2016). They 
occur after ovulation due to an accumulation of blood in the follicular cavity and 
can be palpated or examined by ultrasound. The size of haematomas can 
become a quite large and might reach 10 cm in diameter. This enlargement 
might result in confusion with the diagnosis of a tumour (Curtin, 2003). After the 
absorption of the blood from this mass, a firm and calcified area remains on 
ovary. Haematomas can be differentiated from other neoplastic masses such as 
granulosa cell tumour (GCT) by monitoring inhibin secretion (Curtin, 2003). 
Moreover, the low testosterone level is also an indication that the mass is not a 
GCT. Ultrasound is considered to be a useful tool for differentiation from GTC in 
that haematomas often also have a honeycomb structure due to clustered cysts, 
but they may reduce in size when rechecked a few months later, due to 
regression and reabsorption of fluid (Curtin, 2003). 
1.5.1.3 Teratoma  
Teratoma is a type of ovarian tumour in mares, which arises from germ cells and 
is also named “dermoid cyst” if they arise from ectoderm, skin and hair 
(Vanhaesebrouck et al., 2010). They are also benign and unilateral as GCT, 
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however, the unaffected ovary remains active and the mare cycle normally and 
can carry an embryo despite the presence of a tumour (Catone et al., 2004, 
McCue and McKinnon, 2011, da Encarnacao Fiala et al., 2011). The occurrence of 
this tumour is extremely rare (Lefebvre et al., 2005). The problem of this 
tumour is that it causes pain and discomfort to the mare and can result in colic-
like symptoms, which can mislead the diagnosis. The discomfort and pain is most 
likely due to the bigger size of teratoma tumour which includes many different 
tissue types such as hair, teeth, bone, cartilage, nerve and adipose (fat) tissue 
(Catone et al., 2004). Although teratomas are benign in nature, Vancamp et al. 
(1989) stated that teratomas might lead to adenocarcinoma.  
1.5.1.4 Dysgerminoma  
This tumour also comes from germ cells as with teratomas. However, it 
originates from only one germ cell layer and is very rare and malignant (Gehlen 
et al., 2006, McLennan and Kelly, 1977, Chandra et al., 1998) as it can spread 
quickly from the ovary to the rest of the abdominal cavity and even to the chest 
cavity (Harland et al., 2009). Fortunately, dysgerminoma tumour are 
infrequently found in horses (Harland et al., 2009).  
1.5.1.5 Cystadenoma  
Cystadenomas originate from the ovarian capsule or surface epithelium that 
covers the ovary and produce multiple cyst-like structures inside the ovary 
(McCue and McKinnon, 2011). Most of the normal ovarian tissue and thus the 
ovary itself can be destroyed by a cystadenoma because it is considered locally 
invasive (Hinrichs et al., 1989). However, this kind of tumour is benign and will 
not spread to the horse’s body. Affected mares usually have normal oestrous 
cycles due to the functioning of the unaffected ovary (McCue et al., 2006, Son et 
al., 2005). Although many cases of mares’ cystadenoma tumour are expected to 
have high levels of testosterone, they generally do not result in any behavioural 
changes (Hinrichs et al., 1989).  
1.6 Granulosa Cell tumour (GCT) 
The most common equine ovarian tumour is GCT (Watson, 1999) and its 
occurrence affects the mares’ behaviour, disrupts hormone levels and causes 
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illness. According to Watson (1994) metastasis of this tumour is rare, although it 
has been reported (van der Kolk et al., 1998).  
1.6.1 GCT size & weight 
The diameter of a GCT ovary can range from 10 to 20 cm with yellowish cystic 
stroma (Watson, 1994, McCue et al., 2006). The weight of a GCT reported by 
vanderZaag et al. (1996) was 31.5 kg and the largest reported weight was 59.1 
kg (McCue et al., 2006). Its gross appearance is firm, oval with a smooth surface 
and subcapsular cystic processes. The size of one of the GCT cases used as part 
of this study was 30 cm in diameter with a weight of 15 kg, as presented in 
Figure 1-5.  
 
Figure 1-5: Gross appearance of the complete and hemisected GCT tumour. (Ab. AL 
Ibrahim, Thesis image). 
1.6.1.1 Clinical signs 
As a consequence of the tumour growth, it can have a negative impact on a 
mare’s gait resulting in vague lameness. The reason for this is that the weight of 
the ovary pulls on the ovarian broad ligament suspending the ovary within the 
abdominal cavity (Crabtree, 2013). In addition, the hormonal levels of an 
affected mare might change to cause behaviour changes, in particular 
aggressiveness. Abnormal behaviours include stallion-like aggressiveness, 
mounting other horses and lunging at other mares. There may be an absence of 
normal oestrous cycles, with intermittent or continuous (Assis Neto et al., 2010). 
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1.7 Functional and hormonal changes within the GCT 
and ovary  
A GCT secretes steroid hormones impeding the normal reproductive cycle. This 
tumour enhances several different hormones in the mare such as oestrogens, 
progesterone, and testosterone, which lead to many different behavioural 
abnormalities. Recently inhibin and anti Müllerian hormones (AMH) have been 
reported (Ball et al., 2013) and approximately 90% of mares with GCT have high 
levels of inhibin (Bailey et al., 2002). Previously (Bailey et al., 2000) an inhibin 
test was considered the gold standard in confirming a diagnosis of a GCT but 
nowadays high AMH concentrations are considered the better test. Testosterone 
produced by theca cells of the tumour also used to diagnosis granulosa theca cell 
tumour (GTCT), but it should be noted that testosterone can be elevated for 
other reasons such as during the development of fetal gonads which can cross 
the placenta into the mare’s blood stream.  
1.7.1 Oestradiol (E2) 
Oestradiol is believed to regulate oestrous behaviour (Pycock et al., 1995). 
During the oestrous cycle, the luteal phase length is approximately 16 days and 
the follicular phase length is seven days. A few days before the end of the luteal 
phase, there is a wave of follicle growth. The largest follicle (22-24 mm) is 
selected near the end of the luteal phase, with deviation occurring when one 
follicle continues to grow with regression of the remaining follicles at the end of 
a common growth phase (Ginther et al, 2007). One to two days before this 
deviation the concentration of E2 and LH starts to increase.  
Goudet et al. (1999) identified that the E2 concentration increases with 
follicular diameter expansion. The level of E2 was measured by Knudsen and 
Velle (1961) at anoestrus, oestrus and dioestrus and it was recorded as (7.5 µg, 
37.5 µg and 6.0 µg/100ml, respectively). The normal E2 concentration in serum 
of a non-pregnant mare was from 20-45 pg/ml (Ball et al., 2014). Yoshida et al. 
(2000) reported that the E2 of normal follicular fluid was 200-7000 pg/ml. During 
follicular development at early and late dioestrus or in the late oestrus but 
before ovulation the E2 concentration of follicular fluid gradually increases. 
Furthermore, the follicular wall, which consists of granulosa cells and theca 
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interna, produces more E2 in early and late oestrus compared to late dioestrus 
(Sirois et al., 1990). Almadhidi et al. (1995) noted that the level of E2 
concentration is low in small follicles and that it gradually increases in large 
follicles. 
1.7.2 Aromatase 
Oestrogen is derived from androgen under the impact of aromatase (Almadhidi 
et al., 1995, Belin et al., 2000, Almeida et al., 2011b). During development of 
the dominant follicle the level of E2 is elevated and this is under the influence 
of a steroidogenic enzyme such as aromatase (Belin et al., 2000). Its expression 
is reduced in subordinate follicles with reduced concentration of E2 level. This 
reduction of steroidogenic enzymes might explain the onset of atresia. 
The expression of aromatase has been detected in the mare granulosa cells as 
well as in granulosa cells of many mammalian species (Goudet et al., 1999, 
Nagamine et al., 1998). However, the expression of aromatase using 
immunohistochemistry was not detected in a healthy small follicle investigated 
by (Nagamine et al., 1998). It has been confirmed that aromatase activity in 
mare granulosa cells is elevated, whereas it was also suggested that aromatase 
activity in the theca interna was low (Almadhidi et al., 1995). 
1.7.3 Inhibin 
Inhibin is a disulphide-linked heterodimeric glycoprotein produced by granulosa 
cells (Piquette et al., 1990). It has a negative effect on FSH which leads to a 
decrease in its secretion, and thus inactivity of the contralateral ovary 
(Ellenberger et al., 2007). Inhibin was recorded as a GCT tumour marker in 
human medicine in 1989 (Koebel et al., 2009) whereas, in mares it was reported 
in 1993 and 2002 by (McCue, 1993, Watson et al., 2002a). The inhibin dimer 
consists of an alpha subunit (α) and 2-beta subunits (βA and βB), which create, 
equally active dimers: inhibin A (α βA) and inhibin B (α βB) (Bailey et al., 2002, 
Piquette et al., 1990). According to the experiment conducted by Ellenberger et 
al. (2007) inhibin is situated intra-cytoplasmicly and demonstrated in granulosa 
cells. Davis et al. (2005) stated that a positive immmunoreactivity for inhibin α- 
subunit was expressed in the cytoplasm of neoplastic GC in GCT tumour.  
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Using radioimmunoassay (RIA) for the determination of α-inhibin was considered 
to be a more accurate indicator of GCT occurrence than a specific measurement 
of α βA-inhibin using immunoradiometric assay (IRMA) (Bailey et al., 2002). 
According to a study conducted by Ellenberger et al. (2007) the concentration of 
inhibin B was higher in mares before ovariectomy than in ovariectomised mares 
(1817 pg/ml and 15 pg/ml, respectively) and was more or less similar to the 
concentration of mares in oestrus. Furthermore, it has been stated that 
approximately 90% using RIA of mares diagnosed with GCT have high inhibin 
level.  
1.7.4 CYP17 
CYP17 is detected in ovaries, testis and the adrenal cortex of some mammals 
(Almeida et al., 2011b). In addition, it has been stated that CYP17 acts as an 
enzyme for oestrogen synthesis. Furthermore, CYP17 expression was localized in 
Leydig like cells of newborn pigs and male wild mature pigs. The 
immunolabelling of CYP17 in the preovulatory follicle is localised in the theca 
interna layer (Albrecht and Daels, 1997).  
1.7.5 Anti-Müllerian hormone (AMH) 
Anti- Müllerian hormone (AMH) is a 140 KD dimeric glycoprotein and a member of 
the transforming growth factor superfamily of growth and differentiation factors 
(Almeida et al., 2011a). It is secreted by the Sertoli cells of the testis from fetal 
sexual differentiation to puberty, and is responsible for regression of the 
Müllerian ducts during male sexual differentiation (Ball et al., 2008b). According 
to immunohistochemistry the granulosa cells of the small growing and antral 
follicles produce AMH normally and it can be shown in normal mare ovaries as 
well as in GCTs (Ball et al., 2013). However, its expression is reduced in large 
antral follicles based on the experiment done by Ball et al., (2008).  
AMH has been considered a useful biomarker for GCT in mares. AMH 
concentration is increased (≥ 4.0 ng/ml) in mares with GCT and reduced to 
normal level post-ovariectomy. For example, the AMH concentration in a 13 year 
old Arabian mare suffering from GCT was recorded as 21.6 ng/ml compared with 
normal cyclic mares of 0.36± 0.02 ng/ml (Gharagozlou et al., 2013). Following 
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ovariectomy the AMH concentration in this mare reduced to 0.1 ng/ml 
(Gharagozlou et al., 2014).  
1.8 Histopathology 
Hultgren et al. (1987) classified histologically the juvenile GCT into two types 
with either a macrofollicular or diffuse pattern. The macrofollicular type has 
smaller granulosa cell lined follicles compared to the adult GCT, whereas the 
diffuse type has a distribution of granulosa and theca cells with a possibility of 
lipid accumulation. In addition, this follicular tumour pattern is classified by 
multiple large and small follicles as well as cysts separated by thick 
fibromyxomatus septa. Those structures contain amorphous, basophilic material, 
which is lined by follicular epithelium, appeared as a single layer of cuboidal 
cells. Some of these structures have solid nests and trabeculae, and others have 
cells with round or oval hyperchromatic nuclei covered by different shaped and 
sized oesinophilic cytoplasm (Hultgren et al., 1987). On the other hand, the 
diffuse type includes large cells with prominent plasma membranes and large 
amount of small or rough vacuolated cytoplasm. The stroma that supports the 
neoplastic granulosa cells also comprises large, oval or elongated theca cells 
which have hyperchromatic nuclei and a large amount of clear cytoplasm 
(Hultgren et al., 1987, Davis et al., 2005). Large Leydig like cell and polyhedral 
cells have also been detected between theca cells and beneath granulosa cells 
(Crabtree, 2011, Crabtree, 2013, Bailey et al., 2002, Bustamante, 1998). These 
cells had a finely granular esoinophilic cytoplasm. Clusters of cells were 
observed in tubular form, and cells had round nuclei and finely dotted dense 
chromatin and mild anisokaryesis (Crabtree, 2011, Chopin et al., 2002). Ball et 
al. (2008a) pointed out that the GCT have different shapes: tubular, trabecular 
and cystic. The tubular granulosa cells had a sertoli cell like structure and there 
were polyhedral Leydig like cells in the stroma and no antral follicle were 
detected. Connective tissue cells surrounded cystic structures, which were 
localized all over the fibrous tissue (Charman and McKinnon, 2007). Other stated 
that the GCT consists of cords and trabeculae of neoplastic GC supported by a 
moderate fibrovascular stroma ((Davis et al., 2005). 
Histologically, and based on our findings, the cysts are surrounded by one or 
more layers of cubic or cylindrical cells, arranged in a palisade manner with 
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small round nuclei as presented in Figure 1-6, Figure 1-7 and Figure 1-8. Some 
cells are found as solid clusters as presented in Figure 1-9.  
 
Figure 1-6: Classified GCT1; cystic structure looks like a healthy follicular wall. GCT1 has all 
antral (Yellow arrow), intermediate (Red arrow) and basal (Black arrow) granulosa cells 
(GCs). 400x magnification. (Ab. AL Ibrahim, Thesis image)  
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Figure 1-7: Classified GCT2: cystic like structure but appear as a closed circle cyst. It has all 
antral (Yellow arrow), intermediate (Red arrow) and basal (Black arrow) GCs. 400x 
magnification (Ab. AL Ibrahim, Thesis image). 
 
Figure 1-8: Classified GCT3: cystic like structure but appear as a closed circle cyst. It has 
only few antral (Yellow arrow) GCs. 400x magnification (Ab. AL Ibrahim, Thesis image). 
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Figure 1-9: Classified GCT4: solid nests of granulosa cells. 400x magnification (Ab. AL 
Ibrahim, Thesis image).  
1.9 FOXL2 gene 
1.9.1 Definition 
The term FOXL2 is derived from a large family of forkhead/winged-helix 
transcription factors. The name forkhead is obtained from the Drosophila gene, 
whereas the term winged-helix came about because of the butterfly shape.  
FOXL2 is a single-exon gene of 2.7 kb encoding a highly conserved protein of 376 
amino acids containing a 110-amino-acid DNA-binding forkhead domain. This 
classifies FOXL2 to the family of forkhead transcription factors involved in a 
wide variety of biological processes during development and postnatal life. 
FOXL2 has been recognised as an ovarian differentiation marker in mammals and 
plays a significant role in follicular development and the maintenance of adult 
female fertility (Cocquet et al., 2002). FOXL2 gene is known to be involved in 
Blepharophimosis, ptosis, and epicanthus inversus syndrome  (BPES), eyelid 
abnormalities occur during development and leading to vision limitation due to 
un ability to fully opening the eyelid, as well as the development of ovarian GCT 
(Caburet et al., 2012). 
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1.9.2 FOXL2 mutation  
A range of disease conditions has been associated with a mutation in the isolated 
FOXL2 gene. This is due to the major role it plays in sex regulation, ovarian 
development and GC differentiation. FOXL2 can be considered as an ovarian 
follicle proliferation inhibitor in small and medium follicle whose purpose is to 
prevent premature depletion of ovarian follicles resulting in ovarian failure and 
malignancy (Pisarska et al., 2011). Some findings proposed that FOXL2 might act 
as a cancer suppressor. For instance, follistatin has been seen to be up-regulated 
by overexpression of wild-type FOXL2, compared with the FOXL2 mutation 
C134W. It has been found that activin A-stimulated cell proliferation is 
constrained by follistatin (Cheng et al., 2014). 
 
1.9.3 FOXL2 Immunohistochemistry 
Most follicular developmental stages; primordial, primary and larger secondary 
follicles express FOXL2 protein as detected immunhistochemically (Pisarska et 
al., 2011). The nuclear expression of the FOXL2 gene was identified in almost 
100% of adult GCT patients (Kommoss et al., 2013, Al-Agha et al., 2011) and in 
juvenile GCT patients (Al-Agha et al., 2011). Moreover, one study found that all 
examined cases of GCT patients positively expressed nuclear FOXL2 protein (Hes 
et al., 2011, Yanagida et al., 2017, Takahashi et al., 2013). In a separate study, 
most GCT patient samples were immunostained with FOXL2 (Jamieson et al., 
2010). This has not been shown in any domestic animal species. 
1.10 Hypotheses  
This PhD project will have three main broad aims: 
1. To study epidemiological aspects of ovarian pathology and tumours in the 
mare using text mining.  
2. To study morphometric features of the granulosa and theca cell layers of 
equine antral follicles and granulosa cell tumours using H and E stain. 
3. To find new immunohistochemical or genetic marker(s) for GCT of mares. 
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Chapter 2 Materials, methods and refining 
techniques 
2.1 Text mining methods 
2.1.1  UK data 
Text mining techniques were used to identify individual records of horses with 
and without ovarian pathology, ovarian tumours and more specifically granulosa 
cell tumours (GCT). Proprietary software (Provalis Research) was used for this 
purpose and full detailed instructions on the process involved are provided in 
Appendix 1. In brief, data were uploaded to the software, dictionaries created 
which included a list of as many words as possible that could relate to the 
outcome of interest (ovarian pathology, ovarian tumour or GCT). These 
dictionaries are also provided at Appendix 2. An automated search of the text 
was initiated which identified any record in which any of the words contained in 
each dictionary were present. These records were downloaded in spreadsheet 
format for further investigation that ultimately results in a count of the number 
of individual animals with each condition such that prevalence estimates can be 
calculated. 
2.2 Animals from which ovarian samples were recovered 
The mares used in this study were primarily sourced from University of Glasgow, 
Weipers Centre Equine Hospital cases (n=31 mares), but some (n=5 mares) came 
from practices around the UK. Ovaries recovered from 18 mares were examined 
following euthanasia in a variety of reproductive states: oestrus, dioestrus and 
anoestrus because they arrived in different seasons such as late spring, summer, 
early autumn and winter. Other ovaries recovered from 15 mares were 
ovariectomised and also from three mares with unknown reason of collection. 
All procedures were carried out in accordance with ethical research (Ref 
41a/16), and were approved by the local Research Ethics Committee, School of 
Veterinary Medicine, University of Glasgow.  
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2.3 Ultrasonography 
Ultrasonography on specimens in saline was used to determine the number and 
size of the follicles and occurrence of luteal structures on ovaries. A real time 
digital ultrasonic imaging scanner (Shenzhen Mindray Bio- Medical Electronics 
CO. LTD, Model DP-30 Vet) with to a 7.5 MHZ linear array transducer was used. 
The ovaries were collected, placed in a bag filled with phosphate buffered saline 
(PBS) and placed in an icebox. The linear probe was applied on each ovary 
scanning from lateral to medial or vice versa to detect all follicles or any corpus 
luteum present on each ovary.  
2.3.1 Measurements of follicles and corpus luteum 
The ovaries were scanned approximately one hour after each mare had been 
euthanized or between 1- and 2-hours after ovariectomy.  The images of the 
follicles were frozen on the screen of the ultrasound scanner and individually 
measured. All findings of location and follicular size of individual follicle and 
corpus luteum were recorded on ovarian sheet, which then assisted fluid 
aspiration with individual follicle. This also ensured work commenced with the 
largest follicle first. A vertical and horizontal ‘diameter’ (mm) of each follicle 
was written on the ovarian diagram. The largest follicle from both ovaries was 
given number F1 and the second largest given F2 and so on as presented in Table 
2-1. The diameter of any corpus luteum present was also drawn and measured as 
described above.   
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Table 2-1: An example of ovary and follicular size measurements from five mares with 
normal follicles 
Mare  Date  Ovary size  
ex vivo 
Scan 
Structure 
Left or 
right 
ovary 
Size FF 
1 
  
  
  
  
06.08.14 L 9.3x6.5cm Yes Follicle 1 Left 29.6 x34.9 Yes 
    Yes Follicle Left 23.6 x 36.8 No 
  R 11.5x8.5cm Yes Follicle Right 22.4x21.4  No 
    Yes Follicle 2 Right 28.4x27.2  Yes 
      Follicle Right 62.7x60.3  No 
2 
  
  
  
  
  
14.08.14 L 4.8x3.5cm Yes Follicle  Left 12.5x8.9 No 
      Follicle Left 12.7x13.1 No 
      Follicle LF F2 Left 27.2x28.1  Yes 
  R 8.5x6.5cm Yes Follicle Right 18x13.7 No 
      Follicle MF Right 20.7x19.2 Yes 
      Follicle RF F1 Right 37.3x32.7 Yes 
3 
  
  
21.08.14 L 3.5x2.5cm Yes Follicle MF3 Left 10.3x11.8 Yes 
  R 5.3x4cm Yes Follicle MF1 Right 15.4x13.2  Yes 
      Follicle MF2 Right 11.5 Yes 
4 
  
  
  
11.11.14 L 6.7x5.5 cm Yes Follicle F1 Left 30.4x24 Yes 
      Follicle F2 Left 17.7x15 Yes  
  R 6.2x6 cm Yes Follicle F3 Right 17.3x14.4 Yes 
      Follicle F4 Right 15.4x12.5 No 
5 
  
  
28.11.14 L 4.5x4 cm Yes Follicle F2 Left 18.3x17.9 Yes 
  
R 7.5 x 5.4 
cm Yes Follicle F1 Right 36.3x31.3 Yes 
      Follicle F3 Right 20.6x13.8 Yes 
 
2.4 Follicular fluid (FF) samples 
Follicular fluid samples were collected in the laboratory from individual follicle 
for analysis of Oestradiol (E2) concentration using a five or 10ml syringe with 20 
G 1.5" needle after ultrasound procedures were complete. Follicular fluid was 
collected in 15ml tubes and placed in the icebox while aspiration of other 
follicles was taking place. All tubes were stored in a freezer at -20 °C until the 
E2 hormonal assay was performed. 
2.5 Ovaries, stroma and follicular wall samples   
One ovary at a time was taken from the Phosphate buffer saline (PBS) plastic bag 
that was in the icebox and placed on a sterile petri dish with fresh PBS. The 
follicle was penetrated with an incision by Westcott curved blunt tenotomy 
scissors to visualize the follicular cavity. The follicular wall of each follicle was 
peeled off by blunt dissection and put in a sterile petri dish filled with PBS. This 
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follicular wall was cut into three rectangular shaped pieces. A cube of stroma 
was then cut from the ovary and the ovary hemisected from lateral to medial 
splitting the ovulation fossa into two pieces. Each follicular wall of one follicle 
as well as stroma from each ovary that collected earlier was fixed in an 
individual 50 ml tube of Bouins solution fixative (VWR Chemicals, VWR 
International, 7000.1000). The two pieces of left and right ovaries were put in 
two different jars filled with Bouins solution fixative (VWR Chemicals, VWR 
International, 7000.1000). All tubes were kept at room temperature for 48 hours 
and then changed to 70% ethanol for the first time and after another 48 hours 
for the second time until ready for histopathology. The more recently collected 
ovaries with their follicular wall (n=7) and GCTs (n=5) were fixed in 10% neutral 
buffer formaldehyde for DNA extraction and PCR procedures and some were 
stored in -80 °C freezer as fresh samples either from a normal ovaries (n=2) or 
GCT (n=1) ovaries. In addition, two GCT and three normal ovaries from three 
mares had been preserved in 10% neutral buffer formaldehyde at the beginning 
of the study, and were also used for DNA extraction and PCR procedures. 
2.6 Blood sample 
A blood sample was collected from one euthanized mare under a different 
licence, which allowed the use of leftover blood for research via indwelling 
jugular vein catheters inserted prior to euthanasia. The blood sample was 
withdrawn and transferred to 10 ml EDTA tubes. The tube was centrifuged for 20 
minutes at a temperature of 3°C, speed 3800 rpm and low brake. The buffy coat 
from the EDTA tube was transferred in a 15 ml tube and filled with distilled 
water, centrifuged to wash and then removed red blood cells, poured off, and 
this process was repeated twice to recover a white blood cell pellet. The white 
cell sediment was stored in the freezer at – 80 °C until DNA extraction. 
2.7 Hormonal assay 
Follicular fluid (FF) oestradiol-17β concentration collected during Chapter 4 was 
measured by an ELISA using the Parameter™ Estradiol kit from catalogue number 
(KGE014), R&D System a biotechne brand, USA (Dou et al., 2017) and a 
LabTech LT-4500 microplate reader. All laboratory analyses were carried out in 
accordance with Control of Substances Hazardous to Health (COSHH) guidelines.  
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2.7.1 Oestradiol (E2) ELISA Protocol 
Plates for ELISA were prepared as follows: Two wells for non-specific binding 
(NSB) that contained buffer (Calibrator diluent RD5-62) and Tracer (Oestradiol 
conjugate); two wells for maximum binding or total binding or zero binding (TB) 
that contained buffer (Calibrator diluent RD5-62), E2 primary antibody and 
Tracer (Oestradiol conjugate); twelve duplicated wells of six standards were 
prepared; and four wells of Quality Controls (two wells QCs low + two wells QCs 
High) at the beginning and end of the plates. Follicular fluid samples were added 
to all remaining wells in duplicate. 
2.7.1.1 Quality controls (QCs) preparation  
The following steps made the QCs ‘low’ and QCs ‘high’: 10 µl of each individual 
FF sample were collected in one tube to make a pooled sample. 10 µl of pooled 
sample was added to 990µl of distilled water to make 1000µl (1ml) of 1:100 
dilution. 20 µl of the 1:100 dilutions was added to 80µl of calibrator diluent to 
make 100µl (0.1ml) of 1:500 dilution (QC High). 10 µl of the 1:100 dilution was 
added to 90 µl of calibrator diluent to make 100µl (0.1ml) of 1: 1000 dilution and 
finally 25 µl of the 1:1000 dilutions was added to 25 µl of calibrator diluent 
(double dilution) to make a 1: 2000 dilution (QC Low). 
2.7.1.2 Follicular fluid dilution  
The individual frozen FF sample was thawed and diluted four times, 1:100 in 
distilled water and (1:500, 1:1000 & 1:2000) in calibrator diluent buffer as 
follows: 10 µl of FF was added to 990µl of distilled water to make 1000µl (1ml) 
1:100, 20 µl of 1:100 was added to 80 µl of calibrator diluent to make 100 µl 
(0.1ml) 1:500, 10 µl of 1:100 was added to 90 µl of calibrator diluent to make 
100µl (0.1ml) 1:1000 and finally double the dilution of 1:1000 to make 1:2000, 
25µl of 1:1000 in 25 µl of calibrator diluent to make 50 µl (0.05ml) 1:2000. 
2.7.1.3 Preparation of the standard curve 
The standard curve was prepared by adding 1ml of deionized or distilled water 
to Estradiol standard solution of 30,000 pg/ml. This was left for a minimum of 15 
minutes with gentle mixing prior to making dilutions. 900 µl of Calibrator Diluent 
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RD5-62 was pipetted into the first tube (3000 pg/ml) tube and 400 µl of 
Calibrator Diluent RD5-62 into the remaining tubes. Each tube was mixed gently 
but thoroughly before the next transfer, then 100 µl of stock solution (Estradiol 
Standard 30,000pg/ml) was transferred into 3000pg/ml tube to make 1000µl. 
200 µl was transferred from 1st tube to another starting from the top standard or 
(high standard) 3000pg/ml tube until the low standard 12.3pg/ml tube. The top 
(high) standard starts from 3000pg/ml then 1000pg/ml, 333pg/ml, 111pg/ml, 
37pg/ml, and 12.3pg/ml as presented in Figure 2-1 Calibrator diluent RD5-62 
serves as the zero standard (0pg/ml) 
 
  
100 µl 
Stock 
solution 
200 µl 200 µl 200 µl 200 µl 200 µl 200 µl 
Figure 2-1: Standard curve and calibrator diluent 
2.7.1.4 Assay procedures 
100 µl of Oestradiol primary antibody solution was added to each well, excluding 
the Non specific binding (NSB) wells, then covered with the adhesive strip 
provided and followed by one hour incubation at room temperature on a 
horizontal orbital micro plate shaker (0.12” orbit) set at 500± 50 rpm. Each well 
was aspirated and washed with Wash Buffer (400µl) using a squirt bottle and this 
step was repeated three times for a total of four washes. After the fourth wash 
the plate was inverted and blotted against clean paper towels. 100 µl of 
standard, control, or samples was added to the appropriate wells. 100 µl of 
Calibrator Diluent RD5-62 was added to the zero standard (Bo) wells and NSB 
wells. 50 µl of the E2 conjugate was added to all wells then covered with the 
adhesive strip provided and followed by two hours incubation at room 
temperature on the shaker. Aspiration and washing was repeated four times then 
a 200 µl of substrate solution was added to each well followed by 30 minutes 
30,000 
pg/ml 
3000 
pg/ml 
1000 
pg/ml 
333 
pg/ml 
111 
pg/ml 
37 
pg/ml 
12.3 
pg/ml 
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incubation at room temperature on the bench top, protected from light. 100 µl 
of stop solution was added to each well. At this point, if the colour in the wells 
did not change from blue to yellow or remained green, the plates were gently 
tapped to ensure thorough mixing. The optical density of each well was 
determined within 30 minutes, using a LabTech LT-4500 microplate reader set to 
450 nm.  
2.8 Histopathology 
All ovaries and uteri were examined, inspected for any abnormalities and images 
were taken as shown on Figure 2-2. Those that were collected and scanned after 
euthanasia were transferred to the laboratory for histopathological procedures, 
apart from one ovary that was received from a different practice, which was 
already stored in 10% neutral buffer formaldehyde. Ovarian maps were used to 
identify the position of the follicle on the ovary. The ovary was placed on a petri 
dish filled with PBS and the follicular wall removed after aspiration of FF 
completed. 
 
Figure 2-2: Examining the uterine tract immediately after euthanasia 
2.8.1 Measurement of ovaries and ovarian follicles 
Horizontal and vertical diameters of each ovary were measured using a ruler as 
shown on the Figure 2-3, whereas the horizontal and vertical diameter of each 
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follicle on the monitor screen of the ultrasound scanner was measured as on the 
Figure 2-4. 
 
Figure 2-3: Ovary diameter measurement 
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Figure 2-4: Follicle diameter measurement using ultrasonography 
2.8.2 Hemisecting of ovaries, cutting of stroma, peeling off the 
follicular wall (FW) and preservation 
Following all procedures related to follicular fluid aspiration, peeling off the FW, 
cutting stroma, hemisecting the ovaries and preserving as described earlier, 
samples were sent for histopathology embedding and H&E staining (Kiernan, 
2008). Many ways were investigated to identify the optimal alignment of 
follicular wall in order to view the layers of granulosa cell, theca cell and 
stroma. The FW was cut as a small rectangular piece of tissue. Individual 
samples were placed in a small container filled with Bouins solution fixative 
(VWR Chemicals, VWR International, 7000.1000) or 10% neutral buffer 
formaldehyde, labelled with a specific code number and maintained at room 
temperature for both histology and immunohistochemistry. The GCT ovaries 
were also dissected into small (approximately 10mm) pieces for the same 
examination. 
2.8.3 Tissue processing protocol (wax blocks).  
Histology and immunohistochemistry staining was carried out by Veterinary 
Diagnostic Services at the University of Glasgow, School of Veterinary Medicine 
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which is recommended by (Oliver and Jamur, 2010) . Preparation of H&E staining 
wax has many steps for small tissue samples as presented in the Table 2-2. 
2.8.4  Haematoxylin and Eosin (H&E) staining 
Follicular walls were embedded in wax using Thermo Scientific, Histostar 
machine sections. The block was cut using a Thermo Scientific, FINESSE ME+ 
microtome machine by placing the block in a position where the machine could 
trim the first 10µm in order to get a full face of the block before then setting 
the machine to 2.5µm slice thickness. The section was stretched and placed on 
the warm water bath. The best section was chosen and mounted onto a slide and 
left on hotplate for at least 5-10 minutes, then placed in the 60°c oven for at 
least one hour to ensure it was fixed properly to the slide and that the wax had 
melted. The 2.5µm-backed section was deparaffinised by immersion in xylene 
substrate called a Histo-clear (National Diagnostics, New Jersey, USA), for three 
minutes. The slides were rehydrated for three minutes by passing through (100%, 
90%, 70%) alcohol baths and rinsing in water. Slides were placed in Haematoxylin 
for five minutes, washed with water, then placed in mixed of acid and alcohol 
(70%) and rinsed in Scott’s tap water substitute for three minutes. The slides 
placed in Eosin for five minutes, then washed with water. Sections were 
dehydrated with (70%, 90%, 100%). Finally the section cleared with Histo-clear 
and mounted in mounting media using Histomount (National Diagnostics, New 
Jersey, USA).  
2.8.5  Histological (normal follicular wall) and histopathological 
(GCT) slide examinations 
The granulosa and theca cell layers in each FW section, were quantitatively 
assessed using a Leica DM4000B microscope (Leica Microsystem, Switzerland) 
connected to Leica Application Suite software (version 4.3.0; Leica 
Microsystems, Switzerland) to acquire images. ImageJ (1.49v, Wayne Rasband, 
National Institute of Health, USA) software was used for cell count and thickness 
measurements. Five consecutive rectangular views were spaced over the whole 
length of the follicle wall capturing both the granulosa cell and theca cell layers 
(all at 40 x magnifications) as shown in Figure 2-5. Each rectangle measured 
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140.70x255.27 µm2 as shown in Figure 2-6. All magnifications were viewed by 
multiplying with 10X microscope binocular. 
Table 2-2: H& E stain preparation steps 
Station     Content                Time 
1 70% ALCOHOL 30MINS 
2 95% ALCOHOL 30MINS 
3 ABS ALCOHOL 30MINS 
4 ABS ALCOHOL 30MINS 
5 ABS ALCOHOL 45MINS 
6 ABS ALCOHOL 45MINS 
7 ABS ALCOHOL 1 HR 
8 ABS ALC/XYLENE 30MINS 
9 XYLENE 30MINS 
10 XYLENE 30MINS 
11 WAX 30MINS 
12 WAX 30MINS 
13 WAX 45MINS 
14 WAX 45MINS 
 
In each of the five views granulosa (GC) and theca cells (THC) were counted at 
x40 magnification as shown in Figure 2-7. These cell types were differentiated 
from each other on the basis of cellular morphology. Basal GC were classified as 
cells that were situated at the base of the GC layer. Antral GC were classified as 
cells that were situated closest to the antral surface of the follicle. Intermediate 
GC were classified as the cells that were laid in between the basal and antral 
GC. The thicknesses of the granulosa and theca cells were measured on five 
views under 20x magnification images in order to examine the whole stretch of 
the tissue as shown in Figure 2-8. The thickness of GC layers started from the 
antral GC to the basal GC and thickness of THCs layers started from the top of 
the theca interna cell directly beneath the basal GCs to the end of theca 
interna. The large THC and small THC cells make up the composition of the 
theca layer. The large THC cells exhibit a well-defined cell membrane with large 
cytoplasms, whereas the small THC cells tend to be smaller in size with less 
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cytoplasm. The cells that were included in the assessment had distinct nuclei. 
The entire cell had to be visible for it to be counted.  
 
Figure 2-5: Illustration of how views are taken from a selected follicular wall sample. This 
sample is taken as 200X magnification; the boxes are representative of the five successive 
views taken for further assessment at 400x magnification. 
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Figure 2-6: Rectangle view of follicular wall image 200x magnification 
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Figure 2-7: Counting granulosa and theca cells at 400x magnification, No.1: Basal GCs, 
No.2: Antral GCs, No.3: Intermediate GCs, No 4: Large THCs, No. 5: Small THCs 
 
A B C 
D E
E
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Figure 2-8: Measuring (White lines) the thickness of granulosa and theca cell at 200x 
magnification 
2.8.6 Cells counting and measuring the thickness of granulosa 
and theca cells 
Granulosa cells and small and large theca cells were counted by using Image J 
(1.49v, Wayne Rasband, National Institute of Health, USA) software. Only those 
cells with distinct nuclei were included. Granulosa and theca layers thicknesses 
were acquired under 200x magnification using a Leica DM4000B microscope 
(Leica Microsystem, Switzerland) connected to a Leica Application Suite 
software (version 4.3.0; Leica Microsystems, Switzerland) followed by analysis 
using ImageJ software. The scale was first calibrated with the use of a graticule 
taken with the same magnification to enable measurement of the cell layers in 
μm based on the number of pixels as shown on Figure 2-9. This distance was 
then converted to a measured length on the basis of a standardized scale.  
GCs 
THCs 
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Figure 2-9: Setting a scale (pixel: µm) ratio using ImageJ at 40 magnifications. 100µm equal 
to 398.0201 pixels, thereby producing a scale of 3.9802 pixels/µm. 
2.8.7 Nuclear circumferences 
Image J software was also used on nuclear circumferences for basal, 
intermediate and antral nuclear cells for both follicular wall of antral follicle 
and for GCT. The scale was set using 50 graticule scale image taken under 100 
magnifications to calibrate the software that enable conversion of pixels to a 
known length unit on µm so the scale ratio will be pixels/µm, then 
measurements of the nucleus were taken. All various views at 100x (under oil 
immersion) magnification (multiplied with 10X microscope binocular) were taken 
of a characteristically healthy follicular wall samples (VH, H, EA) and granulosa 
cell tumour samples (GCT1, GCT2, GCT4) in interest of comparison of cellular 
morphology using an Olympus BX51 microscope and Stream Basic (version 1.9.2; 
Olympus soft Imaging Solutions GmbH). In normal follicular wall samples, five 
basal GC, five intermediate GC and five antral GC were randomly selected in 
each view (three views measurement). In other words, 15 basal, 15 intermediate 
and 15 antral GC in three views per section were measured. In GCT samples, five 
cells in three views were randomly selected on the same requirements. In total 
15 basal, 15 intermediate and 15 antral GC in 3 views per sections in GCT1 
(large, follicle-like) and GCT2 cysts (small, thick wall), and in GCT3 cysts (single 
cell layer surrounding fluid antrum, only antral GC), and in GCT4 45 GC within 
solid nests because there is no distinct basal or intermediate or antral GC.  
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2.8.8 Generic Immunohistochemistry (IHC) Protocol using Dako 
Autostainer  
All procedures were done at room temp and slides were placed for five minutes 
in buffer to rinse all Tris buffer pH7.5 + Tween. HIER (Heating-Induced Epitope 
Retrieval) was done using Access Retrieval Unit (Menarini, UK), Buffer Sodium 
Citrate pH6 1 min 40 sec at 125⁰C full pressure and Enzymatic antigen retrieval 
using Proteinase K RTU (Agilent, Dako, USA) was used for antigen retrieval. 
Slides were loaded on to a Dako Autostainer (Agilent, Dako, USA) then rinsed in a 
buffer and placed in Dako Real TM Peroxidase blocking solution (3% hydrogen 
peroxide in PBS made in house) for five minutes followed by a five minutes 
buffer rinse. The first antibody dilution was performed using (universal diluent, 
Dako) for 30 minutes then followed by two buffer rinses for five minutes. The 
appropriate second reagent was applied for 30 minutes depending on which 
species has been raised on first antibody then followed by two buffer rinses for 
five minutes. Slides were loaded on Dako K5007 DAB (Dako, UK) twice for five 
minutes followed by three water rinses and counterstaining with Gills 
Haematoxylin (made in house) for 27 seconds. The slides were then washed in 
water (Scotts Tap Water Substitute) dehydrated, cleared and mounted in 
synthetic resin (DPX, Sigma), which ready for analysis. The details of the primary 
antibodies, enzymatic antigen retrieval agent and secondary antibodies are 
presented in Table 2-3. 
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Table 2-3: The dilution of the primary antibodies, secondary antibodies and enzymatic 
antigen retrieval used 
No. Antibodies Antigen 
Retrieval  
Antibodies 
dilution 
 Secondary Antibodies 
1 INHIBIN 
clone R1 
Dako Cat. 
NO. M3609  
HIER Sod 
Citrate pH6 
1:20 Dako Envision+System HRP 
Labelled polymer Ant-
mouse Cat. No. K4001 
ready to use  
2 AROMATASE 
ABBIOTEC 
Cat. No. 
250549 
Proteinase K 
15 minutes 
1:100 Dako Envision+System HRP 
Labelled polymer Ant-
Rabbit Cat. No. K4003 
ready to use  
3 CYP17A1 
Santa Cruz 
Cat. No. se-
374244 
HIER Sod 
Citrate pH6 
1:1500 Dako Envision+System HRP 
Labelled polymer Ant-
mouse Cat. No. K4001 
ready to use  
4 AMHR2 N- 
Term 
Antibodies-
online Cat. 
No. 
ABIN2616027 
HIER sodium 
citrate pH6 
 
1:200 Dako Envision+System HRP 
Labelled polymer Ant-
Rabbit Cat. No. K4003 
ready to use 
5 FOXL2 
Abcam Cat. 
No. ab5096 
HIER Sod 
Citrate pH6  
1:600 ImmPRESS HRP reagent kit 
anti-Goat IgG Cat. No. MP-
7405 made up as per 
suppliers instruction 
 
 
2.8.9 IHC analysis 
All images were examined under 200x magnification plus 10X objective binocular 
using a Leica DM4000B microscope (Leica Microsystem, Switzerland) connected 
to a Leica Application Suite software (version 4.3.0; Leica Microsystems, 
Switzerland) followed by analysis using ImageJ software (1.49v, Wayne Rasband, 
National Institute of Health, USA). Each image was given a category or a 
percentage of coverage depending on a judgment of the stain intensity, 
distribution at the section and %area covered. For the stain intensity; ‘0’ implies 
no stain, ‘1’ was low stain, ‘2’ was medium stain and ‘3’ was high stain and for 
the spread or distribution ‘1’ was continuous, ‘2’ was individual and ‘3’ implied 
clusters of cells. The area covered was given according to the number of 
granulosa cells, and percentage of cells covered because, for example in those 
classified as GCT3, the total number of GCS is reduced.  
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2.9 FOXL2 sequence determination gene extraction 
2.9.1 First experiment  
2.9.1.1 Samples  
Eight GCT samples from six mares and eleven control samples from seven mares 
were used in this study. All had been fixed in 10% neutral buffered formalin. One 
of the GCT samples (No.2) stored fresh in -80°C and one mare (No.1) was 
presented in both groups because both ovaries were removed during 
ovariectomy. Fresh tissue and blood from the mare (No.7) that is a non-GCT 
tissue sample alongside frozen washed buffy coat from another non-GCT mare 
(No.4) were analysed. The University of Glasgow School of Veterinary Medicine 
Research Ethics Committee – Reference number 41a/16, approved the use of 
tissue and blood for this study. Details of the origin of samples used in the study 
are shown in Table 2-4. 
Table 2-4: Mares used in the study 
Samples 
Mares 
No. 
Collecting 
Date  
Comment  
GCT 1 Left 
Ovary  
16.10.13  13yo Welsh Pony  
2 17.06.14  Unknown mare – 20cm GCT on RHS  
3 07.03.16  
Chestnut Thoroughbred – foaled 12d before 
admission  
4 31.05.16  
GCT of 8.5cm diameter with large cystic cavity 
of 6x4x3cm  
5  10.06.16 8yo Cob 
6 14.09.16 8yo L. ovary weighed 5 kg 
Non GCT 1 Right 
Ovary 
16.10.13 13yo Welsh Pony 
2 
03.04.13 9yo Irish Sport Horse with persistent oestrus and 
difficult behaviour  
3 22.05.13 4yo Piebald Draft horse 
4 09.02.15 1.5yo Welsh Mountain Pony 
5 02.04.16 10yo Thoroughbred Cross with masculine 
behaviour 
6 01.04.16 10yo Connemara Cross 
7 
03.02.17 
Recently Foaled. Had sarcoid and difficult 
behaviour 
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2.9.1.2 Purification of total DNA from animal tissues (spin-column protocol) 
A few important steps were performed before starting the procedures. All 
centrifugation steps were carried out at room temperature (15–25°C) in a 
microcentrifuge and vortexing was performed by pulse-vortexing for 5–10s. The 
buffer ATL and buffer AL were warmed to 56°C until the precipitates had fully 
dissolved to prevent the formation of precipitates upon storage. The appropriate 
amount of ethanol (96–100%) was added to Buffer AW1 and Buffer AW2 as 
indicated on the bottle to obtain a working solution before using for the first 
time. To prevent reducing DNA size, the frozen tissue samples were equilibrated 
to room temperature and repeated thawing and freezing was avoided. 
QIAGEN DNeasy® Blood and Tissue Kit and its protocol (Qiagen. DNeasy® Blood & 
Tissue Handbook. Qiagen; 2006) was used to extract the DNA from samples. 
Tissue samples between 15-20 mg were cut and washed twice in PBS to remove 
any formalin. Tissue was put into 1.5ml DAN/RNA-free Eppendorf tubes and 
180μl of Buffer ATL was added. Then 20μl proteinase K was added, mixed 
thoroughly by vortexing, and incubated in a water bath at 56°C until the tissue 
was completely lysed. It is worth noticing that some tissue required many hours 
of water bath incubation. 200 μl of Buffer AL was added to the sample, and 
mixed thoroughly by vortexing. This was followed by the addition of 200μl 
ethanol (96–100%), and mixing again thoroughly by vortexing. The mixture 
including any precipitate was added to the DNeasy Mini spin column placed in a 
2-ml collection tube then centrifuged at ≥6000 x g (8000 rpm) for one minute. 
The collection tube was discarded and placed the DNeasy Mini spin column in a 
new 2-ml collection tube, then 500 μl Buffer AW1 was added, and centrifuged 
for one minute at ≥6000 x g (8000 rpm). The collection tube was discarded and 
placed the DNeasy Mini spin column in a new provided 2-ml collection tube, then 
500 μl Buffer AW2 was added, and centrifuged for three minutes at 20,000 x g 
(14,000 rpm) to dry the DNeasy membrane. The collection tube was discarded 
and placed the DNeasy Mini spin column in a clean 1.5 ml or 2 ml 
microcentrifuge tube, and pipetted 30μl Buffer AE directly onto the DNeasy 
membrane. This was then incubated at room temperature for one minute, and 
then centrifuged for one minute at ≥6000 x g (8000 rpm). Elution with 30μl 
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(instead of 200 μl) increased the final DNA concentration in the eluate, but also 
decreased the overall DNA yield. 50µl Buffer AE was used for blood. DNA yield 
and quality (260/280 ratio) were measured using the NanoDrop 1000 
Spectrophotometer, after which the DNA was stored at -20°c until required.  
Extracted DNA yield from tissues that eventually went on to sequencing are 
presented in Table 2-5. Although for most DNA extraction overall positive results 
were achieved, FOXL2 amplification from fixed and frozen tissues was 
unsuccessful, indicating DNA degradation. A gel was run of the DNA extracted 
from tissues of various ages presented in Figure 2-10. It can be observed that 
DNA is highly degraded in fixed tissue, with fewer longer reads remaining 
compared to frozen and fresh tissue. Although for reasons unknown, Non-GCT 7B 
DNA appeared very faint in this gel, all downstream reactions and sequencing 
were successful.  
Table 2-5: DNA concentration of final samples sequenced 
Mare Samples  
Collecting 
Date Tissue origin 
Tissue 
state 
Weight 
(mg) 
DNA 
conc. 
(ng/ml) 
260/2
80 
Ratio 
GCT 1 16.10.13 L. Ovary Fixed 19.2 87.56 1.75 
GCT 2A 17.06.14 R. Ovary Fixed 18.8 181.94 1.76 
GCT 2B 17.06.14 R. Cyst wall Frozen 15.9 141.39 2.03 
GCT 2C 17.06.14 R. Stroma Frozen 19.5 368.79 2.05 
GCT 3 07.03.16   Fixed 18.5 135.03 1.86 
GCT 4 31.05.16   Fixed 19.9 446.05 1.76 
GCT 5 10.06.16   Fixed 17.8 132.09 1.77 
GCT 6  14.09.16   Fixed 18.1 197.25 1.9 
Non- GCT 1 16.10.13   Fixed 17.5 43.41 1.67 
Non- GCT 2 03.04.13   Fixed 19 95.67 1.69 
Non- GCT 3 22.05.13 L. Ovary Fixed 19.1 101.85 1.78 
Non- GCT 4 09.02.15 Blood Frozen   37.18 1.92 
Non- GCT 5 02.04.16 R. Ovary Fixed 18.9 157.99 1.78 
Non- GCT 6 01.04.16   Fixed 18.3 114.22 1.7 
Non- GCT 7A 03.02.17 Blood Fresh   666.54 1.88 
Non- GCT 7B 
03.02.17 
L. Follicle 
wall Fresh 17.6 145.4 2.02 
Non- GCT 7C 
03.02.17 
R. Follicle 
wall Fresh 16.8 141.02 2.13 
Non- GCT 7D 03.02.17 L. Ovary Fresh 19.2 101.91 2.04 
Non- GCT 7E 03.02.17 R. Ovary Fresh 18.9 83.77 2.04 
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Figure 2-10: Gel of extracted DNA from tissues of varying ages using 150ng/µl DNA per well.  
Fixed tissues: (GCT1, GCT2A, GCT6, GCT5), Frozen tissue (GCT2B), Frozen blood (Non 
GCT4), Fresh blood (Non GCT 7A), Fresh tissue (Non GCT 7B) 
2.9.1.3 DNA extraction from blood  
The collected blood in EDTA tubes was spun at 2500 rpm, 4°C for 15 minutes. 
The buffy coat layer was extracted and placed in a 1.5 ml eppendorf tube and 
the DNA extracted from the buffy coat on the same day using DNeasy® Blood and 
Tissue kit or the buffy coat was frozen at -80°C until ready for use. The DNA 
yield was measured using NanoDrop 1000 spectrophotometer. The AE buffer 
provided in the DNA extraction kit was used (to set a blank) then stored at-80°C. 
2.9.1.4 Nanodrop protocol  
Initially 1.5 μl of water was loaded on the lower measurement pedestal then the 
sampling arm was closed to initiate. Loading 1.5 μl of AE buffer onto the lower 
measurement pedestal set the blank. The pedestal was wiped with a clean 
laboratory wipe and 1.5 μl of the DNA sample was loaded and read. An example 
of a good quality DNA curve created by DNA samples is as presented in Figure 
2-11. The pedestals were wiped after each sample. The last run was performed 
with AE buffer to check for contamination. 
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Figure 2-11: An Extracted DNA result generated by the NanoDrop1000 
  
2.9.1.5 Primer Design  
The primer design software Primer-BLAST, available on NCBI were used to design 
three sets of primers for Equine FOXL2 as shown in Table 2-6 based on the 
sequence available on NCBI. Primers were prepared to 100pmol/μl with 
(molecular grade) water. For the Polymerase chain reaction (PCR) a Primer Mix 
of both Forward (F) and Reverse (R) primers were prepared to 20pmol/μl of each 
primer. For the Sequencing PCR, the primers were individually prepared to 
3.2pmol/μl, as instructed in the BigDye
® 
Kit Protocol. The binding positions of 
the primers in relation to the equine FOXL2 sequence are presented in Figure 
2-12.  
Table 2-6: Primers details 
Primer Sequences (5'-3') Melting Temp. Product size 
P1 
 
F CAACCTCAGCCTCAACGAGT 59.4°C 294bp 
 R TTGTTGAGGAAGCCCGACTG 59.4°C 
P2 
 
F GCCAAGTTCCCGTTCTACGA 59.4°C 355bp 
 R ACGAGTTGTTGAGGAAGCCC 59.4°C 
P3 
 
F CAACCTCAGCCTCAACGAGT 59.4°C 119bp 
 R GGTAGTTGCCCTTCTCGAACA 59.8°C 
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Figure 2-12: The nucleotide sequence of Equine FOXL2, with the position of the forward and 
reverse primers shown and the expected site of the mutation highlighted in yellow 
2.9.1.6 PCR PROTOCOL  
Decontamination of the PCR working area with 70% ethanol was performed 
followed by PCR preparation with Applied Biosystems AmpliTaq Gold® reagent. 
PCR procedures were applied according to the method of (Walsh et al., 2012, 
Mihm et al., 2006). The PCR products for the three sets of primers ranged from 
118-355 bp were designed. A nested PCR was performed by using the primer pair 
(P2) for the initial PCR, followed by a nested primer pair (P1 or P3) for the 
secondary reaction. The bench top of the flow hood was treated with UV for five 
minutes prior to setting up the PCR reactions. Each of the reagents was thawed 
and gently mixed, and the enzyme solution was gently spun down in a micro 
centrifuge before pipetting. All pipetting steps were carried out in the flow 
hood. PCR was in 30 μl reactions. Along with the reactions required for the total 
number of samples, additional reactions to serve as blank (one for each primer 
pair) were included. In case of one primer pair, the master mix was prepared by 
first adding 3μl of 10X PCR buffer II and 2.4μl of 25mM MgCl2 per reaction and 
water was added to this mixture. The volume of water will vary according to the 
volume of template DNA. The total volume of master mix, primers and template 
was equal to 30 μl. The mixture was gently vortexed followed by a pulse spun in 
the micro centrifuge then UV treated. The master mix was completed by adding 
0.6μl of dNTP mix and 0.3μl of AmpliTaq® Gold DNA polymerase per reaction. 
Each of the primers was prepared to a concentration of 20 pmol/μl. 0.6 μl of 
forward as well as 0.6 μl of reverse primer per reaction was added to the master 
mix then gently vortexed by a short pulse spin. The final concentration of each 
primer in the reaction was 0.4 pmol/μl (400 nmol/l). The mixture was divided 
into each of the PCR tubes. The different DNA templates were added in different 
tubes leaving one tube blank per primer pair. DNA template was added to a final 
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concentration of 4 ng/μl. The final volume was made up to 30 μl and followed by 
a brief vortex and a short pulse spin to each of the PCR tubes. Thermo Hybaid 
Px2 thermal cycler was used to run PCR. For different primers with varying 
annealing temperatures, the temperature of the gradient block was set 
accordingly. The following 35 PCR cycling conditions were used:  
 Stage 1: 95°C, three minutes.  
 Stage 2: Step 1) 95°C, 30 seconds. Step 2) Annealing temperature (57°C), 
30 seconds. Step 3) 72°C, one minute.  
 Stage 3: 72°C, five minutes and hold at 4°C.  
 
2.9.1.7  Agarose Gel electrophoresis   
Agarose Gel electrophoresis was performed to identify the presence of any 
amplified DNA and the size of PCR products. 2.5 L of 5X TBE was prepared by 
adding 135g of Tris base and 68.75g of boric acid and 50ml of 0.5 M EDTA (pH 
8.0). 5X solution of TBE was diluted by 10 times to prepare a working solution of 
0.5X TBE. 2% agarose gel was prepared by adding 3g of agarose to 150 ml of 0.5 
X TBE. The agarose was melted in a microwave until the solution became clear 
then was cooled down to about 50-55°C while swirling the flask occasionally to 
cool evenly. 0.5μl of Ethidium bromide was added to the gel with a gentle mix. 
The ends of the casting tray were sealed with two layers of tape. The combs 
were placed in the gel-casting tray. The melted agarose solution was poured into 
the casting tray and left to cool until solid. The combs were pulled out carefully 
and the tape was removed. The gel was placed in the electrophoresis chamber 
to which was added enough 0.5 X TBE Buffer so that there is about 2-3 mm of 
buffer over the gel. For loading the gel, 5μl of the PCR products in separate 
eppendorf tubes were added to 3μl of loading buffer and 10μl of water. For the 
ladder, 1μl of Invitrogen 100bp DNA ladder (Invitrogen 15628019) and 3μl of 
loading buffer were added to 14μl of water. Each of these tubes was spun down 
in a micro centrifuge. 18μl of sample/sample loading buffer mixture were 
carefully pipetted into separate wells in the gel. 18μl of the ladder/loading 
buffer mixture were pipetted into at least one well of each row of the gel. The 
lid on the gel tank was closed and connected the electrodes then the gel was run 
at 110-125V for approximately one hour. Finally the gel image was viewed and 
recorded under UV trans-illumination.  
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2.9.1.8 Purification of PCR product  
The PCR product was purified to eliminate any unincorporated PCR reagents or 
products <100bp in length that could interfere in subsequent sequencing 
reactions. Purification was performed on the remaining 25μl of PCR product 
using the Qiagen QIAquick
® 
PCR Purification Kit, according to kit protocol with 
20μl of Elution Buffer PE used to elute the samples. The column was incubated 
at room temperature for one minute followed by centrifugation at 17,000g for 
one minute.  
2.9.1.9 Sequencing PCR 
Sequencing reactions (10µl) were performed on a 96-well plate using the 
BigDye
® 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, 4337456). 
All the reagents were thawed and gently mixed. 10μl reactions for the 
sequencing PCR was set up and all primers were prepared to a concentration of 
3.2 pmol/μl. The master mix was prepared by adding 3μl of BigDye sequencing 
buffer and 1μl BigDye terminator ready reaction premix per reaction. 1μl of 
forward primer per reaction was added. The master tube was gently vortexed 
followed by a short pulse spin in a micro centrifuge. The mix was pipetted out 
into separate wells of the 96- well plate. 1μl of the purified PCR product and 4μl 
of water were added to each of the wells. The plate was sealed with caps and 
followed by a short spin. The plate for the sequencing PCR was loaded on Hybaid 
PCR express thermal cycler then run the sequencing PCR with the following (25 
cycles) thermal cycling conditions:  
 Stage 1: 96°C, one minute  
 Stage 2: Step 1- 96°C, 10 seconds. Step 2- 50°C, five seconds. Step 3- 60°C, 
four minutes  
 Hold at 4°C  
 
2.9.1.10 Precipitation  
PCR products precipitation was performed to eradicate any proteins, nucleotides 
and salts from the solution that might interfere with the sequencing machine. 
After the completion of sequencing PCR, the plate was removed and given a 
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short spin before carefully removing the caps. 8μl of deionized water and 32μl of 
molecular grade 100% ethanol were added to each of the wells. The wells were 
resealed, the tray was inverted a few times, and the plate was pulse-spun. The 
plate was incubated at room temperature for 20-30 minutes and was centrifuged 
at 4,000 rpm at 4°C for 30 minutes. The supernatant was removed by tapping 
onto a paper towel then 150μl of 70% ethanol was added and the plate was 
sealed followed by inverting it once or twice and centrifugation at 4,000 rpm for 
10 minutes. The supernatant was removed by tapping and inverting the tray on a 
tissue. The inverted tray along with the tissue was placed in a centrifuge and 
spun at 800 rpm for one minute. The plate was placed in an open PCR block at 
90°C for three minutes to ensure it was dry. Then the plate was ready to be 
sequenced using the Genetic Analyzer as described under 2.9.1.12 
2.9.1.11 PCR and Gel Electrophoresis  
A visualised single thin product band on the gel is required in order to 
immediately progress to sequencing. The majority of samples, however, were of 
insufficient quality to successfully sequence despite successful DNA extraction.  
1. Fixed Tissue 
Primary PCR of fixed tissue using P2 produced faint smears instead of the thin, 
clean bands needed, as presented in Figure 2-13. Primer dimer of <100bp can be 
clearly identified in all wells, while a band can only be detected with the fresh 
Non GCT 7B (FW) samples. Smears above or higher to the expected product size 
of 350bp, are visible for the fixed tissue, indicating DNA degradation.  
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Figure 2-13: Gel of primary PCR using P2 of fixed GCT & Non GCT tissues (with exception of 
fresh Non GCT 7B (FW) tissue).  
A nested PCR was then performed on the fixed tissues using P1 (shorter primer 
pair read length) to see if it would provide better bands. Similar results were 
identified from all fixed tissues, which did not detect any clean bands as 
presented in Figure 2-14.  
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Figure 2-14: Nested PCR of one fixed GCT and two fixed Non GCT samples using P1. 
  
2. Frozen Samples 
A nested approach using primer 2 (P2) followed by primer 1 (P1) was also 
examined on the frozen samples as presented in Figure 2-15 and that produced 
smeared bands identical to fixed tissues. The shorter primer 3 (P3) was applied 
to perform both a primary PCR on frozen tissue and nested PCR of fixed tissues 
as presented in Figure 2-16. The result revealed no clear bands in the fixed 
tissue despite the shorter product length. Bands of the correct length were 
observed in the primary PCR of the frozen tissue. However, a band was also 
found in the P3 Blank, indicating contamination.  
 
Figure 2-15: Gel of nested PCR of the frozen samples: GCT 2C (Solid), GCT 2B (Cystic) and 
NON-GCT 4 blood (a DNA from WBC); using P2 followed by P1. 
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Figure 2-16: Gel of nested PCR using P3 (after P2) of fixed tissues, alongside primary PCR 
using P3 of frozen samples (bottom 3 wells, Blood= NON GCT4 is a DNA from WBC), 
GCT2B&C solid and cystic frozen). Primer dimer bands of <100bp can be seen from fixed 
tissues, and a product of around 100-150bp can be seen from frozen tissue. 
3. Fresh Samples 
Primary PCR of fresh Non GCT 7 DNA tissue using P2, showed several clean bands 
for all samples, with the exception of blood (NON GCT 7A), as presented below 
in Figure 2-17. The required result from a nested PCR became apparent, as there 
were multiple bands using only P2, something that could not be observed with 
PCRs of the fixed tissues. A nested PCR using P1 was performed to resolve any 
non-specific binding; the gel of these PCR products is presented in Figure 2-18, 
which represented clean, single bands in the expected position for the product 
size of 294bp, which were suitable for sequencing.  
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Figure 2-17: Gel of primary PCR using P2 of fresh tissue (LO = Non GCT 7D, LFW = Non GCT 
7B, RO = Non GCT 7E and RFW = Non GCT 7C), and blood (Non GCT 7A is a DNA from 
WBC). LO is left ovary, RO is right ovary, LFW is left follicle wall and RFW is right follicle 
wall 
 
Figure 2-18: Gel of nested PCR using P1 after P2. Blood (Non GCT 7A is a DNA from WBC) 
and FW tissue (LFW = Non GCT 7B, RFW = Non GCT 7C) underwent purification between 
PCRs, while ovarian tissue (LO = Non GCT 7D and RO = Non GCT 7E) did not 
A fundamental difference between gene amplification in blood and tissue can be 
observed from both primary and nested PCR of the fresh samples. In addition, it 
was unclear whether purification between PCR products was required. 
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Therefore, in the nested PCR of fresh tissue both 50ng/reaction of purified PCR 
product (Blood and Follicle wall tissue) and 3μl of unpurified PCR product were 
used (Ovarian tissue). This revealed that purification between the PCRs was not 
necessary.  
4. Gradient PCR  
Following the identification of smeared PCR bands obtained from frozen tissue 
and the multiple bands observed in fresh tissue, it was thought that primer-
annealing temperature might be the cause and needed to be adjusted. To do 
this, gradient PCRs were performed using the Thermo Hybaid Px2 PCR machine. 
However, it was not until fresh tissue became available that it was confirmed 
that the optimum annealing temperature for P2 was 57
o
C. The results of a 
gradient PCR using fresh tissue is presented in Figure 2-19 showing that the 
number of bands does not decrease between 57.0
o
C and 57.8
o
C, and that bands 
drop off after 57.8
o
C. As there was no clear amplification using P1 in the 
gradient primary PCR, and as a nested approach resolved the appearance of 
multiple bands at 57
o
C, an annealing temperature of 57
o
C was also continued for 
P1. Despite contamination observed in P3 and the appearance of multiple bands 
in P2, it can be confirmed that all the primers designed worked to amplify 
FOXL2.  
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Figure 2-19: Gradient PCR on Non GCT 7 (FW) DNA at 4ng/µl using both P1 and P2.  
2.9.1.12 Sequencing  
The plate was sequenced using an Applied Biosystems Genetic Analyzer 3130xl. 
Before the sequencing a few steps were performed: 20μl Hi-Di™ formamide 
(Applied Biosystems, part number 4311320) was added to each well and left in 
the plate for two minutes followed by a brief vortex. The plate was placed into 
a PCR block at 95°C for two minutes then immediately removed directly onto 
ice. The plate was spun at 100g for one minute to remove any bubbles if 
necessary. Finally the plate was sequenced or stored at 4°C until ready to run.  
The fresh Forward Non GCT tissue large follicle wall (LFW) was sequenced after 
a nested PCR with P2 followed by P1 presented in Figure 2-20.  
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Figure 2-20: The sequence of forward Non GCT 7 (LFW) spanning mutation site, highlighted 
in black. A single read can be seen, with defined peaks and no overlapping sequences 
occurring. 
The generated sequences from the fresh tissue (Non GCT) compared to the 
Equine FOXL2 sequence created by P1 are presented in Figure 2-21. 
 
Figure 2-21: The extracted forward nucleotide sequences from the fresh tissue (Non GCT) 
compared to the Equine FOXL2 P1 sequence. The mutation site possible is highlighted in 
yellow and as expected no mutation was seen in the four different samples. LFW: Left 
follicle wall, RFW: Right follicle wall, LO: Left ovary, RO: Right ovary. 
As expected none of the successfully sequenced equine control tissue contained 
the 402C-G nucleotide mutation found in human GCTs. As no other samples 
(fixed, frozen or blood) produced single, clean bands, all sequences generated 
from these PCR products presented long, overlapping reads. This made 
generating an accurate sequence impossible. The data generated from the Non 
GCT 7A blood, processed at the same time as the fresh tissue, is presented in 
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Figure 2-22 showing similar results that were obtained from all fixed and frozen 
samples.  
 
Figure 2-22: A section of the generated forward sequence from Non GCT 7A (Blood) with at 
least 3 overlapping sequences observed. One of the potential sequencing matches for the 
mutation site is highlighted. 
Due to the contamination of P3 blank that appeared on the gel in Figure 2-16 a 
P3 PCR sequencing was performed to identify the source as presented in Figure 
2-23. The contamination was suspected to be from the primer stock solution but 
it can be identified as the FOXL2 gene and it was probably from one of the 
frozen GCT sample, although the main source is unknown. 
 
Figure 2-23: Sequencing results of the P3 blank compared to the FOXL2 sequences 
generated by the use of P3 with area of the mutation highlighted in yellow. 
2.9.1.13 Bioanalyzer findings 
Some of the extracted DNA samples described above and some new nested PCR 
products extracted samples were analysed for quality using the Bioanalyzer of 
the Polyomics Glasgow facility. This is because we suspected primer dimer 
contamination or low quality DNA to interfere with PCR and BigDye sequencing 
results. The DNA samples are the first seven peak graphs and the other four are 
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GCT PCR products as seen in Figure 2-24. The peak at 35nt (nucleotides) is a 
marker peak, which is part of the kit. PCR product is the peak at about 127nt. 
The other peaks (about 35nt) are the primers or primer dimers. The first three 
plots show much more degradation than the other four. The mares called DNA 
NON GCT 3 and DNA NON GCT 6 were rerun on the Figure 2-25 since they were 
slightly over diluted on the first chip. The bioanalyzer traces for the PCR 
products have also been included Figure 2-26. When the chip runs it has a 
marker peak at 35nt (nucleotides) to align all the traces but some of samples 
have additional peaks next to the marker, which are probably PCR primers. 
These may have interfered with the sequencing that was done during the first 
experiment giving a double sequence. In some samples the primer peaks are 
much larger than PCR product such as NON GCT 1 on Figure 2-25. 
 
Figure 2-24: DNA (DNA and ID number) and PCR products (ID number) bioanalyzer. The x-
axis is the size of the fragments and the Y-axis is the amount of sample at any point. 
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Figure 2-25: The first two graphs are the repeated DNA samples and the other 7 are control 
PCR products. 
 
Figure 2-26: The first 6 graphs are the GCT PCR products and the other 5 are the control 
PCR product
 
 
 
Chapter 3 Text mining  
Aims: 
 
1. Investigate epidemiological aspects of mare ovarian pathology and 
granulosa cell tumours. 
2. Text-mine a UK veterinary practice clinical database to facilitate the 
epidemiological investigation of ovarian pathology and ovarian tumours, in 
particular granulosa cell tumours (GCT).  
Objectives: 
 
1. Use Simstat and WordStat1 software to apply text mining to a large UK 
veterinary clinical database. 
2. Estimate the prevalence of ovarian pathology, ovarian tumours and GCT in 
seven first opinion veterinary practices in the UK. 
3. Identify risk factors for the development of ovarian pathology, ovarian 
tumour and GCT to determine clinical features that may aid early 
diagnosis or indicate future risk. 
  
                                         
1 Provalis Research 
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3.1 Introduction 
The equine breeding industry perceives abnormalities of the ovary(s) to be the 
most significant concern reflecting negatively on breeding productivity (McCue 
and McKinnon, 2011). According to (McCue et al., 2006), the susceptibility of 
horses to ovarian tumours is greater than other domestic species accounting for 
approximately 2.5 % of all equine cancers. There does not appear to be any 
breed (McCue et al., 2006, Crabtree, 2013) or age predisposition with ovarian 
tumours having been identified in newborn, 3-month old and 2-20 years olds 
(Gunduz et al., 2010, Crabtree, 2013) as well as in a 15 month old pre-pubertal 
filly (Charman and McKinnon, 2007).  
Mares ovaries are known to be affected by many other pathological diseases 
apart from ovarian tumours such as anovulatory follicle (McCue and Squires, 
2002), ovarian haematoma and luteal dysfunction (Troedsson et al., 2003). 
Examples of ovarian tumours are GCT, teratoma, cystadenoma and 
dysgerminoma, the most common of these being GCT (Watson, 1999). A 
retrospective study of laparoscopic ovariectomy on 157 mares with various 
clinical problems such as infertility, abnormal behaviour due to hormonal 
disturbance, ovarian tumours and neutering was conducted by (Roecken et al., 
2011). The authors used a medical database that had been gathered between 
1996 and 2009 by the Justus-Liebig University, Germany and Utrecht University, 
The Netherlands. The aim of that study was to evaluate the most appropriate 
ovarian treatment and surgical approach amongst the range performed by 
various surgeons during 206 surgeries. They concluded that the best treatment 
for ovarian tumour was indeed surgical removal (ovariectomy), particularly if it 
is unilateral, allowing the contralateral ovary to carry on functioning 6-months 
post operation (De Bont et al., 2010) and that a unilateral laparoscopic approach 
was optimal.  
 
Significant changes have occurred over the last five decades in the modern 
computing system for medical records (Salton and Lesk, 1968, de Bruijn and 
Martin, 2002). Moreover, the use of computer databases in general practice for 
public health auditing and commissioning has increased significantly ((Pringle et 
al., 1995). The collection of data retrospectively and prospectively from either 
veterinary practice records or electronic medical records for research purposes 
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has gradually expanded (Jones-Diette et al., 2014, Lam et al., 2007, Mattin et 
al., 2014, O'Neill, 2012, O'Neill et al., 2012, O'Neill et al., 2013, Oswald et al., 
2010, Radford et al., 2011). Structured and unstructured knowledge types are 
the two main kinds of system used for information storage, data usage and 
investigation. Both are used to extract and analyse stored data (de Bruijn and 
Martin, 2002, Garten et al., 2010).  
A previous analysis using Wordstat and Simstat content analysis software was 
conducted by Lam et al. (2007) to identify reasons for racehorse retirement from 
racing at the Hong Kong Jockey Club  over a period of 10 years. Analysis of a 
total of 3,727 retirement records revealed 95% of the text records could be 
successively extracted in approximately 2-weeks of work. In addition, Anholt et 
al. (2014) has used the same software for disease surveillance in small animal 
veterinary practice in Canada collected from 12 practices over a period of three 
years (2007 to 2009, inclusive). Text-mining allowed the authors to recover cases 
of enteric disease, with high sensitivity and specificity, which they were then 
able to investigate further.   
Natural language processing (NLP) considers text mining as an important element 
to contribute positively in automated analytic procedures (Anholt et al., 2014a). 
Text mining in scientific research has been used to achieve specific objectives 
such as retrospective work to clarify disease prevalence (Chapman et al., 2005, 
Chapman et al., 2004), investigating clinical symptoms and unwanted secondary 
effects (Chapman et al., 2004), medical care outcomes (Penz et al., 2007) and 
prognostication and survival examination (Penz et al., 2007, Bradley et al., 
2005). In this chapter text-mining is used to first estimate the prevalence of 
ovarian pathology, ovarian tumours and more specifically GCT and then to aid in 
the identification of risk factors or prodromal clinical signs for ovarian pathology 
or GCT.   
3.2 Materials and Methods 
3.2.1 Data 
The dataset used in this investigation was collated in 2013 and includes clinical 
data from 1987 to 2012, from seven veterinary practices in the UK (Duz et al., 
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2016). These data included a total of 515,832 records of which 194,466 referred 
to female horses and contain details of identification, date of veterinary record, 
gender, practice, breed and date of birth, which ranged from January 1952 to 
November 2012.  
3.2.2 Development of the categorisation dictionary in free text 
mining software 
WordStat v 7.01 a modular constituent of statistical software Simstat v 2.62 is a 
linguistic based product that enables distinguishing of pre-defined words or 
compound expressions incorporated into a self-characterized categorisation 
dictionary within any given free-text. The output is all rows of information 
("cases") that match any word or words contained within the categorisation 
dictionary. The program includes a feature to ignore terms of minimal semantic 
use (terms between pronouns, conjunctions and verb modifiers) unless these are 
incorporated into the categorisation word dictionary. This element accelerates 
the procedure by removing many repeated words throughout the text that have 
little bearing on the translation of the content.  
The "Frequency tab" in WordStat produces a table of every remaining word inside 
of the dataset and this list can be utilized to facilitate further characterisation 
of the categorisation "inclusion dictionary". This feature makes it significantly 
easier to identify and then include (unpredictable) spelling errors and 
abbreviations that would otherwise not be included as ‘case’ records. This list of 
words and phrases can be exported as a spreadsheet and assessed utilizing other 
software, such as 3MS Excel.  
The software also offers the ability to include words with the same root by 
including the character "*" at the end of the regular root. For instance, “ovar*” 
would identify all cases including a word starting as “ovar”, such as “ovary”, 
“ovarian”, “ovaries”, and so on. The ‘word list’ is an extremely valuable tools as 
it provides the user the means to describe a lexicon that includes every 
applicable term and their varieties that are actually present in the dataset. It is 
                                         
 
3 MS Excel  
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essential to note that this element makes the dictionary exceptionally ‘dataset-
specific’ and if significant quantities of new data are added the lexicon should 
be updated to incorporate new terms that may be present in the new data that 
were not part of the original database.  
As the identification of a particular single word may not always indicate a 
‘case’, negations must be considered. For example, if the characterisation 
dictionary includes the word "oestrus", a sentence, such as "the mare is not in 
oestrus" would be classified as positive, which is clearly incorrect. Recognisable 
proof of such false positives is a critical procedure as it characterizes the 
specificity of the analysis (Anholt et al., 2014b). WordStat also supports the 
utilization of boolean functions ("AND", "OR", "NOT") or different modifiers ("NO", 
"IF", "WHICH") and proximity operators ("NEAR", "BEFORE", "AFTER"). For 
instance, an investigator may determine that any sentence for which "not" is 
present within three words of "oestrus" be categorised in the "not oestrus" group 
rather than “oestrus” group.  A list of rules to eliminate false positive cases can 
be incorporated into an "exclusion dictionary" that could then give a list of those 
cases that ought to be removed from the "inclusion dictionary".  
Together these features of the software help to maximise the sensitivity and 
specificity of the process such that ‘cases’ and ‘unaffected’ animals are 
correctly identified. Nevertheless, the degree of variability in expression in free-
text records is wide and finding rules that fit perfectly is frequently impractical 
and a level of error is always likely to be present. Consequently it is important 
to report sensitivity and specificity of the inclusions dictionaries utilised for the 
specific dataset being mined as has been done as part of this work. 
3.2.3 Inclusion dictionary 
The clinical records dataset was imported into SimStat and by identifying the 
‘horse’ column as the independent variable and the clinical ‘note’ column as the 
dependent variable WordStat was initiated.  
Three separate dictionaries were created in order to identify cases of: ovarian 
pathology; ovarian tumours; and more specifically GCT. The complete lists of 
words and phrases for each of these dictionaries are included in Appendix 2. 
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3.2.4 Statistical analyses 
The prevalence and 95% confidence intervals for each outcome were calculated 
using the methods proposed by Wilson (1927) and recommended by (Agresti and 
Coull, 2000, Brown et al., 2001), which is appropriate for rare outcomes. 
The records of all cases were checked and read in detail. The dates of each 
outcome were confirmed as well as the age at which they occurred. Potential 
risk factors such as vaccination, worming, respiratory disease, digestive or 
orthopaedic diseases etc. were recorded from the preceding clinical records for 
each case horse. The presence or absence of those risk factors was coded 
numerically. For each of the positive cases of each outcome three unaffected 
horses, from the same practice as the case horse and that were represented in 
the dataset at the same time as the case horse, were randomly selected from 
the main database. The same risk factors were evaluated for each of those 
horses from the first entry record to the last entry prior to the date of the 
relevant case. 
Univariable (factors with p< 0.2 were available for inclusion in the next stage), 
followed by multivariable logistic regression analysis was used to identify any 
clinically recorded indicators associated with an increase or decrease in the 
likelihood of a horse ultimately being diagnosed with ovarian pathology or more 
specifically GCT. 
3.3 Results 
3.3.1 Data details 
The 515,832 records included 194,466 records for female horses, 91,724 records 
for male horses, 176,966 records for geldings and 52,676 records with 
unspecified gender. These data included details of variable numbers of female 
horses from each practice with an absolute number of veterinary reports for 
each as presented in Table 3-1.  Of the seven practices six of them had similar 
numbers of records per horse (range 5.1 to 8.8). However practice number ‘7’ 
had significantly more records per horse (13.6) compared with the average of 
the other practices (T-test p-value <0.001). The female horses included in future 
analyses were of different breeds as presented in Table 3-2. However, the 
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greatest proportion of the records (57%) was of unknown breed. The age of those 
females are presented in Figure 3-1. For 23,163 females age was not recorded. 
The mean horse age of records representing female horses was 11.31 years 
(median; 9.95 years). 
Table 3-1: Number of records of female horses from each practice with veterinary reports  
Practice number Number of 
records for 
female horses  
Number of 
horses 
Average number 
of records per 
horse 
1 10,933 1245 8.8 
2 107,622 14601 7.4 
3 3,001 589 5.1 
4 31,720 4996 6.3 
5 16,585 1953 8.5 
6 16,879 2066 8.2 
7 7,726 569 13.6 
Total 194466 26019 7.5 
 
Table 3-2: Number of records for female horses per breed 
Breeds Number of female 
records  
Arab 3,315 
Cob 5,100 
Draught 3,606 
Native 5,387 
Other 19,374 
Pony 3,921 
Thoroughbred 27,455 
Unknown 111,067 
Warm Blood (WB) 6,759 
Welsh 8,482 
Total 194,466 
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Figure 3-1: The number of records for female horses by age. 
3.3.2 Prevalence of different ovarian conditions. 
3.3.2.1 Ovarian Pathology 
In the ovarian pathology dictionary, 143 cases were initially identified from 
194,466 records representing 26,019 female horses. All entries of those cases 
were checked in the main database and 65 cases from all categories were truly 
positive representing cases of anovulatory follicles, cyst-like structure, inactive 
ovaries, irregular oestrus, infertility and so on as shown on Table 3-3. Therefore, 
this gives an ovarian pathology prevalence of 0.25 percent. 
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Table 3-3: Cases of ovarian pathology as identified by the text mining process and confirmed (or otherwise) as such by the reading in detail of each ‘case’ 
record (represented by ‘Test +ve’ or ‘Test-ve’).  
No. Categories Wordstat 
+ve 
Test 
-ve 
Why test –ve Test 
+ve 
Why test +ve 
1 Follicular development 
abnormalities/ 
Hormonal exogenous 
64 58 Gynecology exam/ 
P4 lab test/ scan 
mare 
6 Irregular ovary/inactive ovary/ 
behavioural and painful ovary/no cycling  
2 Follicular development 
abnormalities/ovarian dysfunction 
4 1 Uterine biopsy 
infertility  
3 Long time infertility 
3 Miscellaneous abnormalities 2 1 Same ID no extracted 
on GCT Cat. 
1 Ref for GCT removal 
4 Ovarian tumor/Cystadenoma 5 4 Cystic like structure 
on uterine horn 
1 Enlarged ovary cystic like structure 
5 Ovarian tumor/GCT 59 11 Suspect GCT 48 GCT/ ovariectomy/irregular oestrus/ 
Inactive ovary 
6 Ovarian tumor/Teratoma 2 0  2 Teratoma 
7 Ovulation 
abnormalities/anovulatory 
follicles  
7 3 Possible 
haemorrhagic 
follicle/no sign of 
cystic 
4 Haemorrhagic follicle/treat cystic ovary 
 
Total  143 78  65  
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3.3.2.2 Ovarian Tumours 
The dictionary of ovarian tumours had four categories as described in Table 3-4. 
One of them was dysgerminoma that had no record in the database, while 
teratoma had two potential false positives because it was mentioned as likely 
teratoma or a question mark had been written after the word teratoma. 
Cystadenoma had also five false positive cases due to the sentence that was 
extracted as “cystic like structure”. Overall the category of ovarian tumours 
identified 85 cases from 26,019 female horses, two were GCT positive but as 
expected these two were also extracted as part of the GCT dictionary and 83 
were false positive simply stating ‘large ovary’ or ‘small inactive ovary’ without 
further information relating specifically to tumours. Ultimately the tumour 
dictionary was discarded from the statistical analysis because it added nothing 
more than the GCT dictionary, due to almost complete overlap in case 
identification.  
Table 3-4: Ovarian tumours as identified by text mining and confirmed (or otherwise as 
such) following detailed examination of each ‘case’. 
 
No of 
cases 
Reason for 
identification 
Positive 
cases 
Not true 
positive 
Why not confirmed? 
1 Teratoma  0 1 Teratoma?  
1 Teratoma 0 1 Likely teratoma 
1 Cystadenoma 0 1 -ve x ray dense bone visible at 
the site of cystadv 
5 Cystadenoma 0 5 Cystic like structure 
1 Dysgerminoma 0 1 - 
1 
GCT 
0 1 Multilocular ovaries symmetry 
in sizes. Both ovaries enlarged 
17 0 17 Enlarged ovaries 
8 0 8 Ovarian cysts 
2 0 2 Ovarian adhesion 
3 0 3 Ovarian haematoma 
24 0 24 Painful ovary 
1 0 1 Anoestrus ovaries 
 
17 0 17 Small inactive ovaries 
1 0 1 Persistent oestrus 
1 1 0 LO Large mass (grapefruit), 
multilobulated lesion  
1 1 0 Ovarian tumour 
Total 2 83  
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3.3.2.3 GCT  
In the dictionary of GCT, 115 potential cases were exported in five categories 
from the dataset and out of these only 11 cases were truly positive for GCT 
(Table 3-5). The software extracted those negative cases because the GCT was 
written in the text such as ‘possible GCT’, ‘suspect GCT’, ‘likely GCT’ and so on 
(Table 3-6). Five cases form the false positive table were discarded because the 
software extracted them as tumours on penis and sheath. This occurred due to 
some practices used the same ID number of the dam to their offspring even if 
they were males.  
95 
 
 
Table 3-5: Positive granulosa cell tumour case 
 
  
No. Positive cases text Ovary site 
1 GCT of the LO reported to GUVS started June 2009 Left  
2 LO GCT, RO very small Left  
3 Referred to B. Johnson for GCT removal Right 
4 Clinical Hx and ovarian appearance consistent with 
GCT 
Right 
5 RO small 3-3.5 cm, LO 7cm firm. This finding 
combined with recent behavioural changes, which 
are consistent with early GTCT. Discussing with JPW 
for L ovariectomy laparascopically.  
Left  
6 Visit Hx of behavioural problems > ovariectomy > 
rectal exam, RO palpably normal 6cmx3cm GCT 
Left  
7 LO 15 cm Diam GCT Left  
8 Large mass consistent with GCT, ovary size of 
grapefruit, RO CL and 45mm follicles 
Left  
9 Multilowlated (Multiloculated) Granulosa, mounting 
other mares in field 3 weeks LO very large  
Left  
 
 
10 Stallion like behaviour last 4 mo large granulosa cell 
tumour LO 
 
Left  
11 R O granulosa cell T Multi loculated ovary orange 
size 11ml regulate SID 10 D then re assess behaviour 
 
Right 
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Table 3-6: Potential GCT cases identified by text mining that were, upon detailed 
examination deemed to be false positives.   
No. of not true 
cases 
Why not true? 
3 Possible GCT 
5 Suspect GCT 
2 Likely GCT 
1 To rule out GCT 
3 Blood taken for inhibin Test for GCT 
5 Question mark (?) for GCT 
7 No evidence of GCT 
2 No sign of GCT 
2 No GCT seen on scan 
2 Haemorrhagic follicle or GCT 
1 Appearance GCT 
1 Owner concern about GCT 
1 Results do not support GCT 
1 If GCT owner will not go for surgery 
1 Discussed GCT 
1 Highly suggestive of GCT 
25 Eosinophilic Granulomas 
17 Granulomatous 
1 GCT232 
1 Connective tissue tumors 
1 Sarcoid tumours 
2 Multiple tumours prop. Melanomas 
1 No clear tumors 
1 Round tumours 
2 Eye tumours 
1 Tumours under jaw 
1 Tumors increase in size 
1 No sign of tumours 
1 Gluteal tumours 
1 Detect tumours 
1 Anal tumours 
1 Nostril tumours 
1 Spindle cell tumors, fibrosarcoma  
2 Equine mast cell tumors on horse neck 
Total = 99  
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3.3.3 Sensitivity and specificity  
The sensitivity of the text mining process to identify cases of ovarian pathology 
was 100% (65/65) and the specificity to correctly identify truly negative cases of 
ovarian pathology (i.e. unaffected horses) was 99.7% (25,876/25,954) – see Table 
3-7. 
Table 3-7: Sensitivity and specificity of the ovarian pathology dictionary  
Word stat/Test True status Total cases no. 
+ ve ovarian 
pathology 
- ve ovarian 
pathology 
Word stat as +ve 65 78 143 
A Test – ve  0 25876 25876 
 65 25954 26019 
 
With 65 confirmed cases of ovarian pathology amongst 26,019 female horses, the 
prevalence estimate for definite cases of ovarian pathology was 0.25% (95% 
confidence interval = 0.20% - 0.32%). 
The sensitivity of the text mining process to identify cases of GCT was 100% 
(11/11) and the specificity to correctly identify truly negative cases of GCT (i.e. 
unaffected horses) was 99.6% (25,904/26,008) – see Table 3-8. 
Table 3-8: Contingency table of GCT text mining. 
Word stat True status upon detailed examination Total 
+ ve GCT - ve GCT 
+ve 11 104 115 
– ve  0 25,904 25,904 
 11 26,008 26,019 
 
With 11 confirmed cases of GCT (Table 3-5) amongst 26,019 female horses, the 
prevalence estimate for definite cases of GCT was 0.04% (95% confidence 
interval = 0.02% - 0.08%). If the 15 ‘possible and suspect’ cases of GCT 
(highlighted in bold in Table 3-6) were also included the prevalence estimate 
would have increased to 0.1% (95% confidence interval = 0.07% to 0.15%).
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3.3.4 Risk factors for ovarian pathology and GCT 
Table 3-9 Univariable logistic regression analysis for ovarian pathology 
 
 
 
 
 
 
 
 
 
 
 
Variables – type of clinical 
examination 
P- Value Cases (n= 65) 
Control 
(n = 195) 
Odds 
Ratio 
95% CI 
Orthopaedics ˂ 0.001 29 (44.62%) 150 (76.92%) 0.24 (0.13, 0.44) 
Anti-inflammatory ˂ 0.001 25 (38.46%) 120 (61.54%) 0.39 (0.22, 0.69) 
Antibiotics 0.003 14 (21.54%) 81 (41.54%) 0.39 (0.20, 0.74) 
Sedation 0.003 15 (23.08%) 84 (43.08%) 0.40 (0.21, 0.75) 
Respiration 0.006 6 (9.23%) 47 (24.10%) 0.32 (0.13, 0.79) 
Dressing 0.010 4 (6.15%) 36 (18.46%) 0.29 (0.10, 0.85) 
Digestive disease 0.093 17 (26.15%) 73 (37.44%) 0.59 (0.32, 1.10) 
Vaccination 0.14 20 (30.77%) 80 (41.03%) 0.64 (0.35, 1.16) 
Internal/Ext parasite, 
Deworming, Fungicides 
0.175 4 (6.15%) 23 (11.79%) 0.49 (0.16, 1.47) 
Behaviour 0.183 3 (4.62%) 3 (1.54%) 3.10 (0.61, 15.74) 
Eye Treatment 0.188 6 (9.23%) 9 (4.62%) 2.10 (0.72, 6.15) 
Antiviral 0.279 2 (3.08%) 2 (1.03%) 3.06 (0.42, 22.20) 
Reproductive clinical record 0.339 12 (18.46%) 47 (24.10%) 0.71 (0.35, 1.45) 
Physiotherapy 0.457 2 (3.08%) 3 (1.54%) 2.03 (0.33, 12.43) 
Dietary supplement 0.539 3 (4.62%) 13 (6.67%) 0.68 (0.19, 2.45) 
Hormonal 0.560 5 (7.69%) 11 (5.64%) 1.39 (0.46, 4.17) 
Age 
0.59 
Mean=14.47 
Median=14.80 
Mean=13.73 
Median=12.20 
1.01 (0.97, 1.05) 
 
 
In the univariable analysis for ovarian pathology, six separate categories of 
clinical record (as indicated by a bold p-value) prior to the case date were 
associated with a reduced likelihood of the horse being ultimately diagnosed 
with ovarian pathology Table 3-9. 
Table 3-10: Multivariable logistic regression analysis for ovarian pathology 
Variables P- Value Cases (n= 
65) 
Control 
(n = 195) 
Odds 
Ratio 
95% CI 
Orthopedics ˂ 0.001 29 (44.62%) 150 (76.92%) 0.22 (0.12, 0.41) 
Respiration 0.005 6 (9.23%) 47 (24.10%) 0.29 (0.11, 0.75) 
Eye Treatment 0.030 6 (9.23%) 9 (4.62%) 3.83 (1.19, 12.28) 
 
In the final multivariable analysis for ovarian pathology two types of prior 
clinical record were associated with a reduced likelihood of ovarian pathology 
(previous orthopaedic or respiratory examination) and one type of record 
(previous record of eye treatment) was associated with an increased likelihood 
of ovarian pathology Table 3-10. 
Table 3-11: Univariable logistic regression analysis for GCT 
Variables P- 
Value 
Cases (n= 11) 
Control 
(n = 33) 
Odds 
Ratio 
95% CI 
Reproduction ˂ 
0.001 
9 (81.82%) 7 (21.21%) 16.71 (2.92, 95.68) 
Sedation  0.004 3 (27.27%) 25 (75.76%) 0.12 (0.02, 0.56) 
Physiotherapy 
0.026 3 (27.27%) 1 (3.03%) 12.00 
(1.097,131.2
4) 
Digestive 
disease 
0.045 4 (36.36%) 3 (9.09%) 5.71 (1.03, 31.53) 
Age 
0.064 
Mean=8.16 
Median=8.05 
Mean=13.15 
Median=11.60 
0.88 (0.75, 1.03) 
Antibiotics 0.153 5 (45.45%) 23 (69.70%) 0.36 (0.09, 1.47) 
Orthopedics 0.256 8 (72.73%) 29 (87.88%) 0.37 (0.07, 1.99) 
Antiviral 0.436 1 (9.09%) 1 (3.03%) 3.20 (0.18, 55.95) 
Anti-
inflammatory 
0.443 7 (63.64%) 25 (75.76%) 0.56 (0.13, 2.42) 
Dressing 0.577 3 (27.27%) 12 (36.36%) 0.66 (0.14, 2.95) 
Vaccination 0.596 4 (36.36%) 15 (45.45%) 0.68 (0.17, 2.80) 
Internal/Ext 
parasite, 
Deworming, 
Fungicides 
0.672 2 (18.18%) 8 (24.24%) 0.694 (0.12, 3.90) 
Dietary 
supplement 
0.737 1 (9.09%) 2 (6.06%) 1.55 (0.13, 18.95) 
Respiration 0.828 2 (18.18%) 7 (21.21%) 0.82 (0.14, 4.72) 
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In the univariable analysis for GCT, four separate categories of clinical record (as 
indicated by a bold p-value) prior to the case date were associated with the 
likelihood of the horse being ultimately diagnosed with GCT Table 3-11. 
Table 3-12 Multivariable logistic regression analysis for GCT 
Variables 
P- Value 
Cases (n= 
11) 
Control 
(n = 33) 
Odds 
Ratio 
95% CI 
Reproduction ˂ 0.001 9 (81.82%) 7 (21.21%) 18.37 (2.55, 132.26) 
Sedation 0.012 3 (27.27%) 25 (75.76%) 0.11 (0.01, 0.72) 
 
In the final multivariable analysis for GCT two types of prior clinical records 
were associated with the likelihood of GCT. Having had a previous reproductive 
examination was associated with an 18-fold increase in the likelihood of 
subsequently being diagnosed with GCT. In contrast horses that had a previous 
record of sedation were associated with a reduced likelihood of subsequent GCT 
Table 3-12. 
3.4 Discussion 
A retrospective analysis of equine ovarian pathology in particular ovarian GCT 
and health records of horses collected from seven equine practices distributed 
all over United Kingdom was executed. An analysis of the content of the free 
text records was conducted to ascertain the prevalence of equine ovarian 
pathology and GCT. Most practices had similar numbers of records per horse 
apart from practice number ‘7’ which had significantly more records per horse, 
despite of low number horses compared, with the average of the other 
practices. This practice is located in a remote, rural part of the UK, where the 
density of horses is likely to be low, as is the number of equine veterinary 
practices. It may be that this practice genuinely serves the majority of horses in 
the area and that, due to the relative lack of competition from other equine 
practices, has a more ‘loyal’ client base, demonstrated as significantly more 
visits per horse than the other practices. It is also possible that the type of horse 
and/or horse owner in this area is different. A greater number of visits per horse 
would result if horse owners in the area keep their horses for longer (maybe due 
to the lack of opportunity, market or need to sell).  
This study determined that content mining recovered ovarian pathology and 
ovarian GCT cases from electronic veterinary medical records with high 
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sensitivity and specificity (100%, 99.7% & 100%, 99.6%, respectively). From these 
analyses it is clear that, in the population of female horses represented by these 
records, both ovarian pathology and GCT are rare. No previous estimates of the 
prevalence of either ovarian pathology or GCT have been identified in the 
literature. Anecdotal reports, and clinical experience, would suggest that these 
conditions are indeed rare, but it is possible that due to the nature of the data 
recorded these estimates are underestimates of the true population prevalence. 
Teratoma and dysgerminoma were not encountered in this study and the wider 
literature also indicates that their occurrences are very rare compared to other 
domestic animals (Catone et al., 2004, da Encarnacao Fiala et al., 2011, 
Lefebvre et al., 2005, Gehlen et al., 2006, Chandra et al., 1998, McLennan and 
Kelly, 1977, Vanhaesebrouck et al., 2010).  
Logistic regression analysis was performed to attempt to identify routinely 
recorded clinical features of horses that may be used to predict likely future 
development of ovarian pathology or GCT. For the analysis of ovarian pathology 
the clear finding is that previous orthopaedic or respiratory examinations were 
associated with a reduced likelihood of subsequent ovarian pathology. It is highly 
unlikely that these findings represent any true protective effect of these two 
types of clinical examination. The reason for these findings most likely lies with 
the way the control population were selected at random and the fact that these 
two particular types of examination are very common. So it would appear that 
this analysis simply identified, in the control population, two common types of 
veterinary examination that may be less common in horses that are susceptible 
to ovarian pathology. The reasons for the positive association between previous 
eye treatment and subsequent ovarian pathology are equally difficult to 
understand. The final multivariable model of ovarian pathology suggested that 
previous eye treatment was associated with a 3.8 fold greater risk of ovarian 
pathology. Without any clear aetiological reason or pathway for this association 
this is most likely to be a chance finding. Indeed with only six cases and nine 
controls having had a previous eye treatment this is the most likely explanation 
of this finding.  
With respect to the logistic regression analysis for GCT a similar finding was 
identified (as with respiratory and orthopaedic examination for ovarian 
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pathology) for sedation. However, in this analysis it was clear that previous 
reproductive examination, as one might expect, was very strongly associated 
with subsequent GCT. Four of the cases of GCT that had previous reproductive 
examinations had those examinations on the day that GCT was confirmed, 
clearly indicating a suspicion of GCT on that day. The other five cases had initial 
reproductive examinations between 12 and 108 days before the diagnosis of GCT 
was confirmed. Six out of nine GCT cases that also had a previous reproductive 
examination showed behavioural changes such as mounting other mares, stallion 
like behaviour and most developed these behaviours between three and four 
weeks prior detecting GCT. In all six cases regumate treatment did not alleviate 
their behaviour problems. In addition, two cases had GCT diagnosed around 
foaling or while in-foal: One mare was diagnosed with a GCT post foaling and 
one had a twin on day 40 then aborted on day 90 the same day that GCT was 
confirmed. It is likely that for some of these the prior reproductive examinations 
may have been totally unrelated to any suspicion or clinical signs of GCT. 
However, without greater detail included within the clinical records it is not 
possible to confirm this.  
The mares’ age when the GCT was confirmed in all eleven positive cases ranged 
from 2.4 to 14.9 years. This findings concurred with previous literature which 
reported a variation in age of GCT occurrence that ranged from 2-20 years 
(Watson, 1994). 
Content mining software, that utilizes a phonetic methodology, requires the 
researcher to have a background understanding of the area of investigation, text 
meaning and importance of the words and phrases contained within the data 
(Raja et al., 2008). One of the considerable obstacles as identified by Lam et al. 
(2007) was preparing terminology that can be recognized and common to all 
technicians and users. The recorded veterinary electronic information used in 
these analyses was not initially collected for research purposes, but rather for 
clinical and charging reasons, as with other similar studies (Mattin et al., 2015). 
An unknown number of cases will have been misclassified because of the 
phonetic divergence among veterinary practice data entries as well as missing 
information. In the particular case of CGT, some cases may have irregular 
oestrus cycles and stallion like behaviour but may have no GCT appearance or 
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any follicular activity on ultrasound examination. Additionally, on occasion, 
clinical notes indicated the suspicion of GCT and that a ‘hormonal test for GCT 
confirmation was taken’ but there were no further clinical details, at a later 
date confirming or not a GCT. In cases such as this it is impossible to state if the 
horse ended up with a GCT or not.  
3.5 Conclusion 
Even with the clear limitations, outlined above, related to the use of clinical 
data for research purposes, it is possible to estimate the prevalence (with 
confidence intervals) of different conditions and also identify clinical factors 
that may be used to predict future more serious veterinary problems. However, 
in this particular case the retrieved data did not provide any clear predictive 
factors that could reliably be related to future GCT occurrence.  
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Chapter 4 Morphometric analysis of the 
granulosa and theca layer of equine antral 
follicles 
4.1 Introduction 
Months of the year with shorter day length have an impact on the number and 
diameter of the follicles by suppressing the follicular activity in mares 
(anovulatory season). For the months in which day light is increasing (during the 
transitional period) the number and diameter of follicles increases until the 
ovulation occurs (ovulatory season)(Ginther, 1990). During this transition period 
there are consecutively growing and regressing follicles. During the mid-
anovulatory period the maximum diameter of the largest follicle is from 17.8 - 
20.8 mm while the largest follicle in transitional period ranges from 22.4 to 30 
mm (Donadeu and Ginther, 2002). The initiation of follicular development is an 
indication of beginning of the spring transitional period that might last from 30 
to 90 days with the size of dominant follicle ranging from 20 mm to 30mm 
(Aurich, 2011). 
The length of the mare’s oestrous cycle in the breeding season is 21 days 
although it can range from 18-24 days and the length of dioestrus is from 14-15 
days (Raz and Aharonson-Raz, 2012). The actual length of oestrus consists of 4-7 
days of the cycle although this is affected by season, sometimes ranging from 7-
12 days at the beginning and at the end of the reproductive season while in 
summer it may last just from 3-4 days (Raz and Aharonson-Raz, 2012). However, 
in ponies it has been reported that this period might be extended by two days 
(Aurich, 2011). The mean (SD) ovarian diameter during early oestrus and late 
oestrus has been reported as 51.2mm (±8mm) and 65.0mm (±10mm), 
respectively and the mean (SD) number of antral follicles during early oestrus 
and late oestrus reported as 12 (±2) and 2 (±1), respectively. The mean (SD) 
diameter of the largest follicle during early oestrus and late oestrus has been 
reported as 20.0mm (±2mm) and 46.0mm (±4mm), respectively, and the mean 
(SD) ovarian diameter during early dioestrus and late dioestrus has been 
reported as 45.0mm (±25mm) and 40.0mm (±10mm), respectively). The mean 
(SD) number of antral follicles during early dioestrus and late dioestrus is 6 (±1) 
105 
 
and 11 (±4), respectively and mean (SD) diameter of the largest follicle during 
early dioestrus and late dioestrus has been reported as 12.5mm (±2mm) and 
23.7mm (±3.7mm), respectively (Smok S and Rojas R, 2010).  
During the 24 day oestrous cycle of pony mares, there is normally one major 
follicular wave (Gastal et al., 1999a). The largest follicles during this wave reach 
approximately 23 mm in diameter after growing from an emergent 6mm follicle. 
The largest follicle will continue growing to become a preovulatory follicle with 
a diameter of about 30 mm while the remainder (subordinate follicles) will 
follow an atretic pathway. Detection of largest follicles (> 20 mm in diameter) in 
the pony are generally not recorded until the middle of March (in the Northern 
Hemisphere) or approximately 60 days prior to the ovulatory season (Donadeu 
and Ginther, 2002).  
Mares have two waves of follicular activity waves during an oestrous cycle 
(anovulatory wave and ovulatory wave). The first follicular development wave 
takes place during diestrus and several follicles become atretic. The second 
wave occurs after luteolysis and is associated with oestrus in which the dominant 
follicle becomes the ovulatory follicle (Ginther, 1990). The majority of mares 
ovulate when the size of the follicle reaches 40- 45 mm in diameter (Ginther et 
al., 2007). During each cycle mares exhibit one or two follicular waves. Major 
waves produce dominant and subordinate follicles and minor waves have a large 
follicle, which does not reach the same diameter as a dominant follicle (Raz and 
Aharonson-Raz, 2012). The second wave is the origin of the ovulatory follicle and 
the growing follicles (15 mm in diameter) continue to grow until one ovulates 
and the others undergo atresia (Sirois et al., 1989). According to Ginther et al. 
(2003) the emergence of the largest follicle occurs when it reaches 6-13 mm in 
diameter.  
Developing follicles are surrounded by the ovarian stroma (fibroblast like cell 
tissue) and these particular cells become theca interna cells either in developing 
follicles or in interstitial cells. During any phase of follicular development most 
follicles become either atretic or undergo an involution. The large extension of 
the granulosa cell layer has an impact on the development of preovulatory 
follicle (Aurich, 2011). Luteal cells in mares originate from the granulosa cells of 
the preovulatory follicle, which is different from other species where luteal cells 
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are formed from thecal cells (Aurich, 2011). In the mare a single follicle is 
selected from the cohort of follicles to be a dominant follicle (Gerard et al., 
1998). This largest follicle suppresses FSH which is a requirement of small 
follicles, resulting in their regression (Danica Marković1, 2003). Thus, the 
majority of follicles will become atretic after one follicle has been ‘selected’ to 
be dominant (Sessions et al., 2009). In addition, subcategories of follicles that 
are unable to ovulate or become atretic become persistent anovulatory follicles. 
Preovulatory and transitional follicles differ in their wall colour (Watson and Ai-
zi'abi, 2002). For instance, the preovulatory follicles have an orange to red 
colour whereas the transitional follicles have a yellowish to pale pink colour. 
However, histologically there were no differences between transitional 
anovulatory and preovulatory follicles in terms of granulosa cell arrangement 
above the basement membrane or granulomas cell thickness. These granulosa 
cells were distributed randomly in the upper layers of both follicles with an 
infrequent appearance of mitotic nuclei and pyknotic nuclei. Preovulatory 
follicles contain a thick layer of pulp polyhedral cells with a pale cytoplasm and 
nucleus, whereas the anovulatory follicles have a thin and poorly developed 
theca. In addition, the majority of theca cells maintain a fibroblast type 
morphology with a spindle-shaped darkly staining nucleus. The follicular fluid 
content and the external granulosa layer thickness varied between small antral 
follicles (up to 25 mm) and large antral follicles (> 30 mm). The external layer of 
the larger antral follicles is thin (24±2 mm) and has an aqueous follicular fluid, 
whereas the smaller antral follicles have a jelly like fluid and a thick external 
layer (40±7mm) that consists of six or seven follicular cell layers (Smok S and 
Rojas R, 2010).  
The granulosa cells in follicles and the follicle wall are similar to those of the 
theca interna in terms of having a huge amount of oesinophilic cytoplasm, being 
luteinised, rarely apoptosed and with multiple mitosis. However, there are 
differences in vacuolation, shape and location (Mueller et al., 2009). For 
example, the granulosa cells are partially vacuolated, the cell borders are 
distinctive and have a columnar palisade arrangement, whereas the theca 
interna cells are highly vacuolated and have large round bulbous hyperchromatic 
nuclei that include one or two nucleoli. The theca externa cells are arranged 
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partially in a circle, slightly irregular and are plump in shape. The antral follicles 
have no haemorrhage or blood component. The vascular structures are fully 
developed especially the theca interna, which is dilated distinctively and 
hyperaemic. The basement membrane in a preovulatory follicle separates the 
avascular granulosa and theca interna layers. This theca interna consists of 
glandular cell layers that contain a rich capillary plexus. Moreover, the theca 
externa is composed of a fibrous layer including arterioles and venules (Gastal et 
al., 2006). Kenney et al. (1979), Driancourt et al. (1982) categorised theca 
interna layers into three types: smooth theca, mixed theca (composed of smooth 
layers with islands of large luteal like cells), and hypertrophied theca (which 
contains a thick layer of luteal like cells).  
(Rodgers et al., 2001), reported that the membrane of granulosa cells in the 
bovine is not stable but starts with a single layer that then proliferates into 
several layers as it maturates laterally during follicle development. This 
maturation ends during follicular atresia. In addition, this membrane of 
granulosa cells differs from one area to another and is situated on a basal 
lamina. This differentiation of cells is based on their shape, age and biochemical 
properties as well as the manner of death in atresia. The follicular epithelium 
during degeneration at the atretic phase sloughs toward the antrum and appears 
as a cuboidal layer or flattened lining cells (Oshea, 1968). Apoptosis of the 
ovarian granulosa cells play an essential part in follicular atresia (Peter and 
Dhanasekaran, 2003, Ginther et al., 2007). The regression follicles were 
classified into four groups (Atresia- 0, 1, 2, & 3) based on apoptosis (fragmented 
nuclei) in a study conducted by Pederson et al (2003) as presented on Table 4-1. 
Table 4-1: Classification of atretic follicle (Follicle regression) 
Atresia groups  Classification based on apoptosis 
Atresia 0 Follicle had no sign of Atresia  
Atresia 1 Follicle had apoptotic granulosa cells (GC) and pyknosis with 
an intact remaining thickness of GC and theca cell (THC) 
layers 
Atresia 2 Follicle classified with hyaline membrane appearance 
between GC and THC layer with pyknosis and apoptosis  
Atresia 3 Follicle had GC layer with few pyknosis and apoptosis as well 
as a thick hyaline membrane 
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Occurrence of pyknotic foci and karyorrhexis in the nuclei of granulosa cells is an 
indication of an atretic subordinate follicle (Stage I) and they are classified as 
advanced atretic (Stage II) when pyknosis and karyorrhexis are widely distributed 
(Watson et al., 2002b). In addition, two layers of flattened granulosa cells with a 
thick basement membrane in these follicles can be detected. Kenney et al. 
(1979) also mentioned that the Stage III occurs when the granulosa and theca 
cells separate with only a small amount of connective tissue remaining with the 
thick basal membrane. Furthermore, in Stage II and Stage III the detection of 
capillaries within the theca interna layer is difficult. Kenney and co-authors 
reported that in atretic follicles the oestradiol concentration is very low 
compared to viable follicles (between 600-900 ng/ml) as follows: (stage I - 1150 
ng/ml, stage II - 302 ng/ml, stage III - 15 ng/ml).  
Oestradiol FF concentrations have already been described (Watson and Ai-zi'abi, 
2002). The concentration in preovulatory follicles was higher than the 
concentration in transitional follicle (1063±169.2 ng/ml and 345±112.3 ng/ml, 
respectively). During the breeding season the concentration of E2 was higher in 
dominant follicles than in those aspirated during transition (Watson et al., 
2002b). One day prior to deviation or selection the amount of E2 gradually 
increases and remains raised for one or two days prior to ovulation. The E2 
concentration in the follicular fluid of the healthy mare has been found to be 
high, in the region of 300 to more than 5000 ng/ml (Forst et al., 2003, Bailey et 
al., 2002, Meinecke and Gips, 1987, Peter and Dhanasekaran, 2003, Gastal et al., 
1999b).  
4.1.1 Aim: 
To categorise the ovarian follicular wall specifically the GC and THC 
compartments by measuring their thickness and describing their cellular pattern 
using histology and to examine relationships with follicle health markers 
(intrafollicular steroid hormone concentration and follicle size) and mare 
characteristics (age, reproductive state and disease status). 
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4.1.2 Objectives: 
1. To categorise the follicle walls (FW) into four groups based on histological 
criteria: Very healthy (VH), Healthy (H), Early atretic (EA) and Late atretic 
(LA). 
2. To count and compare between the four groups the three layers of GC: basal, 
intermediate and antral, and the two types of THC: large THC and small THC 
3. To measure the thickness of the GC and THC layers 
4. To determine the E2 hormone concentration in the follicular fluid of the four 
histologically classified categories. 
5. To determine any associations between follicular factors (such as the follicle 
health categories or intrafollicular estradiol) and mare factors (such as 
season of ovary collection, breed type, age or disease status) with GC and 
THC measurements. 
4.2 Materials and Methods 
4.2.1 Animals and tissue samples 
Follicle wall samples were recovered from a total of 63 follicles collected from 
19 mares between August 2014 and May 2016. Mares differed in breed, health 
status, age, season of the year (therefore breeding season), and stages of the 
oestrous cycle when the ovaries were collected. All experimental procedures 
were approved by the University of Glasgow, School of Veterinary Medicine 
Research Ethics Committee (Ref 41a/16). Where required client consent was 
sought. The ovaries were collected from 14 mares after euthanasia, and from 
five mares after surgical ovariectomy carried out at the School of Veterinary 
Medicine, University of Glasgow. A summary of the mare details is presented 
below in Table 4-2. 
The ovaries were each placed in a plastic laboratory bag filled with chilled 0.05M 
Phosphate buffered saline (PBS), and briefly transported on ice or within an 
icebox to the laboratories for measuring and processing. 
Measurements and ovarian maps: ruler and ultrasound procedures. Ovaries 
were ultrasound scanned using a linear 7.5MHz transducer, applied to each ovary 
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scanning from lateral to medial or vice versa to detect all follicles and corpora 
lutea on each ovary. Using the ovulation fossa in the middle of the ovary as a 
landmark the ovary was placed in a petri dish and measured as shown in Figure 
4-1. The diameter of each palpated follicle was measured from the external 
surface using a metal ruler by taking an average width and height in mm.
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Table 4-2: Mares used in this experiment 
Mares ID 
Date of 
ovary 
collection Horse/pony Age  Disease  
Unknown 14.08.14  Unknown   Unknown  Behavioural problem during oestrus, On regumate 
NKR 008 06.08.14 Belgian Warm blood 18 years old Chronic lameness in left forelimb 
NKR 010 21.08.14 Appaloosa pony "Dotty" 7-9 years old  Increasing lameness in front (reason for PTS) 
NKR016 10.10.14 Very small pony 5 years old Secondary parathyroidism nutritional  
NKR18  11.11.14 Sport horse = TB 5 years old PTS because of multiple limb lameness 
NKR 020  28.11.14 TB X   9 years old Deteriorating multi-limb lameness 
NkR021 01.12.14 Chestnut, Welsh A mare 12 years old PPID, Laminitis, COPD (PTS) 
NKR 023 22.12.14 Highland pony  12 years old Chronic lameness =PTS, Had focal ulcers along GIT (PM finding) 
NKR 025 09.02.15 Welsh mountain 1.5 years old Unknown  
NKR 027  11.02.15 Welsh mountain 1.5 years old Unknown  
NKR 029  13.02.15 Welsh mountain 1.5 years old  Unknown  
NKR 034 18.02.15 Welsh mountain 1.5 years old Unknown  
NKR 036 06.03.15 TB X 20 years old  LH lame, Laminitis, Mammary gland mass 
NKR 046  05.06.15 TB 7 years old RDA horse with a chronic forelimb lameness 
Violet  29.10.15 WB 7 year old 
Abnormal behaviour. Stallion like behaviour. Regumate treatment. 
Ovariectomy   
Squiggy 27.04.16 Sport horse 9 years old 
Behavioural issues. Squamous and glandular gastric ulceration. 
Ovariectomy 
Maggie  01.04.16 Connemara X pony  10 year old Behavioural problem. Not responded to regumate. Ovariectomy 
Molly   02.04.16 Connemara x pony 10 years old Masculine behaviour, ovariectomy due to Owner request  
Nia  19.05.16 Mare 11 years old 
Behavioural issue. Responded well to regumate but not cycling 
well. Ovariectomy 
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4.2.2 Follicle processing 
Based on the ovarian map and also manual palpation of the ovaries to locate and 
distinguish large follicles, the largest follicle(s) (ranging from one to two per 
mare) present were aspirated and their follicle walls dissected for histological 
processing. Follicular fluid (FF) was collected slowly without causing turbulence 
using 5- and 10- ml syringes and 20 G 1.5" needles, by puncturing the follicle 
wall through the stroma at the laboratory bench. Fluid from each follicle was 
stored in 15ml tubes and maintained at -20 °C until hormone (oestradiol) assay. 
The follicle was penetrated with an incision by Westcott curved blunt tenotomy 
scissors to visualize the follicular cavity. A blunt dissection of the follicle wall 
followed whereby the wall was peeled off carefully and then placed in a sterile 
petri dish filled with PBS for further processing as shown in Figure 4-2. 
The oestradiol (E2) hormone assay was carried out using an ELISA kit (R&D 
system® a biotechne® brand, Catalogue number KGE014) per manufacturer’s 
instructions, which have also been described in detail in chapter 2. The intra 
assay coefficient of variation (CV) for a Low QC (65/ml), Medium QC (436 ng/ml) 
and High QC (1089 ng/ml) were 7%, 6% and 11% respectively. The inter-assay CV 
for the three QCs were 25%, 14% and 16%, respectively.  
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Figure 4-1: Measuring the diameter of the ovary 
 
 
Figure 4-2: Blunt dissection of the follicle showing the follicular cavity after fluid aspiration 
  
114 
 
Three rectangular pieces of each dissected follicular wall were prepared. After 
all follicles were sampled, the ovary was hemisected sagitally through the 
ovulation fossa, and a cube of ovarian stroma was dissected from the two inside 
surfaces bordering the ovulation fossa as shown in Figure 4-3. The first collected 
samples were fixed in Bouins solution Fixative (VWR Chemicals, VWR 
International, 7000.1000) for 24-72 hours, washed twice in 70% ethanol at 48h 
intervals, and stored in 70% until histological processing, and some later 
collected samples were fixed in 10% neutral buffer formaldehyde as this was 
recommended by the histopathologists. 
 
Figure 4-3: Cube section of the stroma close to ovulation fossa. 
4.2.3 Histology of the follicular wall 
The follicular walls (FW) were cut in small rectangular pieces of tissue and 
carefully placed onto the embedding cassettes in order to obtain a cross-section 
view of the layers of granulosa cell (GC), theca cell (THC) and the underlying 
stroma without any of the layers sloughing during histological processing. Follicle 
walls were embedded in wax in the Diagnostic Laboratories of the School of 
Veterinary Medicine, using their Thermo Scientific, Histostar machine, then 
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sectioned at 2µm thickness using a Thermo Scientific, FINESSE ME+ microtome 
machine, and stained with haematoxylin and eosin prepared by the Veterinary 
Diagnostic Services laboratory, University of Glasgow, as per standard protocol 
(described in Chapter 2).  
4.2.4 Histological assessment of follicle health status and 
morphometric measurements 
In this study we aimed to categorise the follicle walls into Very Healthy growing 
(VH), Healthy and highly differentiated (H), Early Atretic with beginning 
disruption of the GC and THC compartments (EA), and Late Atretic with no 
functional GC layer (LA) based on published histological criteria particularly 
relating to dominant follicles and follicle apoptosis. The morphometric 
measurements were then taken to a) establish a database for GC and THC 
compartments in developing antral follicles, and b) to see whether our 
subjective evaluation was supported by differences in objective measurements 
taken. 
The granulosa and theca cell layers in each follicle wall section, were 
quantitatively assessed using a Leica DM4000B microscope (Leica Microsystem, 
Switzerland) connected to a Leica Application Suite software (version 4.3.0; 
Leica Microsystems, Switzerland) to acquire images, followed by measurements 
using the ImageJ (1.49v, Wayne Rasband, National Institute of Health, USA) 
software. Five consecutive rectangle views were spaced over the whole length of 
the follicle wall capturing both the GC and THC layers (all at 40 x 
magnifications) as shown in Figure 4-4. Each rectangle measured 140.70x255.27 
µm2 as shown in Figure 4-5. The aim was that the follicular tissue was not 
collapsed and laid out level on the histological slide, with no or negligible folds 
in the granulosa layer. 
In each of the five views all GC and THC were counted at x40 magnification as 
shown in Figure 4-6. These cell types were differentiated from each other on the 
basis of cellular morphology. Basal GC were classified as GC that were located at 
the base of the GC layer bordering the basal lamina with nuclei mostly in 
laminar position. Antral GC were classified as GC that were located at the antral 
surface, closest to the fluid-filled antrum of the follicle. Intermediate GC were 
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classified as the GC that were located in between the basal and antral GC. The 
thicknesses of the GC and THC were measured on those five views under 20x 
magnification as shown in Figure 4-7 using a graticule scale measurement as 
described in details in Chapter 2. The thickness of GC layer was measured from 
the antral GC to the basal GC, and the thickness of THC layers was measured 
from the granulosa side of theca interna cells directly beneath the basal GC to 
the discernible border of the theca interna with stroma cells = theca externa. 
The large THC and small THC cells make up the composition of the theca layer. 
The large THC cells exhibit a well-defined cell membrane with large cytoplasm 
similar to large luteal cells, whereas the small THC cells are clearly smaller in 
size with a much reduced cytoplasm: nucleus ratio. The cells that were included 
in the assessment all had distinct nuclei. The entire cell has to be visible for it 
to be counted. Other cells that can be viewed partially on that particular view 
would not be taken into consideration.  
 
Figure 4-4: Illustration of how views are taken from a selected FW sample. This sample is 
taken at 200x magnification, and the boxes are representative of the 5 successive views 
taken for further assessment at 400x magnification 
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Figure 4-5: Rectangle view of a FW image at 200x magnification 
  
GC 
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Figure 4-6: Counting GC and THC at x400 magnification, A: shows Basal GC (no.1 purple 
colours), B: shows Intermediate GC (no.3 green colours), C: shows Antral GC (no2 blue 
colours), D: shows small THC (no.5 yellow colours), E: shows large THC (no.4 pink colours) 
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Figure 4-7: Measuring the thickness of GC (Blue arrows) and THC (Black arrows) at x200 
magnification 
4.2.5 Statistical analysis  
The Null Hypotheses tested using statistical analyses were: 
a) There would be no difference in the thickness of GC and THC layers 
between follicle health categories of (control mare) follicle walls (FW) 
b) There would be no difference in cells counts between follicle health 
categories of FW 
i. between the three layers of GCs: basal, intermediate and antral 
and 
ii. between the two types of THCs: large THC and small THC cells  
c) There would be no difference in the FF E2 concentration of follicles 
belonging to the four histologically classified categories. 
GC 
THC 
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An initial descriptive statistical analysis of the cell numbers in the GC and THC 
layers (basal, intermediate and antral, large THC and small THC), follicle 
diameter and follicular fluid oestradiol (FFE2) concentration in follicles of 
different histological health categories was performed. Non-parametric Mann-
Whitney or Kruskall Wallis tests were then performed after a lack of normality 
was detected (i.e. the distribution of the data demonstrated evidence of a lack 
of normality using the Shapiro-Wilks normality test) and box plots were created 
to identify potential differences in each of the histological measurements 
between each of the four follicle health categories VH, H, EA and LA. The same 
tests were also used to determine any associations with other potential factors, 
such as follicle size (large or small), breeding season (winter, summer, 
transition), breed category (pony or horse), age and disease status of mares 
(none, mild-chronic, severe) which were coded numerically. Follicular diameter 
and FFE2 concentration were treated as continuous variables. 
4.3 Results  
4.3.1 Gross findings 
The wall of large fresh follicles appeared relatively smooth and it was possible to 
peel it off easily. In healthy or EA follicles the FW had a reddish appearance due 
to visible blood vessels over its surface, Figure 4-8, whereas this was not present 
in LA follicles. It was also noticed that in some follicles brown fat appeared 
between the theca externa and follicle wall, as shown in Figure 4-9. 
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Figure 4-8:  The peeled FW containing GC and THC layers from an healthy or EA follicle 
which has a reddish appearance because of its high vascularisation and blood vessels 
being visible. 
 
 
Figure 4-9: Fatty brownish appearance between the follicular wall following its dissection and 
the theca externa/stroma. 
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4.3.2 Histological findings 
The follicular walls from 63 follicles were classified into four health categories 
VH (10 follicles), H (11 follicles), EA (10 follicles) and LA (32 follicles) as detailed 
below: A follicle was considered to be very healthy (VH) when the GC layer 
appeared to be of uniform thickness, basal GC were arranged in a palisade with 
a high proportion to the total of GC, slight appearance of or few intermediate 
GC, and the antral GC were lined up in an interrupted palisade arrangement as 
shown in Figure 4-10.  
 
 
Figure 4-10: Very healthy follicular wall category. A (FWD 10.3x11.8 mm measured in two 
dimensions), B (FWD 25x18.8 mm), C (FWD 13.8x13.3 mm), D (FWD 19x17 mm): Examples 
from different follicles 
Furthermore, large THC and small THC appeared within the heterogeneous 
population of theca cells, with approximately 1/3 of THC population being large 
THC. The second category included follicles classified as healthy H based on the 
presence of a slight disarray of basal GC, although the following may also have 
been present: A degree of palisade arrangement was still present, but in some 
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areas it was somewhat difficult to differentiate between basal, intermediate and 
antral GC; a few gaps or vacuolation was visible between the basal GC; and a 
small degree of pyknosis (<5 per view) was present, often seen in intermediate 
and antral GC populations. In addition, the small and large THC cells were still 
part of the heterogeneous THC layer; however, the large THC proportion was 
increased in population as shown in Figure 4-11.  
 
 
Figure 4-11: Healthy follicular wall category. A (FWD 29.6x34.9 mm measured in two 
dimensions), B (FWD 17.7x17.3 mm), C (FWD 25.5x16.6 mm) D (FWD 38.2x31.2 mm): 
Examples from different follicles 
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The third category is the early atresia EA follicle category. In this group the GC 
layer was decreased in thickness; mild sloughing of the antral granulosa cells 
might be present; there seem to be more intermediate GC which together with 
the basal GC appear more disorganised, and cells are overlapping, which led to a 
decrease in the adherence to the THC layer; and the degree of pyknosis was 
increased (> 5 per view) in the GC layer. Moreover, most of the THC were small 
THC, the presence of a vascular supply was evident in the theca interna; and the 
accumulation of an eosinophilic connective tissue substance (a thin amorphous 
membrane) was becoming apparent within the THC layer underlying the 
granulosa, as shown in Figure 4-12. 
 
 
Figure 4-12: Early Atretic FW category. A (FWD 18.2 mm) B (FWD 22.1x20.4 mm measured in 
two dimensions), C (FWD 29.6x29.2 mm) D (FWD 17x18 mm): Examples from different 
follicles 
Late atresia is the fourth category of histologically classified follicles: In this 
group there is a complete absence of GC, so the GC layer has sloughed off, (and 
the THC layer now contained mainly small smooth spindle like cells considered 
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to be small THC with an elongated darkly stained nucleus. Moreover, a distinct, 
thick sub-basal amorphous eosinophilic band is present. In some views sloughing 
of the THC layer below or above this band was seen, and the remaining THC 
layer now shows vasculature loss as seen in Figure 4-13. 
  
Figure 4-13: Late atretic FW category. A (FWD 6.15 mm), B (FWD 13.6 mm) C (FWD 16.35 
mm), D (FWD 40.9 mm): Examples from different follicles 
  
4.3.3 Analysis of the association between the different follicle 
health categories and other parameters 
4.3.3.1 Follicle wall diameter (FWD) 
The analysis of associations of follicle health category or time of year of follicle 
collection (breeding season), age and disease status of mare with follicular size 
is shown in Table 4-3. A tendency towards significance was observed for follicle 
health status (P< 0.06), with healthy and early atretic follicles tending to have 
greater diameters than very healthy or late atretic follicles. There was a 
significant association between FWD and disease category (P < 0.05), with 
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follicles from mares without disease having greater diameters than if collected 
from mares with disease. As one would expect follicle diameter was also very 
strongly associated with our distinction of follicle size (p<0.001).  
Table 4-3: Association between a range of parameters and FWD. VH (very Healthy), H 
(Healthy). EA (Early Atretic), LA (Late Atretic), LF (Large follicles from 20mm), SF (Small 
Follicles < 20mm). Bold indicates a statistically significant p-value. 
Factors   Follicular wall diameter 
(mm) 
Health status P-value No. of follicle  Mean ±SE Mean Median 
VH 0.059 10 18.9±1.8 20.1 
H  11 23.2±1.9 22.3 
EA  10 23.7±1.9 21.1 
LA  32 18.8±1.1 17.6 
F. Size Cat     
LF  <0.001 32 22.2±0.8 23.1 
SF   31 15.4±0.6 16.0 
Breeding season     
Winter 0.893 11 20.1±1.9 18.1 
Summer  32 20.8±1.2 20.8 
Transition  20 19.9±1.4 19.2 
Breed     
Horse 0.424 40 19.8±1.0 18.1 
Pony  20 20.4±1.4 20.8 
Age     
0-2 YO 0.506 13 20.8±0.9 20.8 
2-10 YO  31 20.2±1.3 19.9 
> 10 YO  17 19.1±1.3 17.5 
Disease     
No disease 0.028 35 21.6±0.9 21.0 
Chronic mild  4 12.9±2.9 12.7 
Severe  24 19.8±1.5 17.8 
 
4.3.3.2 Follicular fluid oestradiol (FFE2) concentrations  
There was a significant association between follicle size class and health status 
and FF E2 concentration (P = 0.014, < 0.001, respectively) as presented in Table 
4-4. A Mann Whitney test was used to compare combined the VH and H groups 
versus EA and LA groups (P< 0.001). Large and very healthy or healthy follicles 
had significantly greater E2 concentrations than atretic or small follicles, 
respectively. It is noticeable that fluid from LA follicles still contains some E2 
despite loss of the GC layer (8.7±4.9 ng/ml). Although not statistically significant 
at P<0.05, follicular fluid from ponies tended to have greater oestradiol 
concentration than horses despite similar FWD. There was no association 
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between breeding season and follicular fluid oestradiol concentration indicating 
that the range of follicles recovered particularly in summer or winter contained 
follicles with very different health and functional status.  
Table 4-4: Association between the predictive follicle and mare parameters and FFE2 
concentration. VH (very Healthy), H (Healthy). EA (Early Atretic), LA (Late Atretic), LF (Large 
follicles from 20mm), SF (Small Follicles < 20mm). Bold indicates a statistically significant p-
value.  
Factor   Follicular fluid E2 
Concentration (ng/ml) 
Health status P-value No. of follicle Mean ±SE Mean Median 
VH <0.001 10 210.5±87.8 103.5 
H  11 167.4±41.8 107.8 
EA  5 28.5±14.2 16.0 
LA  20 8.7±4.9 1.2 
F. Size Cat     
LF  0.014 23 151.8±45.5 66.9 
SF   23 33.5±10.4 2.9 
Breeding season     
Winter 0.730 10 128.7±76.2 48.3 
Summer  16 113.1±46.5 42.1 
Transition  20 58.2±21.5 9.5 
Breed     
Horse 0.112 26 55.6±19.6 8.4 
Pony  17 126.8±48.3 66.9 
Age     
0-2 YO 0.962 13 68.4±26.2 49.0 
2-10 YO  16 57.3±20.0 9.5 
> 10 YO  15 120.0±57.9 37.0 
Disease     
No disease 0.172 22 66.5±32.2 5.6 
Chronic mild  4 44.8±21.2 43.0 
Severe  20 131.0±43.7 63.6 
 
4.3.3.3 Granulosa cell layer 
The late atretic category was eliminated from the comparison because it had no 
GC at all. The differences in granulosa cells counts (Basal, Intermediate and 
Antral GC) and thickness, between VH, H and EA follicles are shown in Table 4-5. 
There was a reduction in the absolute number of basal GC in EA follicles 
(27.2±3.3) compared to VH and H follicles (39.2±1.9, 36.5±1.3, respectively, 
P=0.004). This led to a tendency for a higher % of basal GC in VH compared with 
H and EA follicles, and a concomitant tendency for lower % antral GC between 
VH and EA follicles. The reduction in GC thickness on which the EA classification 
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was partly based did not reach significance (EA follicles show a non-significant > 
10µm reduction in thickness when compared to VH follicles). 
Table 4-5: Association between follicle health category and mare factors and basal, 
intermediate and antral GC counts and thickness. VH (very Healthy), H (Healthy). EA (Early 
Atretic), LA (Late Atretic), LF (Large follicles from 20mm), SF (Small Follicles < 20mm). Bold 
indicates a statistically significant p-value. 
Outcomes Factor   GC counts and 
thickness 
Response Health status P-value No. of 
follicle 
Mean ±SE 
Mean 
Median 
Basal GC VH 0.004 10 39.2±1.9 37.3 
 H  11 36.5±1.3 37.6 
 EA  10 27.2±3.3 24.4 
% Basal GC VH 0.142 10 51.6±2.7 51.9 
 H  11 46.2±2.2 44.1 
 EA  10 46.0±5.4 37.0 
Antral GC VH 0.711 10 12.9±1.0 11.6 
 H  11 13.7±0.6 13.8 
 EA  10 18.1±6.6 11.4 
% Antral GC VH 0.122 10 16.4±0.6 16.3 
 H  11 17.1±0.9 16.8 
 EA  10 21.5±2.9 19.8 
Intermediate GC VH 0.730 10 26.0±3.3 24.6 
 H  11 30.4±3.2 29.0 
 EA  10 26.7±5.9 28.8 
% Intermediate GC VH 0.756 10 31.9±2.8 30.9 
 H  11 36.7±2.6 39.5 
 EA  10 32.5±5.3 35.0 
Total GC VH 0.772 10 78.1±4.7 76.6 
 H  11 80.6±3.9 81.0 
 EA  10 72.0±13.1 65.5 
GC Thickness VH 0.160 10 43.4±3.8 44.1 
 H  11 39.4±2.9 39.5 
 EA  10 32.8±6.7 31.5 
 
There is no effect (P>0.05) of follicle size category on all GC measurements as 
presented in Table 4-6. 
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Table 4-6: Association between the follicle size category and GC counts and thickness. VH 
(very Healthy), H (Healthy). EA (Early Atretic), LA (Late Atretic), LF (Large follicles from 
20mm), SF (Small Follicles < 20mm). Bold indicates a statistically significant p-value. 
Outcomes Factor   GC counts and 
thickness 
Response F. Size Cat. P-value No. of 
follicle 
Mean ±SE 
Mean 
Median 
Basal GC LF (1) 0.180 20 32.3±1.9 34.6 
 SF (2)  11 38.2±2.6 36.8 
% Basal GC LF (1) 0.483 20 47.3±2.7 44.0 
 SF (2)  11 48.9±3.4 50.8 
Antral GC LF (1) 0.292 20 12.3±0.9 12.8 
 SF (2)  11 19.5±5.7 13.8 
% Antral GC LF (1) 0.099 20 17.0±0.7 16.3 
 SF (2)  11 20.7±2.6 18.9 
Intermediate GC LF (1) 0.409 20 28.9±3.3 30.9 
 SF (2)  11 25.7±3.4 26.6 
% Intermediate GC LF (1) 0.148 20 35.7±2.8 40.1 
 SF (2)  11 30.4±2.9 29.4 
Total GCs LF (1) 0.804 20 73.5±5.4 79.7 
 SF (2)  11 83.5±8.5 69.6 
GC Thickness LF (1) 0.680 20 36.4±3.1 39.2 
 SF (2)  11 42.4±5.3 36.5 
 
The breeding season or time of year of follicle collection showed a significant 
association with the percentage of basal and intermediate GC: transitional 
follicles had less %basal GC but more intermediate and % intermediate GC and 
more total GC when compared to winter but particularly summer follicles, which 
led to a non-significant increase in GC thickness. This is illustrated in Table 4-7.  
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Table 4-7: Association between the breeding season and GC counts and thickness. VH (very 
Healthy), H (Healthy). EA (Early Atretic), LA (Late Atretic), LF (Large follicles from 20mm), SF 
(Small Follicles <20mm). Bold indicates a statistically significant p-value. 
Outcomes Factor   GC counts and thickness 
Response Breeding 
season 
P-value No. of 
follicle 
Mean ±SE 
Mean 
Median 
Basal GC Winter 0.670 7 35.3±2.1 35.0 
 Summer  12 32.0±3.4 34.0 
 Transition  12 36.2±2.0 35.4 
% Basal GC Winter 0.025 7 50.3±4.3 51.6 
 Summer  12 53.4±3.6 52.6 
 Transition  12 40.9±2.0 38.9 
Antral GC Winter 0.224 7 12.0±0.7 12.0 
 Summer  12 11.8±1.3 11.7 
 Transition  12 19.6±5.2 15.0 
% Antral GC Winter 0.264 7 16.8±0.7 16.5 
 Summer  12 18.4±0.8 18.8 
 Transition  12 19.2±2.6 16.1 
Intermediate GC Winter 0.006 7 24.7±4.6 20.8 
 Summer  12 20.0±3.3 20.7 
 Transition  12 37.4±3.1 39.8 
% Intermediate GC Winter 0.034 7 32.9±4.5 32.4 
 Summer  12 28.2±3.4 28.9 
 Transition  12 39.9±2.6 42.9 
Total GC Winter 0.012 7 72.0±4.8 66.8 
 Summer  12 63.8±7.3 67.9 
 Transition  12 93.2±6.8 96.0 
GC Thickness Winter 0.160 7 34.5±2.4 34.6 
 Summer  12 31.5±4.0 35.6 
 Transition  12 47.9±4.6 47.2 
 
Ponies tended to have a lower % antral GC with a higher %intermediate GC, 
which was confirmed using a Mann Whitney test, and is presented in Table 4-8. 
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Table 4-8: Association between the breed category and GC counts and thickness. VH (very 
Healthy), H (Healthy). EA (Early Atretic), LA (Late Atretic), LF (Large follicles from 20mm), SF 
(Small Follicles < 20mm). Bold indicates a statistically significant p-value. 
Outcomes Factor   GC counts and thickness 
Response Breed P-value No Mean ±SE Mean Median 
Basal GC Horse  0.443 15 35.3±1.9 35.0 
 Pony   15 32.8±2.6 34.4 
% Basal GC Horse  0.494 15 48.5±2.6 50.5 
 Pony   15 46.9±3.5 44.0 
Antral GC Horse  0.901 15 16.9±4.3 12.2 
 Pony   15 12.8±1.2 13.0 
% Antral GC Horse  0.120 15 19.8±1.9 18.4 
 Pony   15 16.8±0.9 16.0 
Intermediate GC Horse  0.078 15 24.2±2.4 25.0 
 Pony   15 31.6±4.3 37.4 
% Intermediate GC Horse  0.120 15 31.7±2.5 29.6 
 Pony   15 36.3±3.5 41.9 
Total GC Horse  0.254 15 76.5±6.4 69.0 
 Pony   15 77.2±7.2 89.6 
GC Thickness Horse  0.885 15 40.2±4.1 38.1 
 Pony   15 36.7±3.9 38.9 
 
Prepubertal mares had a lower % basal GC, tended to have more antral GC, and 
had more intermediate GC numbers and percentage, as well as more total GC, 
when compared to the 2 to 10 year and older categories in Table 4-9. 
Specifically, Mann Whitney analysis showed significantly higher intermediate GC 
numbers (P < 0.005) between prepubertal aged mares (0-2 years old) and adult 
(>2-10 year old) mares (P< 0.005, CI 95.57%), with a tendency between 
prepubertal (0-2 years old) and adult mares >10 years old (P= 0.07, CI 95.44%), 
but no difference between >2-10 and >10 year old mares. 
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Table 4-9: Association between the age of the mare and GC counts and thickness. VH (very 
Healthy), H (Healthy). EA (Early Atretic), LA (Late Atretic), LF (Large follicles from 20mm), SF 
(Small Follicles < 20mm). Bold indicates a statistically significant p-value 
Outcomes Factor   GC counts and thickness 
Response Age P-value No Mean ±SE Mean Median 
Basal GC 0-2 YO 0.559 10 34.6±2.6 34.1 
 >2-10 YO  12 31.7±3.3 34.9 
 >10 YO  8 36.9±1.2 35.9 
% Basal GC 0-2 YO 0.003 10 38.4±1.5 38.3 
 >2-10 YO  12 53.3±3.7 53.3 
 >10 YO  8 51.0±3.5 51.2 
Antral GC 0-2 YO 0.093 10 20.9±6.1 14.9 
 >2-10 YO  12 11.5±1.4 10.5 
 >10 YO  8 12.2±0.8 11.6 
% Antral GC 0-2 YO 0.316 10 20.3±3.0 18.5 
 >2-10 YO  12 18.0±0.8 17.6 
 >10 YO  8 16.3±0.6 16.3 
Intermediate GC 0-2 YO 0.010 10 38.6±3.1 39.8 
 >2-10 YO  12 20.5±3.6 18.2 
 >10 YO  8 25.7±4.2 22.9 
% Intermediate 
GC 
0-2 YO 0.033 10 41.3±2.8 43.9 
 >2-10 YO  12 28.7±3.5 29.3 
 >10 YO  8 32.7±3.7 33.6 
Total GC 0-2 YO 0.021 10 94.2±8.0 96.0 
 >2-10 YO  12 63.7±7.5 65.4 
 >10 YO  8 74.8±4.8 69.3 
GC Thickness 0-2 YO 0.300 10 44.5±5.0 40.3 
 >2-10 YO  12 32.3±4.6 30.3 
 >10 YO  8 40.0±4.2 39.5 
 
There was no association between disease status and GC counts and thickness as 
shown in Table 4-10. 
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Table 4-10: Association between mare disease status and GC counts and thickness. VH 
(very Healthy), H (Healthy). EA (Early Atretic), LA (Late Atretic), LF (Large follicles from 
20mm), SF (Small Follicles < 20mm). Bold indicates a statistically significant p-value. 
Outcomes Factor   GC counts and thickness 
Response Disease P-value No Mean ±SE Mean Median 
Basal GC No disease  0.148 17 31.8±2.4 33.4 
 Chronic mild  2 45.3±7.7 45.3 
 Severe  12 36.2±1.3 35.9 
% Basal GC No disease  0.324 17 46.0±3.2 44.1 
 Chronic mild  2 50.7±3.0 50.7 
 Severe  12 50.0±2.8 51.2 
Antral GC No disease  0.174 17 16.4±3.9 12.8 
 Chronic mild  2 16.8±0.0 16.8 
 Severe  12 12.4±0.6 12.4 
% Antral GC No disease  0.319 17 19.4±1.8 19.2 
 Chronic mild  2 18.7±1.8 18.7 
 Severe  12 16.7±0.5 16.6 
Intermediate GC No disease  0.741 17 29.1±3.8 29.6 
 Chronic mild  2 28.3±1.7 28.3 
 Severe  12 25.8±3.3 22.9 
% Intermediate GC No disease  0.684 17 34.5±3.3 
 
36.2 
 Chronic mild  2 30.6±1.2 30.6 
 Severe  12 33.3±2.9 33.6 
Total GCs No disease  0.435 17 77.3±7.9 83.6 
 Chronic mild  2 90.4±9.4 90.4 
 Severe  12 74.4±3.9 69.2 
GC Thickness No disease  0.962 17 37.6±4.3 39.9 
 Chronic mild  2 38.5±11.2 38.5 
 Severe  12 39.8±3.3 38.5 
 
4.3.3.4 Theca cell layer 
Follicle health category affected all thecal measurements with greatest THC 
thickness measured in healthy follicles as shown in Table 4-11. Individual 
comparisons using Mann Whitney also confirmed that numbers of large THC in LA 
was reduced (5.1±0.9) compared to VH, H and EA (45.5±6.4, 53.2±3.8, 16.9±7.7; 
respectively), whereas, it is the opposite with small theca cells (80.7±5.1) 
compared to VH, H and EA (47.2±5.3, 49.9±6.6, 40.1±4.1; respectively). The % 
large and small THC was equally altered between VH and H versus LA follicles 
(P< 0.005, CI 95.04%). When large THC percentage was combined for VH and H 
follicles versus EA and LA follicles Mann-Whitney showed also a significant 
reduction in atretic follicles (P < 0.001, CI 95.01%). There was no difference in 
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absolute numbers of small THC between VH, H and EA categories, but there was 
a significant increase in % small THC in EA compared to VH and H follicles. 
Table 4-11: Association between follicle health status and THC counts and thickness. VH 
(very Healthy), H (Healthy). EA (Early Atretic), LA (Late Atretic), LF (Large follicles from 
20mm), SF (Small Follicles < 20mm). Bold indicates a statistically significant p-value. 
Outcomes Factor   THC counts and thickness 
Response Health status P-value No Mean ±SE Mean Median 
Large THC VH <0.001 10 45.5±6.4 42.0 
 H  11 53.2±3.8 51.0 
 EA  10 16.9±7.7 7.2 
 LA  32 5.1±0.9 3.3 
% Large THC VH <0.001 10 48.9±5.5 47.1 
 H  11 53.4±4.0 49.8 
 EA  10 20.9±8.1 11.0 
 LA  32 6.8±1.5 3.5 
Small THC VH <0.001 10 47.2±5.3 53.6 
 H  11 49.9±6.6 50.0 
 EA  10 40.1±4.1 37.3 
 LA  32 80.7±5.1 79.0 
% Small THC VH <0.001 10 51.1±5.5 52.9 
 H  11 46.6±4.0 50.2 
 EA  10 79.1±8.1 89.0 
 LA  32 93.2±1.5 96.5 
Total THC VH 0.001 10 92.7±6.4 86.5 
 H  11 103.0±6.5 97.0 
 EA  10 57.1±7.9 64.0 
 LA  32 85.8±5.2 81.6 
THC Thickness VH <0.001 10 99.8±10.5 90.4 
 H  11 101.7±8.3 91.2 
 EA  10 47.9±5.9 46.7 
 LA  32 71.0±4.7 64.6 
 
Examining the effect of follicle size category on the large and small THC 
compartment showed that large THC seemed to be one quarter and small THC 
three quarters of the total THC in both categories as presented in Table 4-12. 
This table shows a significant increase in small THC and all THC numbers in small 
follicles < 20mm (P= 0.04 and P= 0.03) whereas the thickness was not 
significantly affected.
 
 
 
Table 4-12: Association between follicle size category and THC counts and thickness. VH 
(very Healthy), H (Healthy). EA (Early Atretic), LA (Late Atretic), LF (Large follicles from 
20mm), SF (Small Follicles < 20mm). Bold indicates a statistically significant p-value. 
Outcomes Factor   THC counts and 
thickness 
Response F. Size Cat. P-value No Mean ±SE Mean Median 
Large THC LF (1) 0.874 32 21.0±3.7 12.5 
 SF (2)  31 22.5±5.0 8.0 
% Large THC LF (1) 0.967 32 24.7±4.2 21.7 
 SF (2)  31 22.9±4.7 7.2 
Small THC LF (1) 0.041 32 55.6±4.4 56.2 
 SF (2)  31 71.9±5.8 73.2 
% Small THC LF (1) 0.967 32 75.3±4.2 78.3 
 SF (2)  31 77.0±4.7 92.8 
Total THC LF (1) 0.031 32 76.6±4.9 80.3 
 SF (2)  31 94.4±5.1 92.6 
THC Thickness LF (1) 0.221 32 70.2±4.6 67.8 
 SF (2)  31 84.7±6.6 73.1 
 
When comparing the effect of breeding season on the large and small THC and 
theca thickness presented in Table 4-13 an increase in large THC numbers and 
percentage was seen in winter compared to summer and transition follicles (% 
large THC 41.0±8.3, 14.9±3.8, 28.8±5.0; respectively). In contrast, the small theca 
cell percentage decreased in winter compared with summer and transition 
follicles (58.9±8.3, 85.1±3.8, 71.2±5.0; respectively). Furthermore, a significant 
difference in THC thickness (P= 0.004) was detected between winter and summer 
follicles (100.1 ±10.7, 64.8±4.6; respectively; P <0.005) using a Mann Whitney test. 
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Table 4-13: Association between breeding season and THC counts and thickness. VH (very 
Healthy), H (Healthy). EA (Early Atretic), LA (Late Atretic), LF (Large follicles from 20mm), SF 
(Small Follicles < 20mm). Bold indicates a statistically significant p-value. 
Outcomes Factor   THC counts and 
thickness 
Response Breeding season P-value No Mean ±SE 
Mean 
Median 
Large THC Winter 0.001 11 39.6±9.6 45.4 
 Summer  32 13.1±3.5 2.4 
 Transition  20 25.8±4.8 23.9 
% Large THC Winter 0.001 11 41.0±8.3 43.9 
 Summer  32 14.9±3.8 2.9 
 Transition  20 28.8±5.0 30.9 
Small THC Winter 0.275 11 50.0±7.3 38.8 
 Summer  32 63.6±4.9 60.5 
 Transition  20 71.0±7.6 63.5 
% Small THC Winter 0.001 11 58.9±8.3 56.1 
 Summer  32 85.1±3.8 97.1 
 Transition  20 71.2±5.0 69.1 
Total THC Winter 0.073 11 89.6±9.6 83.4 
 Summer  32 76.7±5.1 79.9 
 Transition  20 96.8±5.3 87.2 
THC Thickness Winter 0.004 11 100.1 ±10.7 94.9 
 Summer  32 64.8±4.6 61.6 
 Transition  20 84.7±7.1 78.4 
 
There was no effect of breed category on large and small THC count and 
thickness as presented in Table 4-14. 
Table 4-14: Association between breed category and THC counts and thickness. VH (very 
Healthy), H (Healthy). EA (Early Atretic), LA (Late Atretic), LF (Large follicles from 20mm), SF 
(Small Follicles < 20mm). Bold indicates a statistically significant p-value. 
Outcomes Factor   THC counts and thickness 
Response Breed P-value No Mean ±SE Mean Median 
Large THC 1 Horse 0.188 40 20.6±4.2 7.3 
 2 Pony  20 25.9±4.7 27.9 
% Large THC 1 Horse 0.136 40 21.6±4.1 5.6 
 2 Pony  20 29.6±5.3 35.2 
Small THC 1 Horse 0.180 40 67.3±4.8 68.5 
 2 Pony  20 58.0±6.6 53.6 
% Small THC 1 Horse 0.136 40 78.5±4.1 94.4 
 2 Pony  20 70.4±5.3 64.8 
Total THC 1 Horse 0.938 40 87.8±4.6 82.9 
 2 Pony  20 83.9±6.4 85.1 
THC Thickness 1 Horse 0.158 40 75.0±4.5 66.6 
 2 Pony  20 85.7±8.6 85.6 
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There was an association of large and small THC counts and thickness with mare 
age as presented in Table 4-15, specifically prepubertal fillies had a higher 
number and percentage of large THC, and a lower % small THC. Surprisingly, 
theca cell thickness was greatest in the older mares > 10 years of age, and they 
tended to have 10 and 20 more THC per view than prepubertal and 2-10 year old 
mares. 
Table 4-15: Association between mare age and THC counts and thickness. VH (very 
Healthy), H (Healthy). EA (Early Atretic), LA (Late Atretic), LF (Large follicles from 20mm), SF 
(Small Follicles < 20mm). Bold indicates a statistically significant p-value. 
Outcomes Factor   THC counts and 
thickness 
Response Age P-value No. of 
follicle 
Mean ±SE 
Mean 
Median 
Large THC 0-2 YO 0.005 13 31.2±5.7 27.2 
 >2-10 YO  31 14.6±3.8 3.0 
 >10 YO  17 28.6±7.3 12.2 
% Large THC 0-2 YO 0.009  13 35.5±5.9 36.6 
 >2-10 YO  31 17.1±4.2 2.7 
 >10 YO  17 27.9±6.7 13.3 
Small THC 0-2 YO 0.404 13 57.7±7.0 56.0 
 >2-10 YO  31 63.1±5.9 57.6 
 >10 YO  17 69.0±7.0 73.8 
% Small THC 0-2 YO 0.009 13 64.5±5.9 63.4 
 >2-10 YO  31 82.9±4.2 97.3 
 >10 YO  17 72.1±6.7 86.7 
Total THC 0-2 YO 0.091 13 88.9±5.6 83.4 
 >2-10 YO  31 77.7±6.0 77.4 
 >10 YO  17 97.7±5.8 87.8 
THC Thickness 0-2 YO 0.009 13 76.7±5.9 80.2 
 >2-10 YO  31 68.9±5.9 63.9 
 >10 YO  17 95.7±8.1 91.2 
 
Follicles from mares with severe disease tended to have more large THC, and a 
higher % large THC, with a lower % small THC and most total THC as shown in 
Table 4-16. Interestingly, it was the follicles from mares with mild disease that 
had greatest THC thickness (P= 0.01), although the numbers were very low. 
Therefore, a Mann Whitney test was applied combining follicles from mares with 
chronic mild and severe disease compared with follicles recovered from mares 
with no disease, and it confirmed that follicles from mares with disease had a 
thicker THC compartment (P< 0.005, CI 95.13 %).   
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Table 4-16: Association between mare disease status and THC counts and thickness. VH 
(very Healthy), H (Healthy). EA (Early Atretic), LA (Late Atretic), LF (Large follicles from 
20mm), SF (Small Follicles < 20mm). Bold indicates a statistically significant p-value. 
Outcomes Factor   THC counts and 
thickness 
Response Disease P-value No Mean ±SE 
Mean 
Median 
Large THC No disease  0.068 35 16.1±3.5 7.4 
 Chronic mild  4 26.5±13.6 23.6 
 Severe  24 29.3±5.7 21.0 
% Large THC No disease  0.059 35 18.0±3.7 6.7 
 Chronic mild  4 29.1±12.7 31.0 
 Severe  24 31.6±5.6 32.9 
Small THC No disease  0.960 35 62.4±4.4 63.4 
 Chronic mild  4 62.2±19.1 50.1 
 Severe  24 65.5±7.0 59.9 
% Small THC No disease  0.059 35 82.0±3.7 93.3 
 Chronic mild  4 70.9±12.7 69.0 
 Severe  24 68.4±5.6 67.1 
Total THC No disease  0.088 35 78.5±4.8 80.2 
 Chronic mild  4 88.7±19.3 100.5 
 Severe  24 94.8±5.5 89.0 
THC Thickness No disease  0.013 35 65.3±3.8 63.9 
 Chronic mild  4 107.5±26.2 112.4 
 Severe  24 89.7±6.9 79.8 
 
4.4 Discussion  
Oestrous cycles in ponies are longer compared to the mare (Aurich, 2011), with 
follicles emerging at 6mm and then reaching a maximum size of about 30 mm. 
The largest follicle > 20 mm in ponies cannot be recognized until mid-March or 
60 days before ovulatory season (Donadeu and Ginther, 2002). This explains why 
all our collected follicles prior to mid-March had not reached the maximum size 
of the largest follicle. Draincourt et al. (1982) have stated that the pony mares 
begin their ovulatory oestrous cycles in May, which is later than large mares (in 
March) and stop earlier on September compared to large mares (at the end of 
October). Therefore, the average length of the oestrous cycles for pony mare 
and large mares are 25 days and 22.7 days, respectively. Small antral follicles 
activity in pony mares increased dramatically at the beginning of the ovulatory 
season compared to the end of it and in anoestrus (Donadeu and Pedersen, 
2008). Our findings support this as we found many follicles in the pony mares 
during the beginning of the transition period. The length of the transition phase 
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might vary due to an intermittent period of oestrous behaviour, which could 
continue for several days and weeks. 
The counts of growing follicles and primordial follicles were not affected by 
breed (Kenney et al., 1979, Driancourt et al., 1982). Our histological study 
showed that the counts of GC and THC were also not significantly affected by 
breed categories.  
According to Watson and Ai-zi'abi (2002) the transitional follicles had a yellowish 
to pale pink colour and the preovulatory follicles had orange to red colour. In 
the current study the finding was exactly the same for the transitional follicles 
collected but we did not specifically characterise preovulatory follicles. Kenney 
et al. (1979) classified grossly the yellowish colour of the follicular cavity with 
remarkable blood vessels on the surface as representing the early atretic phase. 
This yellowish-coloured surface with blood vessels was noticed in some follicles 
in our examination, but did not contribute to our classification based on 
histological findings. Pedersen et al. (2003) classified atretic follicles based on 
apoptosis and pyknotic appearance on GC and THC, as well as the appearance of 
a thick membrane between both cell types. In our study, the atretic follicles 
were classified into early atretic, when the palisade arrangement of basal GC 
became irregular and mixed with intermediate and antral GC and the amorphous 
membrane started to appear, or as late atretic when there was no GC layer as 
well as the hyaline or amorphous membrane becoming very noticeable and 
separating the theca layers into two parts. Pyknosis and apoptosis were 
distinguished in atretic follicles, but could to a small extent also be seen in the 
healthy category. Cells undergoing apoptosis have disarray in their connections 
with the neighboring cells (Duvall and Wyllie, 1986), therefore, follicles with a 
granulosa layer showing detachment between cells and the theca would be 
considered to be atretic. This supports our classification into the EA category 
and LA category separate from that of H category. The degree of separation of 
cells seen in EA category and LA category are far more extensive than what was 
seen in H category follicles.  
The thickness and the arrangement of GC above the basement membrane in 
transitional anovulatory and preovulatory follicles are histologically the same, 
but there are differences in theca interna (Watson and Al-zi'abi, 2002). The 
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preovulatory follicle consists of a thick layer of polyhedral cells with a nucleus 
and a pale cytoplasm, whereas the anovulatory follicle contains a thin and 
undeveloped theca. 
The observed difference associated with disease conditions might be due to the 
fact that the majority of follicle walls were collected from mares with no 
diseases while only 4 follicles were collected from mares with chronic mild 
diseases, and follicles from mares with severe diseases actually had absolute 
highest intrafollicular oestradiol, thus belonged to the healthy follicle 
categories.   
The unusual Mean and Median of follicles collected in the non-breeding season is 
due to the presence of one large follicle produced high levels of oestradiol (798 
ng/ml) compared to those in the transitional period. We also saw an unusual 
tendency for a breed association (with intrafollicular oestradiol concentrations, 
because follicles from ponies produced more oestradiol. 
Although a degeneration of follicles occurred in the LA category, those types of 
follicles still show some intrafollicular oestradiol. This outcome agrees with 
other studies (Kenney et al., 1979). Similar to our study and follicle health 
categorisation, Sessions et al. (2009) classified the follicles as healthy based on 
high concentrations of oestradiol, whereas the ones with low concentrations 
were categorised as atretic. These authors also detected that there were no 
significant changes in mean diameter between healthy and atretic follicles, 
which is again supported by our findings. 
The variation that occurred in the intermediate GC number and percentage in 
the two follicle size categories might be due to the large follicle group having 
almost double the number of follicles than small follicles. 
The thickness of the cellular layers amongst relatively healthy population does 
not vary that much, however, it should be noted that the granulosa cell layer in 
healthy samples would be relatively uniform in thickness (absence of sloughing 
and hyperplasia). The significant variation in the large and small theca cell 
numbers and percentage, and the THC thickness associated with follicle health 
category may be influenced by the large number of LA follicles compared to VH, 
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H and EA follicles in our study. However, as histomorphological alterations agree 
with previous reports of equine follicle atresia, we attribute the changes seen 
more to the health status than follicle numbers analysed.   
Although mitosis was not considered in our analysis and histological 
categorisation, mitotic figures were found in theca cells mostly in the VH, H and 
EA categories. This agrees with previous descriptions (Kenney et al., 1979) 
where mitotic figures were observed in both granulosa and theca cells. 
4.5 Conclusion  
Overall histomorphological measurements of antral follicle walls in mares 
appeared to mostly be affected by health status rather than mare factors. 
However, differences were seen in follicles from prepubertal mares, ponies, 
diseased mares and follicles collected in transition or winter, and subsequent 
statistical analyses which need to include several predictive factors in one model 
will determine whether associations remain with season, age, disease or breed 
category. 
Comparison of various parameters between different follicle health groups 
categorised visually based on histological criteria demonstrates that the GC and 
THC compartment thickness and the cell counts of the cell layers were similar 
between VH and H categories which also had similarly high intrafollicular 
oestradiol concentrations. However, H follicles were 4 mm larger in diameter 
and thus larger than the size of dominant follicles at the time of selection, while 
VH follicles appear to be pre-selection cohort follicles. Overall, the granulosa 
cell layer in healthy specimens is uniform in thickness due to an absence of 
sloughing or hyperplasia. The effects of follicle atresia were clearly seen in both 
cell compartments and in intrafollicular oestradiol, but not in diameter. Follicles 
categorised as LA lost their GC layer, but also showed a much reduced THC 
compartment even when compared with EA follicles. In fact, onset of atresia, 
while still maintaining a full GC layer, began to affect the THC compartment 
with reduced theca thickness seen during early atresia. 
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Chapter 5 Identifying histomorphological and 
immunohistochemical alterations in mare 
granulosa cell tumours (GCT) and antral follicles  
5.1 Introduction  
Granulosa cell tumours (GCT) developing within ovaries are the overarching 
neoplasm in mares (Watson, 1994), they develop gradually, are consistently 
benign and occur unilaterally (Troedsson et al., 2003). In GCT most of the 
ovarian tissue contains multiple macrofollicular cysts, with cysts being composed 
of granulosa cells surrounded by theca or luteal like cells within a fibrovascular 
stroma (McCue et al., 1991, vanderZaag et al., 1996). Histological examination 
of GCT also revealed clusters of granulosa cells isolated by stroma that 
contained spindle-shaped cells corresponding to thecal tissue (Fernandes et al., 
2011). In addition, GCT are characterised by microfollicular Exner bodies, 
trabecular cords of granulosa cells, and large Leydig like polyhedral cells in the 
surrounding theca.  
Such histological GCT analyses show that tumour transformation occurs mainly in 
granulosa cells (GC), leading to a dysregulation in GC proliferation. Yet we know 
that some functions of differentiated GC and theca cells (THC) are maintained, 
such as GC inhibin and THC androgen synthesis, providing systemic diagnostic 
markers for a large proportion of GCT in mares. This is very much in contrast to 
antral follicle wave and dominant follicle development where differentiation, 
ultimately leading to enhance oestradiol synthesis, slows proliferation of 
follicular cells. A comparative approach investigating the synthesis of follicular 
differentiation markers may, therefore, aid our understanding of GCT 
pathogenesis in mares. 
The main functions of inhibin are in GC development and proliferation, steroid 
hormone secretion and oocyte growth. The production of inhibin by granulosa 
cells has been recognised to contribute to a reduction of the ovulatory quota 
(the selection mechanism) in mares by downregulation of FSH. In healthy large 
follicles the expression of inhibin α and βA subunits was detected in granulosa 
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cells (Nagamine et al., 1998). In contrast, they found that the expression of 
inhibin α subunit was identified in small healthy follicles but inhibin βA subunits 
were not found, possibly indicating that the inhibin A dimer was not synthesised.  
The concentration of inhibin increases gradually and reaches a peak at 
preovulation ensuring low FSH and dominant follicle selection; inhibin is also 
elevated when GCT is present (Crabtree, 2013). Approximately 87% of GCT in 
mares have high inhibin concentrations. The cytoplasms of granulosa cells in GCT 
have been immunostained with inhibin α and also Anti-Muellerian Hormone 
(AMH) by (Evkuran Dal et al., 2013). While inhibin IHC has been done by many 
researchers, few reports exist of enzymes involved in androgen production by 
theca cells, such as 17 α hydroxylase and those involved in oestradiol production 
in GC such as the cytochrome P450 aromatase (Watson, 1999). The cytochrome 
P450 aromatase converts androgen to oestrogen, but its expression in the 
granulosa cells detected using IHC appears very low but adequate even in 
transitional follicles (Watson, 1999, Watson and Ai-zi'abi, 2002). Immunostaining 
for aromatase in granulosa cells was seen in follicles from 5mm in diameter until 
the preovulatory stage (Belin et al., 2000).  
In contrast to inhibin and aromatase expression in GC, CYP17 only immunostains 
theca cells. The P450 cytochrome 17 enzyme is present in ovary, testis and 
adrenal cortex samples (Almeida et al., 2011b). Immunolabelling of CYP17 in the 
preovulatory follicle is seen in the theca interna layer (Albrecht and Daels, 1997, 
Watson et al., 2004).  
In ovaries from healthy mares and in GCT the expression of AMH is high but is 
reduced in large antral follicles (Almeida et al., 2011a). Immunostaining of AMH 
in GCT has previously been observed in all parts containing GC, such as tubular 
or trabecular GC nests or cysts, as well as being found in polyhedral Leydig like 
cells in the interstitial tissue or the stroma (Ball et al., 2008b). It is, however, 
unclear whether AMH type 2 receptor (AMHR2) presence, essential for 
intracellular AMH actions, is regulated in antral follicles and whether its 
expression regulates AMH actions in GCT tumour cells. 
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5.1.1 Aim: 
By using histological (H&E and IHC) approaches determine follicular and mare 
factors that are associated with granulosa and theca cell expression of proteins 
related to antral follicle differentiation, and investigate how such expression 
may be dysregulated in GCT and whether characteristic alterations in GC nucleus 
size occur when GC transform to tumour cells in cysts or solid nests compared 
with equine antral follicles from control mares. 
5.1.2 Objectives:  
1. Determine the localization and expression pattern of the functional 
hormone, enzyme and receptor markers inhibin, aromatase, CYP17 and 
AMHR2, in equine antral follicles from control mares and in GCT using 
IHC. 
2. Determine any associations between predictive follicle and mare factors 
and the control FW expression pattern of these functional markers. 
3. Determine any associations between GCT category and the expression 
pattern of these functional GC or THC markers, and compare control FW 
with diseased GCT cysts or solid nests in their expression pattern. 
4. Measure and compare GC nuclear circumference in very healthy (VH), 
healthy (H) and early atretic (EA) antral follicles, GCT cysts, and solid GC 
islets within GCT. 
5.2 Materials and Methods:  
5.2.1 Animal and tissue samples  
Forty follicle walls (FW, average size of the follicles was 21.4mm), were 
dissected from normal ovaries of sixteen mares (age range from 1.5 to 20 years 
old), and classified into four categories based on histological health status with 
ten follicles in each category: very healthy (VH) healthy (H), early atretic (EA) 
and late atretic follicles (LA) as described in chapter 4. The FW were processed 
for H&E sections, and the same blocks were then used for 
immunohistochemistry. 
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Ten GCT tissue samples from five mares (two samples were collected from the 
GCT of each mare, from one cystic and one solid area of the GCT) were 
processed for H&E sections, and cystic and solid areas within each section were 
histologically classified into four categories: GCT 1 (a very large cyst like 
structure with the cyst wall stretched like a FW and resembling the very healthy 
and healthy FW categories), GCT 2 (the cystic structure is round like a small 
antral follicle, with a GC layer surrounding the cyst antrum and containing 
antral, intermediate and basal GC), GCT 3 (the cystic structure is round, but 
only has a single cell layer surrounding a fluid antrum, with cells resembling 
antral GC) and GCT4 (solid nests of GC residing within and clearly discernable 
from the surrounding interstitial/stromal tissue). 
For the study of nuclear size= circumference, 15 FW were dissected from the 
normal ovaries of 10 mares, representing 5x VH, 5x H and 5x EA follicles, and ten 
GCT tissue samples were recovered from five mares as described above. All 
samples were routinely processed for H&E sections. 
5.2.2 Immunohistochemistry (IHC) technique on follicle wall and 
GCT sections 
The IHC was performed as described in detail in Chapter 2.The tissues were 
embedded in wax blocks at the required orientation to give a cross section of 
the FW or GCT cyst (Thermo Histostar embedding centre), sectioned at a 
thickness of 2.5 µm (Thermo Finesse NE+ Microtome) and rehydrated. Sections 
then underwent Heat-Induced Epitope Retrieval (HIER) followed by incubation in 
the first antibody solution at room temperature using the Dako Autostainer 
(Agilent, Dako, USA). The first and second antibodies are as detailed and using 
the listed dilutions as presented in Table 5-1. Please note that while the 
‘inhibin’ antibody was in fact raised against the N-terminus of the human inhibin 
alpha subunit (with inhibin being a dimer of inhibin alpha and inhibin beta 
subunits), high alpha subunit expression is normally a prerequsite for high inhibin 
protein expression; thus the result description will refer to ‘inhibin’ protein 
expression and not just expression of the alpha subunit.  
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Table 5-1: IHC antibodies 
No. Antibodies Antigen 
Retrieval  
Antibodies 
dilution 
Secondary Antibodies 
11 INHIBIN alpha 
clone R1 
Dako Cat. 
NO. M3609  
HIER Sod 
Citrate pH6 
1:20 Dako Envision+System HRP 
Labelled polymer Ant-mouse 
Cat. No. K4001 ready to use 
22 AROMATASE 
ABBIOTEC 
Cat. No. 
250549 
Proteinase 
K 15 
minutes 
1:100 Dako Envision+System HRP 
Labelled polymer Ant-Rabbit 
Cat. No. K4003 ready to use  
33 CYP17A1 
Santa Cruz 
Cat. No. se-
374244 
HIER Sod 
Citrate pH6 
1:1500 Dako Envision+System HRP 
Labelled polymer Ant-mouse 
Cat. No. K4001 ready to use 
44 AMHR2 N- 
Term 
Antibodies-
online Cat. 
No. 
ABIN2616027 
HIER sodium 
citrate pH6 
 
1:200 Dako Envision+System HRP 
Labelled polymer Ant-Rabbit 
Cat. No. K4003 ready to use 
 
 
5.2.3 IHC and nuclear measurements  
Images for immunohistochemical evaluation of the protein expression pattern 
were captured using a Leica DM4000B microscope (Leica Microsystems, 
Switzerland) and Leica Application Suite software (version 4.3.0; Leica 
Microsystems, Switzerland), whereas images for nuclear circumference 
measurements under oil immersion were captured using an Olympus BX51 
microscope and Stream Basic (version 1.9.2; Olympus soft Imaging Solutions 
GmbH). All images were analysed by the same operator, and each one was given 
a score relating to stain intensity and distribution pattern, and a percentage to 
show coverage of the specific cell layer analysed (%area). For the stain intensity, 
score 0 means no stain, 1 is low, 2 is medium and 3 is high stain intensity; in 
relation to the spread or distribution score 1 reflects continuous distribution, 
while score 2 reflects individual cells being stained, and 3 clusters of cells being 
stained. The percentage of the area covered was considered a better 
measurement than absolute cell numbers, as, for example, in GCT3 the number 
of GC was actually reduced, but protein expression may still have been seen in a 
high % of the GC. 
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Nuclear circumferences of 15 basal, 15 intermediate and 15 antral GC in 3 views 
(5 GC in each location) across each section were measured for five VH, H and EA 
follicles using Image J software. The GCT nuclear circumferences were similarly 
measured in 15 basal, 15 intermediate and 15 antral GC in three GCT1 views per 
section, and in 25 basal, 25 intermediate and 25 antral GC in five GCT2 cysts 
across each section, for a total of 10 GCT sections. For GCT3 25 antral GC were 
also measured in five cysts (5x GC per cyst) per section, and for GCT4 45 GC 
were measured in 3 different solid GC nests (15x GC per GC nest) per section. 
More views were analysed across the GCT sections for GCT2 and GCT3 due to 
their smaller cystic structure and varied distribution in the section. 
The magnification of the microscope binocular was 10X, therefore, each IHC 
section was viewed at 200X magnification, and nuclear circumference was 
measured at 1000x magnification under oil immersion. Stain intensity, 
distribution and %area were estimated over the whole section. The 
measurements were based on a previous study in ovarian human samples (Hes et 
al., 2011) where they classified the intensity staining as negative, weak, 
moderate or strong. Their distribution score was focal (<50% of positive 
neoplastic cells) or diffuse (>50% of positive neoplastic cells) while our 
distribution categories included a continuous vs. individual vs. cluster like 
distribution. 
5.2.4 Statistical analysis 
The Null Hypotheses tested using statistical analyses were: 
I) For IHC results: no differences exist in Inhibin, Aromatase, CYP17A1 and 
AMHR2 stain intensity classified as 0 (=no stain) and 1 (=weak) to 3 (=strong); 
stain distribution classified as 1 (=continuous), 2 (=individual) and 3 (clusters); 
and %area stained estimated (%area) subjectively by the same operator, 
between: 
a) Follicle health categories of control FW, 
b) GCT categories of GCT samples, and 
c) FW combined (VH, H, EA, LA for theca cell layer) and GCT combined (GCT1, 
GCT2, GCT3, GCT4). 
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II) For IHC results in control FW: no correlation exists between follicle diameter 
or follicular fluid (FF) oestradiol (E2) and %area estimated by the same operator. 
III) For nuclear circumferences: no differences exist in GC nuclear 
circumferences between the different locations within the GC layer, between 
FW and GCT categories, and between the healthy control and diseased GCT 
tissues. 
Data were analysed using the descriptive statistic function and the normality 
tests in Minitab 18. Because data were not all normally distributed, statistical 
comparisons were carried out using Kruskal-Wallis and Mann-Whitney tests, to 
detect the associations between a) follicle health category in control follicle 
walls (VH, H, EA, and LA for Theca), and b) GCT area category (category 1,2,3,4) 
and individual protein expression measurements. The associations of stain 
intensity and distribution categories for all proteins with the follicular diameter 
and follicular fluid oestradiol in control FW were also tested using the Kruskal-
Wallis and Mann-Whitney tests. The correlation between estimated %area and 
follicular diameter as well as follicular fluid oestradiol concentrations in control 
follicles was determined using the Spearman Rho function (Minitab 18). Nuclear 
circumferences of granulosa cells of the follicular wall and GCT were analysed 
using descriptive statistics and Kruskal-Wallis followed by Mann-Whitney tests for 
individual comparisons. 
5.3 Results:  
5.3.1 Immunohistological findings 
For each follicle wall health category there were ten follicles analysed from 
between five to eight mares, VH follicles came from eight individual mares, H 
and EA follicles came from seven individual mares and LA follicles came from 
five individual mares. For each GCT category there were 10 sections analysed 
obtained from one apparently solid and one apparently cystic tissue sample per 
GCT recovered from five mares.  
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The expression of inhibin protein in GC only was detected in the follicle walls of 
three different health status categories; very healthy (VH), healthy (H) and early 
atretic (EA) but not in late atretic (LA) follicles lacking the GC compartment as 
shown in Figure 5-1 and Figure 5-2. The expression of inhibin protein in GC in 
GCT categorised as GCT1 (which looks like a healthy follicular wall), GCT2 and 
GCT3 (circular cystic like structures; GCT2 has antral, intermediate and basal 
GC, whereas GCT3 has only a few antral GC remaining), and GCT4 (solid nests of 
GC) in Figure 5-3 and Figure 5-4. 
Examples of different inhibin stain intensity, distribution and percentage area 
detected in the FW and GCT sections can be seen in Figure 5-5 and Figure 5-6. 
 
Figure 5-1: Inhibin expression exclusively in GC in VH (A1 and A2) and H (B1 and B2) 
follicles. A1 and B1 are at 200x magnification, and A2 and B2 are at 400x magnification. 
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Figure 5-2: Inhibin expression exclusively in GC of EA follicles (A1 and A2). As the GC layer 
has disappeared in LA follicles, no positive immunoreactivity is seen (B1 and B2). A1 and 
B1 are at 200x magnification, and A2 and B2 are at 400x magnification.  
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Figure 5-3: Inhibin expression exclusively in GC of GCT categorised as GCT1 (A1 and A2) 
and GCT2 (B1 and B2). A1 and B1 are at 200x magnification, and A2 and B2 are at 400x 
magnification. 
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Figure 5-4: Inhibin expression exclusively in GC of GCT categorised as GCT3 (A1 and A2) 
and GCT4 (B1 and B2). A1 and B1 are at 200x magnification, and A2 and B2 are at 400x 
magnification. 
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Figure 5-5: Inhibin expression exclusively in GC showing different stain intensity at 200x 
magnification (ABCD1) and 400x magnification (ABCD2); A1 & A2 show H follicle walls with 
high expression and B1 &B2 H follicle walls with medium expression, C1 & C2 show GCT2 
with low expression and D1 & D2 show GCT2 with relatively high expression. 
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Figure 5-6: Inhibin expression exclusively in GC showing examples of different stain 
distribution and %area at 200x magnification (ABC1) and 400x magnification (ABC2); A1&A2 
show FW with continuous distribution and almost 100% GC area covered from a H follicle, 
B1&B2 show FW with individual distribution and almost 70% area covered from a H follicle; 
C1&C2 show a GCT4 with continuous distribution and almost 90% area covered. There are 
no images for clustered distribution as inhibin always stained continuously or on occasion 
individually. No THC or stromal stain was seen. 
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The expression of aromatase protein was only seen in GC of the FW categorised 
as VH, H and EA, but not in LA lacking the GC compartment as shown below in 
Figure 5-7 and Figure 5-8. The expression of aromatase was not detected in any 
of the four GCT categories as presented in Figure 5-9 and Figure 5-10. 
Examples of different aromatase stain intensity, stain distribution and %area 
detected in FW and GCT sections can be seen in Figure 5-11 and Figure 5-12. 
 
Figure 5-7: Aromatase expression exclusively in GC in VH (A1 and A2) and some cells of H 
(B1 and B2) FW categories. A1 and B1 are at 200x magnification, and A2 and B2 are at 400x 
magnification. 
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Figure 5-8: Aromatase expression exclusively in GC in cells of the EA FW category (A1 and 
A2) but not in LA follicles were the GC compartment is lacking (B1 and B2) . A1 and B1 are 
at 200x magnification, and A2 and B2 are at 400x magnification. 
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Figure 5-9: No positive aromatase immunoractivity was seen in GCT categorised as GCT1 
(A1 and A2) and GCT2 (B1 and B2). A1 and B1 are at 200x magnification, and A2 and B2 are 
at 400x magnification. 
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Figure 5-10: No positive aromatase immunoractivity was seen in GCT categorised as GCT3 
(A1 and A2) and GCT4 (B1 and B2). A1 and B1 are at 200x magnification, and A2 and B2 are 
at 400x magnification. 
 A1 A2 
B1 B2 
GC 
GC 
GC 
GC 
Stroma 
Stroma 
159 
 
 
Figure 5-11: Aromatase expression exclusively in GC of FW showing different stain 
intensities at 200x (ABC1) magnification and 400x (ABC2) magnification; A1 & A2 show VH 
FW with high expression, B1 &B2 H FW with medium expression and C1 & C2 H FW with low 
expression. 
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Figure 5-12: Aromatase exclusively in GC of FW showing different stain distribution and 
%area at 200x (ABC1) magnification and 400x (ABC2) magnification; A1&A2 show FW with 
continuous distribution and almost 85% GC area covered from a H follicle, B1&B2 show FW 
with individual distribution and almost 40% area covered from a EA follicle. 
The expression of CYP17 was detected very strongly in the THC of VH and H FW 
categories, and strongly in EA FW with slightly less expression in THC bordering 
the amorphous membrane in LA FW as shown in the Figure 5-13 and Figure 5-14. 
The expression of CYP17 protein in THC in GCT categorised as GCT1, GCT2, GCT3 
and GCT4 is shown in Figure 5-15 and Figure 5-16 and clearly showed individual 
clusters of cells with strong expression of CYP17 in the stromal/interstitial areas 
in GCT1 and 2, and individually staining interstitial cells in GCT3 and GCT4 
Examples of different CYP17 stain intensity, stain distribution and percentage 
area detected in FW and GCT sections can be seen in Figure 5-17 and Figure 
5-18. As shown in Figure 5-19 the expression of CYP17 in the LA FW category is 
very reduced and sometimes barely seen, and this is might be due to the 
reduction and degradation of large theca cells in LA follicles. 
The expression of CYP17 was detected in mostly clusters but also some 
individual interstitial tissue or stroma cells of all GCT categories as presented in 
Figure 5-20. The positively immunostained cells appeared to be similar to large 
theca cells of FW, which supports the idea that it is these large theca-like cells 
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that produce androgens in GCT mares showing increased circulating androgens. 
It can be noticed (Figure 5-13 B2) that there was some background staining both 
in the cytoplasm of the granulosa cell layer above the theca and also below in 
the theca externa, which was unexplained but may be due to the antibody being 
manufactured for immunoblots and not for immunohistochemistry. 
 
Figure 5-13: CYP17 expression in THC of VH (A1 and A2) and H (B1 and B2) FW categories. 
A1 and B1 are at 200x magnification, and A2 and B2 are at 400x magnification. 
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Figure 5-14: CYP17 expression in THC of EA (A1 and A2) and LA (B1 and B2) FW categories. 
A1 and B1 are at 200x magnification, and A2 and B2 are at 400x magnification. 
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Figure 5-15: CYP17 expression in interstitial stromal tissue of GCT1 (A1 and A2) and GCT2 
(B1 and B2) categories. A1 and B1 are at 200x magnification, and A2 and B2 are at 400x 
magnification. 
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Figure 5-16: CYP17 expression in interstitial stromal stromal tissue of GCT3 (A1 and A2) and 
GCT4 (B1 and B2) categories. A1 and B1 are at 200x magnification, and A2 and B2 are at 
400x magnification. 
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Figure 5-17: CYP17 expression in THC showing different stain intensity at 200x 
magnification (ABC1) and 400x magnification (ABC2); A1 & A2 show a VH follicle with high 
expression, B1 &B2 a H follicle with medium expression and C1 & C2 a LA follicle with low 
expression. 
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Figure 5-18: CYP17 expression in THC and interstitial stromal tissue showing different stain 
distribution and %area examples with 200x magnification (ABC1) and 400x magnification 
(ABC2); A1&A2 show frequent clustering and almost 70% GC area covered from a VH FW, 
B1&B2 show less frequent clustering and almost 25% area covered from GCT1, and C1&C2 
shows individual cells and very small clusters and only 10% area covered from a GCT3. 
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Figure 5-19: CYP17 expression in THC and interstitial stromal tissue showing a severe 
reduction in staining of LA FW and GCT categories with 200x magnification (ABCD1) and 
400x magnification (ABCD2); A1&A2 show a low stain from a LA FW, B1&B2 shows even 
less staining from another LA FW, C1&C2 shows only two localised small clusters or 
individual cells from a LA FW, and D1&D2 shows a low number of flat interstitial cells 
stained from GCT1 (Black arrows). 
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Figure 5-20: CYP17 expression in interstitial stromal tissue cells in GCT some of which 
appear like individual or clustered Large THC (Black arrows) at 200x magnification (ABCD1) 
and 400x magnification (ABCD2); A1&A2 show GCT1, B1&B2 GCT2, C1&C2 GCT3 and 
D1&D2 an example of GCT4.  
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The expression of AMHR2 protein was frequently detected in GC and THC 
(clusters of large THC) in the three FW categories VH, H and EA, but in LA 
follicles AMHR2 expression was detected only in individual THCs as shown in 
Figure 5-21 and Figure 5-22. The expression of AMHR2 was detected in all GCT 
categories both in the GC and the interstitial/stromal tissue as presented in 
Figure 5-23 and Figure 5-24. 
Examples of different stain intensity, stain distribution and percentage area 
stained detected in FW and GCT sections can be seen in Figure 5-25 and Figure 
5-26. 
 
Figure 5-21: AMHR2 protein expression in GC and THC of VH (A1 and A2) and H FW (B1 and 
B2). A1 and B1 are at 200x magnification, and A2 and B2 are at 400x magnification. 
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Figure 5-22: AMHR2 protein expression in GC and THC of an EA follicle (A1 and A2), and 
AMRH2 expression in individual THC of LA FW (B1 and B2). A1 and B1 are at 200x 
magnification, and A2 and B2 are at 400x magnification. 
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Figure 5-23: AMHR2 protein expression in GC and interstitial/stromal theca like cells in 
GCT1 (A1 and A2) and GCT2 categories (B1 and B2). A1 and B1 are at 200x magnification, 
and A2 and B2 are at 400x magnification. 
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Figure 5-24: AMHR2 protein expression in GC and interstitial/stromal theca like cells in 
GCT3 (A1 and A2) and GCT4 categories (B1 and B2). A1 and B1 are at 200x magnification, 
and A2 and B2 are at 400x magnification. 
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Figure 5-25: AMHR2 expression in GC and THC of FW showing different stain intensity at 
200x magnification (ABC1) and 400x magnification (ABC2); A1 & A2 show H FW with high 
expression, B1 &B2 VH FW with medium expression and C1 & C2 VH FW with low 
expression. 
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Figure 5-26: AMHR2 expression in GC and THC layer or interstitial stromal tissue of GCT 
showing different stain distribution and %area at 200x magnification (ABC1) and 400x 
magnification (ABC2); A1&A2 show continuous distribution and 100% GC area covered 
from GCT1, B1&B2 show individual distribution and approximately 25% area covered from a 
LA FW, and C1&C2 show clusters and approximately 30% of the interstitial area covered 
from a GCT3. 
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5.3.2 Analysis of the association between follicle health or GCT 
category and FW and GCT functional parameters 
5.3.2.1 The association between FW health status categories and follicular 
wall diameter (FWD) and follicular fluid oestradiol (FFE2) 
concentration  
There was no association between FW health status categories and FWD 
(p=0.536) but there was an association between FW health status categories and 
FFE2 concentration (P< 0.001) as presented in Table 5-2. Specifically EA and LA 
categories had significantly lower FFE2 concentrations than VH and H categories. 
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Table 5-2: Association between FW health status and FWD and FFE2 concentration 
 
 
 
 
 
 
 
Outcome variable FW categories  
Mean ± SE Mean (Median) 
No. = each group has 10 distributed Follicles 
P-value 
VH  H EA LA  
FWD mm 18.9±1.8 (20.1) 
N=8 mares 
23.4±2.1(22.6) 
N=7 mares 
21.8±2.22 (20.8) 
N=7 mares 
20.3±2.9 (17.7) 
N=5 mares 
0.536 
FF E2 
Concentration 
ng/ml 
210.5±87.8 
N=8 
E2=10 (follicle no.) 
174.8±45.4 
N=7 
E2=10 (follicle no.) 
26.9±14.6 
N=5 
E2=5 (follicle no.) 
6.8±3.1 
N=4 
E2=9 (follicle no.) 
<0.001 
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5.3.2.2 The association between FW and GCT categories and inhibin GC stain 
intensity, distribution and percentage area covered 
There was no association between FW and GCT categories and inhibin stain 
intensity and distribution. But EA follicles tended to have a smaller %area 
covered in GC, confirmed using Mann Whitney, compared with VH and H 
follicles, and a significant difference was also detected between GCT categories 
with respect to inhibin GC percentage area covered (P= 0.012) as presented 
Table 5-3. A Mann Whitney test among GCT categories detected a significant 
reduction in inhibin GC percentage area covered in GCT3 compared with both 
GCT1 and GCT2 (P< 0.005) (Figure 5-27). 
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Table 5-3: Association between FW and GCT categories and inhibin GC stain intensity, distribution and percentage area covered.  
 
Outcome 
variable 
FW categories 
Mean ± SE Mean (or median)  
No. = each group has 10 distributed Follicles 
P-
value 
 
 
GCT categories 
Mean ± SE Mean (or median) 
No. = each group has 10 tissue samples from 5 mares 
(1mare=2 samples) 
P-
value 
VH  H EA LA GCT1 GCT2 GCT3 GCT4 
Inhibin GC 
stain 
intensity 
2.8±0.1(3) 2.7±0.2 (3) 2.1±0.3 (2.5) - 0.293 1.2±0.1(1) 1.6±0.2 (2) 1.6±0.2 (2) 1.7±0.2 (2) 0.298 
Inhibin GC 
stain 
distribution 
1.0±0.0 (1) 1.1±0.1(1) 1.4±0.2 (1) - 0.284 1.0±0.0 (1) 1.0±0.0 (1) 1.0±0.0 (1) 1.0±0.0 (1) 1.000 
Inhibin GC 
percentage 
area covered 
95.5±2.6a 95.0±3.0a 58.5±14.7b - 0.105 78.5±1.8a 78.5±1.98a 69.5±0.9b 73.0±3.5ab 0.012 
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Figure 5-27: Inhibin GC percentage area covered among GCT categories 
 
5.3.2.3 The association between FW and GCT categories and aromatase GC 
stain intensity, distribution and percentage area covered.  
Aromatase was not expressed in any GC of the GCT categories but it was 
expressed in VH, H and EA FW categories. However, there were no significant 
differences amongst the categories in any of the aromatase parameters (Table 
5-4 and Figure 5-28) 
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Table 5-4: Association between FW categories and aromatase GC stain intensity, distribution and percentage area covered. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outcome variable Follicle wall categories  
Mean ± SE Mean  
No. = each group has 10   distributed Follicles 
P-value 
VH  H EA LA 
Aromatase GC stain intensity 0.9±0.3 (1) 1.0±0.2 (1) 0.9±0.2 (1) - 0.871 
Aromatase GC stain distribution 1.1±0.3 (1) 1.4±0.3 (2) 1.3±0.3 (2) - 0.744 
Aromatase GC %area  47.0±11.5 37.0±9.6 26.0±7.7 - 0.358 
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Figure 5-28: Aromatase GC percentage area covered among FW categories. 1 (VH), 2 (H), 
and 3 (EA) 
5.3.2.4 The association between FW and GCT categories and CYP17 stain 
THCs intensity, distribution and percentage area covered. 
There was no expression of CYP17 on GC as expected, because it is expressed 
only in theca cells of FW, and a low number of interstitial cells of GCT. As shown 
in Table 5-5 below a significant difference was detected in the THC stain 
intensity and percentage area covered with respect to FW health status 
categories (P=0.003 and P<0.001). Both stain intensity and percentage area 
covered were significantly lower in the LA FW compared with other FW.
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Table 5-5: Association between FW and GCT categories and CYP17 THC stain intensity, distribution and percentage area covered. 
 
 
Outcome 
variable 
Follicle wall categories  
Mean ± SE Mean (median) 
No. = each group has 10 distributed Follicles 
P-value GCT categories 
Mean ± SE Mean (median) 
No. = each group has 10 tissue samples from 
5 mares (1mare=2 samples) 
P-value 
VH  H EA LA GCT1 GCT2 GCT3 GCT4 
CYP17 THC 
stain intensity 
3.0±0.0 
(3) 
2.9±0.1 
(3) 
3.0±0.0 
(3) 
1.0±0.4 
(1) 
0.003 2.9±0.1 
(3) 
3.0±0.0 
(3) 
2.5±0.3 
(3) 
3.0±0.0 
(3) 
0.611 
CYP17 THC 
stain 
distribution 
3.0±0.0 
(3) 
3.0±0.0 
(3) 
3.0±0.0 
(3) 
1.8±0.5 
(3) 
0.319 3.0±0.0 
(3) 
3.0±0.0 
(3) 
3.0±0.0 
(3) 
3.0±0.0 
(3) 
1.000 
CYP17 THC 
percentage 
area covered 
79.5±1.7 76.0±3.1 66.5±3.2 11.2±4.8 <0.001 6.6±1.6 9.4±2.0 10.2±2.4 8.5±1.7 0.615 
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5.3.2.5 The association between FW and GCT categories and AMHR2 stain 
intensity, distribution and percentage area covered. 
There was a decrease of AMHR2 GC stain intensity and percentage area covered 
in atretic FW categories (EA and LA) compared to healthy FW categories (VH and 
H) (P< 0.05). The same reduction was also seen in THC stain intensity and 
percentage area (P= 0.001 and <0.001, respectively) with a change in 
distribution in atretic follicles as presented in Table 5-6. GCT3 showed a 
significantly lower AHMR2 GC stain intensity and percentage area compared with 
the other GCT categories, with an altered distribution. This alteration in the 
distribution was also seen in THC (interstitial cell) AMHR2 expression in GCT3 
and GCT4 compared with the other two GCT categories. 
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Table 5-6: Association between FW and GCT categories and AMHR2 GC and THC stain intensity, distribution and %area  
 
 
 
Outcome 
variable 
 
 
Follicle wall categories  
Descriptive Stat 
Mean ± SE Mean (median)  
No. = each group has 10 Follicles 
P-value GCT categories 
Descriptive Stat 
Mean ± SE Mean (median) 
No. = each group has 10 tissue samples from 5 
mares (1mare=2 samples) 
P-value 
VH  H EA LA GCT1 GCT2 GCT3 GCT4 
AMHR2 GC stain 
intensity 
1.6±0.2 
(2) 
1.8±0.1 
(2) 
1.0±0.0  
(1) 
- 0.007 1.2±0.1 
(1) 
1.8±0.1 
(2) 
0.8±0.1 
(1) 
1.9±0.3  
(2) 
0.004 
AMHR2 GC stain 
distribution 
1.0±0.0 
(1) 
1.0±0.0  
(1) 
1.0±0.0  
(1) 
- 1.000 1.6±0.2  
(2) 
1.4±0.2  
(1) 
2.4±0.4  
(3) 
1.2±0.2  
(1) 
0.034 
AMHR2 GC 
%area 
76.0±4.9 77.0±7.1 55.5±3.7 - 0.006 44.0±10.3 48.0±8.9 5.3±2.8 65.5±6.7 <0.001 
AMHR2 THC 
stain intensity 
1.7±0.2 
(2) 
1.8±0.1 
(2) 
1.0±0.0  
(1) 
1.0±0.0 
(1) 
0.001 1.0±0.0  
(1) 
1.0±0.0  
(1) 
1.2±0.1 
(1) 
1.5±0.2  
(1.5) 
0.179 
AMHR2 THC 
stain 
distribution 
1.0±0.0 
(1) 
1.0±0.0 
(1) 
2.0±0.0  
(2) 
2.0±0.0 
(2) 
<0.001 2.0±0.0  
(2) 
2.0±0.0  
(2) 
3.0±0.0  
(3) 
3.0±0.0  
(3) 
<0.001 
AMHR2 THC 
%area 
69.0±5.0 69.5±5.4 19.2±4.4 14.7±3.0 <0.001 6.9±1.9 5.0±0.0 8.1±2.5 8.5±1.1 0.252 
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5.3.2.6 Comparison of control FW and diseased GCT tissues 
In the comparison of control healthy with diseased tissues (FW vs. GCT 
categories combined) significant differences were detected in inhibin GC stain 
intensity and percentage area covered (P< 0.001) with median GC stain intensity 
and mean percentage area covered being higher on the FW than GCT categories. 
In addition, significant differences were found in AMHR2 stain distribution and 
percentage area covered (P< 0.005, 0.001) with median GC stain distribution 
having altered in the GCT categories and mean GC percentage area being lower 
in GCT compared with FW as presented in Table 5-7. Also, significant differences 
were found with respect to CYP17 THC stain percentage area covered and the 
AMHR2 THC stain distribution and percentage area covered (P< 0.001), with 
mean THC percentage area of CYP17 and AMHR2 in FW categories higher than in 
interstitial cells of GCT, which also showed an altered distribution of AMHR2 
expression as presented in Table 5-8. Exclusion of GCT3 from the GCT categories 
(being similar to LA FW) did not affect these results. Note that GCT did not 
express aromatase enzyme in GC in contrast to FW particularly from VH follicles, 
but also from H and EA follicles. 
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Table 5-7: Comparing the combined FW (VH, H and EA) with the combined GCT categories in the hormone (inhibin) and receptor (AMHR2) expression 
measurements in GC. 
Outcome variable Follicle wall categories 
Mean ± SE Mean 
No. = each group10 Follicles 
GCT categories 
Mean ± SE Mean 
No. = each group has 10 tissue samples 
from 5 mares (1mare=2 samples) 
0verall P-value 
 FW (No.=30 without LA) GCT (No.=40 all GCT categories)  
Inhibin GC stain intensity 2.5±0.1 1.5±0.1 <0.001 
Inhibin GC stain distribution 1.2±0.1 1.0±0.0 0.253 
Inhibin GC percentage area 83.3±5.9 74.9±1.3 <0.001 
AMHR2 GC stain intensity 1.5±0.1 1.4±0.1 0.678 
AMHR2 GC stain distribution 1.0±0.0 1.7±0.1 0.002 
AMHR2 GC percentage area 69.5±3.5 40.7±5.1 <0.001 
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Table 5-8: Comparing the combined FW (VH, H and EA) with the combined GCT categories in the enzyme (CYP17) and receptor (AMHR2) expression 
measurements in THC/interstitial cells. 
Outcome variable Follicle wall categories 
Mean ± SE Mean 
No. = each group10 Follicles 
GCT categories 
Mean ± SE Mean 
No. = each group has 10 tissues samples 
from 5 mares (1mare=2 samples) 
0verall P-value 
 FW (No.=40 all FW categories) GCT (No.=all GCT categories  
CYP17 THC stain intensity 2.5±0.2 2.9±0.1 0.285 
CYP17 THC stain distribution 2.7±0.1 3.0±0.0 0.441 
CYP17 THC percentage area 58.3±4.7 8.7±1.0 <0.001 
AMHR2 THC stain intensity 1.4±0.1 1.2±0.1 0.124 
AMHR2 THC stain distribution 1.5±0.1 2.5±0.1 <0.001 
AMHR2 THC percentage area 43.1±4.7 7.1±0.8 <0.001 
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5.3.2.7 The association between inhibin stain categories and control FW 
diameter (FWD) 
There was a significant difference in FWD of the different inhibin GCs stain 
intensity and distribution categories (both P< 0.05) as presented in Table 5-9. 
Clearly, follicles with high GCs stain intensity had a larger FWD (resembling the 
size of dominant follicles just after selection) than the follicles with lower stain 
intensity, and the >20mm follicle has not only most stain intensity but also a 
continuous distribution of stain in granulosa cells. 
 Table 5-9: Association between inhibin GC stain intensity and distribution and FWD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibin expression P-value No=30 FWD (mm) Mean 
±SE Mean 
FWD (mm) 
Median 
Stain intensity GC 0.017    
0 (No stain)     
1 (Low)  5 16.3±1.9 17.5 
2 (Medium)  4 16.0±2.9 15.4 
3 (High)  21 23.6±1.3 22.8 
Stain distribution 
GCs 
0.039    
1 (Continuous)  25 22.4±1.3 21.9 
2 (Individual)  5 16.3±1.9 17.5 
3 (Clusters)   - - - 
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5.3.2.8 The association between aromatase stain categories and control FWD 
A significant difference in FWD of the different aromatase GCs stain intensity 
and distribution categories (both P< 0.05) as presented in Table 5-10. The 
follicles with most aromatase stain and continuous distribution have larger 
diameters (> 25 mm) thus may be dominant follicles. In addition, it is apparent 
that follicles with a diameter of approximately 20mm have reduced stain 
intensity and those in the smaller group (18 mm) generally do not stain 
positively. 
 
Table 5-10: Association between aromatase GC stain intensity and distribution and FWD. 
 
 
 
 
 
 
 
 
 
 
Aromatase 
expression 
P-value No = 30 FWD (mm) 
Mean± SE Mean 
FWD (mm) 
Median 
Stain intensity GC 0.02    
0 (No stain)  8 18.1±1.1 17.8 
1 (Low)  17 20.7±1.5 20.8 
2 (Medium)  4 30.3±3.1 31.1 
3 (High)  1 23.2 23.2 
Stain distribution 
GC 
0.045    
1 (Continuous)  6 25.9±3.8 25.4 
2 (Individual)  16 21.3±1.4 20.9 
3 (Clusters)    - - 
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5.3.2.9 The association between CYP17 stain categories and control FWD  
Neither CYP17 THC stain intensity or distribution category were associated with 
FWD as presented in Table 5-11. This lack of statistical significance may be due 
to the fact that almost all FW showed strong positive immunoreactivity, and 
were only categorised as having a cluster distribution.  
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Table 5-11: Association between CYP17 THC stain intensity and distribution and control 
FWD. 
 
5.3.2.10 The association between AMHR2 stain categories and control 
FWD 
No differences were detected in the FWD of different AMHR2 stain intensity or 
distribution categories, in either GC or THC, as presented in Table 5-12. It 
should be noted that the AMHR2 stain distribution was continuous in all GC 
analysed, in contrast to aromatase and inhibin GC findings. 
  
CYP17 expression P-value No =40 FWD (mm) Mean 
±SE Mean 
FWD (mm) 
Median 
Stain intensity THC 0.656    
0 (No stain)  4 21.1±6.0 22.2 
1 (Low)  4 21.2±4.8 18.2 
2 (Medium)  1 14.3 14.3 
3 (High)  31 21.3±1.1 20.8 
Stain distribution 
THC 
0.964    
1 (Continuous)     
2 (Individual)     
3 (Clusters)   36 21.1±1.1 20.6 
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 Table 5-12: Association between AMHR2 GC and THC stain intensity and distribution and 
FWD. 
 
 
5.3.2.11 The association between inhibin stain categories and control 
FFE2 concentration  
 In the follicles analysed FFE2 concentration was highest as the GC inhibin stain 
intensity increased and when the distribution was continuous (both p-values 
<0.05) as presented in Table 5-13.  
  
AMHR2 expression  
(GC) 
P-value No=30 FWD (mm) 
Mean ±SE Mean 
FWD (mm) 
Median 
Stain intensity GC 0.917    
0 (No stain)     
1 (Low)  16 21.6±1.9 20.8 
2 (Medium)  14 21.1±1.4 21.4 
3 (High)     
Stain distribution 
GC 
    
1 (Continuous)  30 21.4±1.2 20.90 
2 (Individual)     
3 (Clusters)      
AMHR2 expression  
(THC) 
P-value No=40 FWD (mm) 
Mean ±SE Mean 
FWD (mm) 
Median  
Stain intensity THC 0.955    
0 (No stain)     
1 (Low)  25 21.5±1.6 20.0 
2 (Medium)  15 20.4±1.5 20.8 
3 (High)     
Stain distribution 
THC 
0.715    
1 (Continuous)  20 21.2±1.4 21.4 
2 (Individual)  20 21.0±1.8 19.8 
3 (Clusters)      
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Table 5-13: Association between inhibin GC stain intensity and distribution and FFE2 
concentration  
 
 
 
 
5.3.2.12 The association between aromatase stain categories and 
control FFE2 concentration  
In the follicles analysed FFE2 concentration increased as aromatase stain 
intensity increased (P=0.039) and was higher in those that stained in a 
continuous pattern (p=0.02) as presented in Table 5-14.  
  
Inhibin expression P-value No =25 FFE2 (ng/ml) 
Mean ±SE Mean 
FFE2 
(ng/ml) 
Median 
Stain intensity GC 0.027    
0 (No stain)     
1 (Low)  5 29.6±16.9 8.1 
2 (Medium)  4 76.9±11.8 74.7 
3 (High)  16 220.7±58.5 139.6 
Stain distribution 
GC 
0.012    
1 (Continuous)  20 192.0±48.4 119.5 
2 (Individual)  5 29.6±16.9 8.1 
3 (Clusters)   - - - 
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Table 5-14: Association between aromatase stain GC intensity and distribution and control 
FFE2 concentration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.2.13 The association between CYP17 stain categories and control 
FFE2 concentration  
There was a tendency for THC with the highest stain intensity also having highest 
FFE2 concentrations as presented in Table 5-15. All of the stain distributions 
were in clusters. 
  
Aromatase 
expression 
P-value No=25 FFE2 (ng/ml) 
Mean ±SE Mean 
FFE2 
(ng/ml) 
Median 
Stain intensity GC 0.039    
0 (No stain)  8 52.0±17.0 47.5 
1 (Low)  14 154.0±49.0 92.2 
2 (Medium)  2 308.4±34.5 308.4 
3 (High)  1 798.2 798.2 
Stain distribution 
GC 
0.02    
1 (Continuous)  5 423±134 343 
2 (Individual)  12 121.6±35.9 92.2 
3 (Clusters)    - - 
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Table 5-15: Association between CYP17 THC stain intensity and distribution and FFE2 
concentration  
 
 
 
 
5.3.2.14 The association between AMHR2 stain categories and control 
FFE2 concentration  
In THC AMHR2 expression, FFE2 concentration was higher as stain intensity went 
from low to medium (P=0.013) and when the stain distribution was continuous 
(P< 0.001), as presented in Table 5-16. 
  
CYP17 expression P-value No=34 FFE2 (ng/ml) 
Mean ±SE Mean 
FFE2 
(ng/ml) 
Median 
Stain intensity THC 0.060    
0 (No stain)  4 10.6±6.7 5.8 
1 (Low)  3 5.5±2.0 6.2 
2 (Medium)  1 87.1 87.1 
3 (High)  26 150.1±40.1 74.7 
Stain distribution 
THC 
    
1 (Continuous)     
2 (Individual)     
3 (Clusters)   30 133.6±35.6 70.3 
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Table 5-16: Association between AMHR2 GC and THC stain intensity and distribution and 
FFE2 concentration  
 
 
 
 
5.3.2.15 Correlation of the percentage area covered with FWD and FFE2 
concentrations. 
A normality test was applied to all data relating to the protein expression 
percentage area covered, which demonstrated evidence of a lack of normality 
therefore Spearman Rho tests were applied to study any correlations as 
presented in Table 5-17.
AMHR2 expression 
(GC) 
P-value No=25 FFE2 (ng/ml) 
Mean ±SE Mean 
FFE2 (ng/ml) 
Median 
Stain intensity GC 0.443    
0 (No stain)     
1 (Low)  11 190.3±83.4 50.6 
2 (Medium)  14 135.3±34.5 97.4 
3 (High)     
Stain distribution 
GC 
    
1 (Continuous)  25 159.5±40.8 76.6 
2 (Individual)     
3 (Clusters)      
AMHR2 expression  
(THC) 
P-value No=34 FFE2 (ng/ml) 
Mean ±SE Mean 
FFE2 (ng/ml) 
Median 
Stain intensity THC 0.013    
0 (No stain)     
1 (Low)  19 110.7±52.1 8.6 
2 (Medium)  15 129.7±32.6 87.1 
3 (High)     
Stain distribution 
THC 
<0.001    
1 (Continuous)  20 192.7±48.3 119.5 
2 (Individual)  14 14.0±5.9 4.36 
3 (Clusters)      
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Table 5-17: Correlation of the percentage area covered in GC or THC with FWD and FFE2 concentration in control follicles. FWD (N0. =30 follicles), FFE2 
concentration (N0. =25 follicles). 
 Inhibin percentage 
area GC 
Aromatase percentage 
area GC 
Cyp17 percentage 
area THC 
AMHR2 percentage 
area GC 
AMHR2 percentage 
area THC 
Outcome 
variables  
Spearman 
Rho 
correlation 
coefficient 
P-value Spearman 
Rho 
correlation 
coefficient 
P-value Spearman 
Rho 
correlation 
coefficient 
P-value Spearman 
Rho 
correlation 
coefficient 
P-value Spearman 
Rho 
correlation 
coefficient 
P-value 
FWD 0.471 0.009 0.453 0.012 0.118 0.468 0.163 0.389 0.104 0.523 
FFE2  0.504 0.010 0.548 0.005 0.617 <0.001 0.276 0.182 0.748 <0.001 
 
Both FWD and FFE2 concentrations were positively correlated with percentage inhibin and aromatase percentage area covered in GC 
(P<0.05). In addition FFE2 concentration was positively correlated with the CYP17 and AMHR2 percentage area covered in THC (both p 
values <0.001).  
In the main the follicles appearing on the right hand side of the scatter plots (representing coverage of 85-100%) for inhibin and 
aromatase GC percentage area covered in Figure 5-29 and Figure 5-30 were those that were classified as healthy and very healthy or as 
large follicles.
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Figure 5-29: Scatter plots for inhibin GC percentage area covered versus FWD and FFE2 
concentration in control FW. Health status: VH = very healthy), H = healthy, EA = early 
atretic. Follicle sizes are represented as LF (Large follicles from 20mm) SF (Small follicles < 
20mm). FWD (No.= 30 follicles), FF E2 concentration (No.=25).  
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Figure 5-30: Scatter plots for aromatase GC percentage area covered versus FWD and FFE2 
concentration in control FW. Health status: VH = very healthy), H = healthy, EA = early 
atretic. Follicle sizes are represented as LF (Large follicles from 20mm) SF (Small follicles < 
20mm). FWD (No.= 30 follicles), FF E2 concentration (No.=25). 
As CYP17 was only expressed in theca cells a correlation was performed for THC 
percentage area with FWD and FFE2 concentration, as presented in Figure 5-31 
and revealed significant correlation only with FFE2 concentration (P= 0.01,Table 
5-17). The majority of follicles that expressed CYP17 had between 65-85% area 
covered. Those that were below 50% area covered were all late atretic follicles 
with very low E2 production.  
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Figure 5-31: Scatter plots for CYP17 THC percentage area covered versus FWD and FFE2 
concentration in control FW. Health status: VH = very healthy), H = healthy, EA = early 
atretic. Follicle sizes are represented as LF (Large follicles from 20mm) SF (Small follicles < 
20mm). FWD (N0.=40 follicles), and FFE2 concentration (No.=30 follicles). 
There were no significant correlations between AMHR2 GC percentage area 
covered and FWD and FFE2 concentration as presented in Table 5-17 and Figure 
5-32. The THC AMHR2 percentage area covered was not correlated with FWD but 
there is a significant correlation with FFE2 concentration (P-value 0.01) as 
presented in Table 5-17 and Figure 5-33. There does appear to be a clear 
differentiation between follicles that have greater than 60% THC area covered 
and those with less than 30% area covered with all atretic follicles in the latter 
group and almost all healthy follicles in the former group (Figure 5-33). 
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Figure 5-32: Scatter plots for AMHR2 GC percentage area covered versus FWD and FFE2 
concentration in control FW. Health status: VH = very healthy), H = healthy, EA = early 
atretic. Follicle sizes are represented as LF (Large follicles from 20mm) SF (Small follicles < 
20mm). FWD (No.= 30 follicles), FF E2 concentration (No.=25). 
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Figure 5-33: Scatter plots for AMHR2 THC percentage area covered versus FWD and FFE2 
concentration in control FW. Health status: VH = very healthy), H = healthy, EA = early 
atretic. Follicle sizes are represented as LF (Large follicles from 20mm) SF (Small follicles < 
20mm). FWD (N0.=40 follicles), and FFE2 concentration (No.=30 follicles). 
  
5.3.3 Nuclear Circumference between FW and GCTs 
The nuclear circumferences of GC (antral, intermediate and basal) were 
measured in follicles of different FW health categories (VH, H, EA; 
representative images shown in Figure 5-34 and Figure 5-35). The nuclear 
circumferences of GC were also measured in the different GCT categories 
(GCT1, GCT2, GCT4) as presented in Figure 5-36 and Figure 5-37. Late atretic 
FW were excluded from the analysis because LA FW have no GC. The GCT3 cysts 
only have a single layer of very few antral cells (Figure 5-38) so could not be 
included in the FW and GCT comparisons. 
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Figure 5-34: Nuclear circumferences of GC in VH (A) and H (B) FW health categories at 
1000x magnification. Black arrows indicate antral GC, Blue arrows intermediate GC and 
White arrows basal GC. 
A 
B 
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Figure 5-35: Nuclear circumferences of GC in the EA FW health category at 1000x 
magnification. Black arrows indicate antral GC, Blue arrows intermediate GC and White 
arrows basal GC. 
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Figure 5-36: Nuclear circumferences of GC in the GCT1 category showing basal and 
intermediate GC (A), and antral GC (B) at 1000x magnification. Black arrows indicate antral 
GC, Blue arrows intermediate GC and White arrows basal GC. 
  
A 
B 
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Figure 5-37: Nuclear circumference of GC in GCT categories GCT2 (A) and GCT4 (B) at 
1000x magnification. In GCT2 Black arrows indicate antral (to the cyst antrum) GC, Blue 
arrows intermediate GC and White arrows basal GC. In the solid GC nests of GCT4 15 
nuclear circumferences were measured across the view with colour of arrows only 
indicating the top, middle or bottom of the view. 
 
A 
B 
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Figure 5-38: Antral (lining the cyst antrum) GC in the GCT3 category at 200x magnification 
(A) and 1000x magnification (B), Black arrows indicate antral GC.  
A 
B 
208 
 
5.3.3.1 Follicular wall GC nuclear circumference 
Table 5-18 shows that there were no overall significant differences at p<0.05 in 
GC nuclear circumferences of antral, intermediate or basal GC between follicles 
of different health status. However, Mann Whitney analysis showed that basal 
GC in early atretic FW had a smaller nuclear circumference than healthy basal 
GC (P= 0.04), but there was no significant difference between very healthy and 
early atretic follicles (p= 0.2). A comparison of GC in the different locations 
showed that antral GC have the smallest nuclear circumference (44.7±1.9) 
followed by intermediate GC (54.5±1.6), and basal GC have the largest nuclear 
circumference (62.9±3.1), (basal vs. antral GC P< 0.001 and intermediate vs. 
antral P= 0.001) with a tendency between intermediate and basal GC (P= 0.1).  
Table 5-18: Comparison of FW GC nuclear circumferences by health status. No represent 5 
different follicles  
FW circumferences 
outcomes 
Health 
status 
P-value No Mean ±SE 
Mean 
Median 
Antral GC VH 0.932 5 44.0±4.4 45.5 
 H  5 45.8±2.8 47.0 
 EA  5 44.4±3.2 46.1 
Intermediate GC VH 0.228 5 53.2±2.0 53.3 
 H  5 58.4±2.5 61.0 
 EA  5 51.9±3.2 49.6 
Basal GC VH 0.101 5 66.0±6.2 68.4 
 H  5 69.7±3.2 72.2 
 EA  5 53.0±4.0 52.6 
 
There was no significant difference between large and small follicles in terms of 
GC nuclear circumferences as presented in Table 5-19. However, it does appear 
that as one goes from antral, through intermediate to basal GCs the nuclear 
circumference increases similar to what was shown above. 
Table 5-19: Comparison of follicle size categories in their FW GC nuclear circumferences. 
FW circumferences 
outcomes 
F. Size 
Cat. 
P-value No Mean±SE 
Mean 
Median 
Antral GC LF 0.289 9 43.0±2.6 44.1 
 SF  6 47.3±2.5 47.9 
Intermediate GC LF 0.637 9 55.3±2.0 56.9 
 SF  6 53.3±2.7 53.5 
Basal GC LF 0.906 9 63.5±4.5 63.1 
 SF  6 61.9±4.4 64.8 
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There were no significant associations between mare factors such as breeding 
season, breed category, age or disease status and the GCs nuclear 
circumferences (data not presented). 
 
5.3.3.2 GCT nuclear circumferences 
The mean of the antral GC in the GCT3, which was excluded from the overall 
analysis, was (62.6±3.1, Median 58.29). There were no significant differences in 
nuclear granulosa cell layers circumferences between GCT1 and GCT2 as 
presented in Table 5-20. A Mann Whitney test was used to detect any 
associations of location (antral, intermediate and basal) with GC nuclear 
circumference in GCT 1 and GCT2. It revealed that basal nuclear GC were 
significantly larger than intermediate (P= 0.03) and antral nuclear GC (P= 0.001).
 
 
 
Table 5-20: Effect of categories on GCT GC nuclear circumferences. No. represent 5 
different GCT tumours which were used for each GCT category. 
GCT circumferences 
outcomes 
Health 
status 
P-value No Mean±SE Mean Median 
Antral GCs GCT1 0.251 5 49.6±3.4 48.0 
 GCT2  5 57.8±4.6 59.3 
Intermediate GCs GCT1 0.602 5 64.7±9.0 55.3 
 GCT2  5 63.2±4.2 60.0 
Basal GCs GCT1 0.602 5 75.0±7.7 67.7 
 GCT2  5 71.6±2.3 72.8 
 
When the antral, intermediate and basal nuclear GC in the GCT categories were 
combined as presented in Table 5-21 it was found that the nuclear 
circumference of GC in solid nests of GCT4 were significantly larger than antral 
GC in GCT1 and GCT2 (P= 0.01), and the combined GC nuclear circumference 
tended to be smaller in GCT1 and GCT2 versus GCT4. 
Table 5-21: Comparison of health status and combined nuclear GC layers within GCT 
categories. 
GCT circumferences 
outcomes combined 
Health 
status 
P-value No Mean±SE 
Mean 
Median 
Antral, Intermediate 
& Basal GCs 
GCT1 0.057 
 
15 63.1±4.7 61.0 
Antral, Intermediate 
& Basal GCs 
GCT2  15 64.2±2.6 65.1 
Combined GCs (Solid, 
no Antral, 
Intermediate & basal) 
GCT4   15 74.0±4.1 68.2 
 
5.3.3.3 FW and GCT comparison 
The comparison between FW and GCT GCs nuclear circumferences showed that 
there were overall differences in antral and intermediate cell layers as 
presented in Table 5-22. Mann Whitney tests revealed significant differences 
between the nuclear circumferences of antral GC (51.5±2.2) and intermediate 
GC (61.3±2.5) (P= 0.001), between antral GCs and basal GCs (68.9±2.6) (P < 
0.001) and between intermediate GCs and basal GCs (P= 0.011). 
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Table 5-22: Comparison of all categories of FW and GCT in their GC nuclear circumferences. 
Note that GCT4 did not have different GC layers, but top, middle and bottom nuclei were 
measured within one view. 
FW & GCT 
circumferences  
outcomes 
Health 
status 
P-value No Mean±SE 
Mean 
Median 
Antral GC VH 0.014 5 44.0±4.4 45.5 
 H  5 45.8±2.8 47.0 
 EA  5 44.4±3.2 46.1 
 GCT1  5 49.6±3.4 48.0 
 GCT2  5 57.9±4.6 59.3 
 GCT4  5 67.6±5.7 64.6 
Intermediate GC VH 0.026 5 53.2±2.0 53.3 
 H  5 58.4±2.5 61.0 
 EA  5 51.9±3.2 49.6 
 GCT1  5 64.7±9.0 55.3 
 GCT2  5 63.2±4.2 60.0 
 GCT4  5 76.2±7.8 72.5 
Basal GC VH 0.126 5 66.0±6.2 68.4 
 H  5 69.7±3.2 72.2 
 EA  5 53.0±4.0 52.6 
 GCT1  5 75.0±7.7 67.7 
 GCT2  5 71.7±2.3 72.8 
 GCT4  5 78.1±8.3 73.3 
 
Even when GCT4 (being solid) was excluded from the analysis performed above, 
no changes to the overall results were observed. 
Table 5-23 shows that in GCTs the nuclear circumference (67.1±2.3) is increased 
by approximately 20% compared with those from the control follicle walls 
(54.0±1.7), which differs significantly (P-value <0.001). In addition, Mann 
Whitney tests revealed a significant difference between all antral GC of FW 
(44.7±1.9) and all antral GC of GCT (52.8±2.8) (P= 0.03). Moreover, there is a 
strong location effect with differences between antral GC (48.0±1.8) and 
intermediate GC (58.3±2.3) (P <0.001), antral GC and basal GC (67.0±2.6) (P< 
0.001) and between intermediate GC and basal GC (P= 0.01). 
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Table 5-23: Comparison of the GC nuclear circumference between all VH, H and EA FW 
combined and all GCT1, GCT2 and GCT4 combined. 
FW (VH, H& EA) 
& GCT (GCT1, 
GCT2& GCT4 
(solid)) 
Combined 
circumferences 
outcomes 
Health 
status 
P-value No Mean± SE 
Mean 
Median Confidence 
Antral, 
Intermediate & 
Basal GC 
1 (FW) <0.001 45 54.0±1.7 52.6 95.01% 
 2 (GCT)  45 67.1±2.3 65.1  
 
 
 
5.4 Discussion  
In support of previous studies we show that follicular differentiation markers 
such as inhibin expression in GC and CYP17 expression in THC are maintained in 
GCT tumour cells, while aromatase expression is not seen in GCT, although 
essential for follicular oestradiol synthesis and thus differentiation. The 
expression of the receptor AMHR2 was detected in both GC and THC 
compartments in antral follicles, but also in GCT indicating there is not only 
known GC AMH expression, but tumour GC and the theca like interstitial cells 
can respond to AMH. We show contrasting results to a previous study Ellenberger 
et al. (2007) which found that late stage III of atresia based on (Kenney et al., 
1979) classification has the highest expression of inhibin. Our study shows that 
LA follicles have no inhibin expression as the GC layer is lost. However, we do 
show that EA follicles still have a high level of inhibin expression. In an 
experiment conducted by (Nagamine et al., 1998) a difference in inhibin subunit 
expression was found between large healthy and small healthy follicles, with 
large follicles expressing α and βA subunits, but small follicles only expressing 
the α subunit. In our experiment only inhibin α expression was examined in large 
and small follicles, and there was no significant difference between these size 
categories. 
It has been reported that 2 mares managed to preserve their pregnancy while 
having GCT (Watson, 1994). Chopin et al. (2002) have another interesting 
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outcome in that the mare was cycling and conceived while high levels of inhibin 
were secreted in plasma. A majority of GCT is associated with the presence of 
high systemic concentrations of inhibin which suppress FSH release. When the 
tumour was recorded in pregnant mares it is unclear whether the GCT 
transformation occurred before or after the pregnancy developed (Ball et al., 
2014). In our study, one case had GCT ovariectomy 12 days after foaling, so 
might have developed GCT during her pregnancy or shortly before without 
influencing cyclicity.  
The expression of inhibin and AMH has previously been detected in the 
cytoplasm of GC in GCT (Evkuran Dal et al., 2013) and this together with our 
findings  makes inhibin and AMH or AMHR2 useful GCT markers. Davis et al. 
(2005) showed that inhibin α subunit antibody moderately immunostained the 
cytoplasm of granulosa cells in GCT which is similar to our findings. The 
significant difference of inhibin expression among GCT categories in our study 
was due to low number of GC in GCT 3 that reduced the amount of stain 
intensity and percent area covered. 
Expression of aromatase is confined to GC (Belin et al., 2000). Our findings 
support this as aromatase expression was seen in all GC of VH, H and EA 
follicles, but not in LA follicles as they lack the GC layer. Moreover, aromatase 
expression was not detected in any of our equine GCT categories. The 
immunostaining of aromatase in granulosa cells is generally high; we did not see 
any THC staining using the aromatase antibody in contrast to another study 
(Almadhidi et al., 1995). 
We only found CYP17 expression in THC of antral follicles, and in clusters of 
theca like cells in the interstitial tissue or stroma in GCT. This partly supports 
other reports of thecal CYP17 expression (Albrecht and Daels, 1997). The THC 
CYP17 stain intensity and distribution pattern differed between FW health with 
clusters of CYP17 expressing large theca cells extending previous reports 
describing thecal androgen production (Watson et al., 2004). There were no 
differences seen between GCT categories, but this makes sense as there is no 
clear theca compartment, only interstitial tissue and stroma. 
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The AMH expression in normal equine ovaries is mainly confined to preantral and 
small antral follicles but not seen in primordial follicles with one layer of 
flattened granulosa cells (Ball et al., 2008b). In addition, when the small antral 
follicle size reached approximately 2-3 mm the expression of AMH increased, 
however, when follicles reached > 30 mm in diameter the AMH expression 
decreased. In our study of equine follicle walls, a reduction of AMHR2 expression 
was detected in early atretic follicles and AMHR2 completely disappeared in late 
atretic follicles where the granulosa cells are missing and the THC layer is much 
reduced. Similar to other reports of AMH expression in equine follicles and GCT 
(Almeida et al., 2011a, Ball et al., 2008b), our results showed the same 
localization of AMHR2 for both control follicles (apart from LA follicles) and GCT. 
The expression of AMHR2 reduced in intensity due to the reduction of GC 
numbers in EA and their sloughing in LA follicles, and this effect was mimicked in 
the different GCT categories, where GC numbers severely declined in GCT3. In 
GCT immunolabelling for AMH expression decreases in large polyhedral, Leydig 
like cells were seen (Ball et al., 2013), however, we show maintained expression 
of AMHR2 in the interstitial/stromal compartment of all GCT categories. 
When comparing between FW and GCT, the thecal CYP17 and AMHR2 expression 
differed due to the presence of large numbers of THC in FW from VH, H and EA 
follicles, while only nests or clusters of theca like cells were seen in the four 
GCT categories. 
The follicle with the largest diameter also expressed more inhibin and aromatase 
due to the presence of a large number of GC. As a result intrafollicular 
concentrations of oestradiol increased, as both inhibin and aromatase will 
upregulate steroid hormone production in GC and THC; we know that inhibin 
supports thecal androgen production which can then be used as the precursor for 
oestradiol synthesis in GC, and in our study the intrafollicular oestradiol 
concentrations and CYP17 expression were correlated, with FFE2 increasing 
simultaneously with CYP17 expression in THC. The intrafollicular oestradiol 
concentration was also associated with thecal AMHR2 stain distribution pattern, 
for instance, follicles with low follicular fluid oestradiol concentration showed 
an individual staining which might reflect the follicles becoming atretic, while 
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high oestradiol concentration was associated with continuous distribution of 
AMHR2 expression. 
It was noticed that inhibin expression in GC was very low in follicles shown on 
the left in the scatter plots, being small and mostly classified as atretic. 
The basal GC were found to have larger nuclear circumferences in both FW and 
GCT cysts of GCT1 and 2 compared with antral and intermediate GC, with a 
consecutive decline from basal to intermediate to antral GC. This makes sense in 
normal ovaries and follicle walls as the basal layer is the proliferating layer 
within the GC compartment during follicle growth. Accordingly, the basal GC 
nuclei in healthy follicles were also larger than those in EA category follicles. 
The size of basal GC nuclei did not differ between large or small follicles and 
was not affected by any predictive mare factors (breeding season, breed, age 
and disease). When the nuclear circumferences of GC were compared between 
FW and GCT, the size of the antral GC nuclei (in GCT 1-3) was found to be larger 
in GCT, and this might be due to the degree of proliferation in GC during tumour 
development. In the solid nests of GCT4 all GC nuclei are like basal GC nuclei in 
shape and size, and it appears that they are just multiplying but keeping the 
phenotype of the basal layer. The nuclear circumference of GC within solid islets 
appeared to vary more between tumours than the nuclear circumference of GC 
within cysts, and nuclei of GC in solid nests tended to be larger than antral GC 
nuclei. 
5.5 Conclusion  
Location within the normal antral follicle GC compartment and tumour cyst 
walls, atresia, tumour transformation, and GCT category affect GC nuclear size 
with largest nuclei likely reflecting highest DNA content and increased nuclear 
activity. 
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Chapter 6 Mutation of the forkhead box L2 
(FOXL2) gene and FOXL2 expression in control 
ovaries and GCT of mares 
6.1 Introduction  
The FOXL2 transcription factor has been shown to regulate ovarian function in 
vitro and in vivo in the mouse as a model species. Firstly, FOXL2 is crucially 
involved in sex differentiation of the gonads, where it downregulates SOX9 
expression and thus leads to ovary differentiation in the embryo, and also 
maintains the ovarian/follicular phenotype in the adult female, as 
downregulation of FOXL2 expression causes transformation of follicles to 
seminiferous tubules and the appearance of Sertoli like cells (Caburet et al., 
2012). 
Secondly, FOXL2 maintains the ovarian reserve and represses granulosa cell (GC) 
proliferation by affecting cell cycle progression, gonadotrophin response and 
steroidogenesis. It is considered to regulate cell (oxidative) stress response 
(Benayoun et al., 2011) and its over expression induces apoptosis of a GC cell 
line (KGN cells) in vitro (Kim et al., 2011). In contrast to this apoptotic function, 
FOXL2 enhances the (anti-apoptotic) oestrogen conversion by inducing the 
aromatase gene CYP19A1 (Benayoun et al., 2009). Thus, FOXL2 can play a 
positive or negative part in GC apoptosis regulation. 
The FOXL2 transcription factor gene is one of the genetic determinants of 
premature ovarian failure in women: Several mutation variants (including 
deletions and heterozygous single nucleotide mutations) have been described 
which lead to the BPES / premature ovarian failure syndrome, as well as 
premature ovarian failure without BPES (Gersak et al., 2004). This illustrates 
that resultant alterations in the FOXL2 protein and its cellular localization can 
lead to premature activation and thus premature depletion of the follicle 
reserve in women. Similar to the human BPES syndrome, FOXL2 mRNA expression 
has been localised in murine developing eyelids as well as in murine adult 
ovarian follicles thus constituting an animal model for this syndrome (Pisarska et 
al., 2011).  
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Thus the wildtype protein is considered to have repressive and apoptotic 
functions, while altered proteins may be involved in the dysregulation of GC 
proliferation and follicular development: A single nucleotide polymorphism (SNP) 
in the FOXL2 gene sequence within the winged helix (DNA binding) domain has 
been identified in human adult type GCT, resulting in an altered protein which 
may be causally involved in tumour progression (Cheng et al., 2013). The point 
mutation is a C-G (Cytosine-Guanine) mutation at nucleotide position 402 in the 
human coding sequence (C402G; NCBI NM_023067.4), which causes a substitution 
of the highly conserved cysteine with tryptophan at amino acid position 134 
(C134W; NCBI NP_075555.1) (Bugno et al., 2008). This SNP was identified in 
almost all adult-type GCT biopsies and in varying percentages of other ovarian 
tumours if they contained GC, but not in circulating leucocyte DNA, thecal or 
epithelial ovarian tumours (Pisarska et al., 2011). 
Elucidating the pathogenesis of GCT in women is very important; GCT constitute 
2-5% of all ovarian cancers and have a high risk of recurrence after surgery (Shah 
et al., 2009, Schumer and Cannistra, 2003), and there is a clear need for early 
diagnosis and better prognostic markers, with high mortality at 20-30% due to 
poor diagnosis of recurrent and advanced stages (Schumer and Cannistra, 2003); 
unfortunately, surgery is still the only treatment option. In fact, there are four 
important functions by which wildtype FOXL2 may normally be a tumour 
suppressor according to Caburet et al. (2012): first, encouraging apoptosis of 
extremely damaged cells, and transcriptomic analyses have indeed revealed that 
apoptotic pathways are downregulated by the known mutation (Benayoun et al., 
2013); second, encouraging stability of genome and DNA repair; third, reducing 
entry into the cell cycle, and transcriptomic analyses have also revealed that 
cell cycle genes were activated by the known mutation (Benayoun et al., 2013), 
and finally, obstructing growth factor signalling. 
It may be that localized somatic (granulosa) cell mutations of the FOXL2 gene 
occur or accumulate in adult women, which then enhances GCT progression and 
invasiveness despite surgery (Shah et al., 2009). As in women, GCT are also the 
most frequent gonadal tumour in mares, with similar morphological and 
functional (inhibin and AMH producing) features to the human adult type GCT, 
which mainly consist of granulosa cells but might also be composed of theca 
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cells, lutein cells and/or fibroblasts. In human GCT granulosa cells are aligned in 
trabecular, insular, macro and micro-follicular or diffuse cellular patterns (Wang 
and Lai, 2014), which is very similar to equine GCT. In mare’s surgical removal 
of the diseased ovary while invasive is in almost all reported cases completely 
curative and restores fertility, but similar to women may not prevent the 
occurrence of GCT on the other ovary. Both in the human condition and in the 
mare the pathogenesis of GCT is unclear, and while FOXL2 mRNA and protein 
expression, and the (GC) somatic mutation have now been studied in human 
ovaries, the involvement of the FOXL2 gene in equine ovarian function and GCT 
development is completely unknown (Shah et al., 2009, Koebel et al., 2009). 
At the time of study a partial equine coding sequence (cds) for FOXL2 existed on 
the public database (NCBI EF202823.1), which contained the winged helix 
domain with a 100% match to the human sequence, and thus spanned the human 
C402G mutation locus (shown in Figure 6-1). This allowed the amplification and 
sequencing of FOXL2 DNA in our follicular and GCT samples. Subsequently, the 
equine genome database with full nucleotide (predicted) coding sequence and 
translated protein sequence of the FOXL2 gene became available, allowing 
direct matching to the human adult-type GCT SNP (C405G in the equine cds NCBI 
XM_023621016.1) and the predicted amino-acid change (C135W in the equine 
amino acid sequence NCBI XP_023476784.1). Therefore, this study firstly aimed 
to isolate the relevant partial FOXL2 gene from mare ovarian tissues to then 
identify whether the human FOXL2 SNP (C402G) occurred in DNA extracted from 
mare GCT tissues, but not in normal antral follicles. Secondly, in order to begin 
clarify FOXL2 roles in ovarian, and specifically follicular function in the mare, an 
excellent ovarian model species for women, this study also aimed to describe 
any alterations in FOXL2 expression in antral follicles of different health and 
developmental stages compared with the expression in different cystic or solid 
GCT samples. 
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Figure 6-1: Equine and Human FOXL2 gene sequences 
 
Human GCT generally consisted of granulosa cells and might be composed of 
theca cells, lutein cells and/or fibroblasts. Those granulosa cells aligned in 
trabecular, grand like, insular, macro and micro-follicular or diffuse cellular 
patterns (Wang and Lai, 2014).  
6.1.1 Aim: 
The overall aim was to identify any ovary-specific mutation in the FOXL2 gene in 
mare control ovaries and GCT, and then begin describe the expression and 
putative function of the FOXL2 gene in follicle and GCT development in mares. 
6.1.2 Objectives: 
1. Using molecular techniques, we aimed to isolate and sequence the partial 
FOXL2 gene from ovarian biopsies including antral follicle walls, and from 
GCT biopsies, which include solid areas and cysts. 
2. Identify whether a comparative point mutation exists in equine GCTs: an area 
not previously researched to our knowledge. 
3. Determine the localization of the FOXL2 protein in GCT cysts and solid areas, 
and in antral follicle walls from VH, H, EA and LA categories. 
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6.2 Materials and Methods 
6.2.1 Next Generation Sequencing (NGS) 
This experiment was taking place because of the impossibility of generating 
single and uncontaminated by primer dimer PCR products from extracted DNA of 
all fixed ovaries, which led to overlapping sequences using the BigDye protocol 
(Biosystems, 2016) and the in-house Genetic Analyzer. Therefore, the decision 
was taken to perform one last (primer 3) PCR on freshly extracted DNA samples 
and send PCR products for next generation sequencing (NGS) to Glasgow 
Polyomics, University of Glasgow. Prior to NGS the quality of PCR products and a 
small number of DNA samples extracted from fixed and frozen follicle walls and 
GCT was checked using the Agilent Bioanalyzer; again there was evidence of 
primer dimers in the PCR products. However, this did not interfere with NGS, 
and the short primer sequences were easily removed during the subsequent 
bioinformatic processing (described in chapter 2) 
6.2.1.1 Tissue samples  
DNA was extracted from ten control samples (seven solid ovarian stroma and 
three antral FW areas dissected from healthy ovaries of five mares) and 10 GCT 
samples (one cystic and/or one solid area dissected from GCT of seven mares) as 
presented in Table 6-1.  
6.2.1.2 Molecular techniques  
DNA was extracted using the Qiagen DNeasy® Blood & tissue kit, Cat. Number 
69504 (Qiagen., 2006) according to manufacturer’s instructions, using either the 
AE buffer (Qiagen DNeasy kit, 10 mM Tris-HCL, 0.5 mM EDTA, pH 9.0) used for 
eluting the DNA, or a lower pH buffer (10 mM Tris-HCL, 1 mM EDTA buffer at 
pH8) used for gel DNA extraction and also in final elution from the filter (see 
Table 6-1). 
A PCR amplification of a 119bp sequence spanning the human SNP (CG point 
mutation, nucleotide position 183 in the published equine sequence EF202823.1) 
was carried out on the 20 samples using the primer set 3 designed by Primer-
BLAST (NCBI) as presented in Figure 6-2 (5’ to 3’ Forward primer: 
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CAACCTCAGCCTCAACGAGT TM=59.4 °C, 5’ to 3’ Reverse primer 
GGTAGTTGCCCTTCTCGAACA TM=59.8 °C, see also Table 2-3 in Chapter 2. 
Primers were initially prepared to 100pmol/μl with (molecular grade) water. For 
the PCR, a Primer Mix of both Forward and Reverse primers was prepared to 
20pmol/μl of each primer, to give an 800nM concentration. The PCR reactions 
were prepared using Applied Biosystems AmpliTaq Gold® reagents (Biosystems., 
2010). Each 30μl reaction contained 3.0μl 10x Buffer II, 2.4μl MgCl2, and 
sufficient molecular grade water to bring the final reaction volume to 30μl. This 
volume was centrifuged and treated with 9999 units of UV to eradicate any 
potential DNA contaminants. Subsequently, 0.6μl Invitrogen (10mM) dNTP mix 
was added, along with 0.3μl AmpliTaq Gold® DNA Polymerase and 1.2μl of the 
primer mix (0.6µl Forward, 0.6µl: 20pmol mix). The final mix was then 
transferred into 500μl PCR tubes, and 40x PCR cycles were run as outlined in 
Chapter 2, cycling between 95°C (30 seconds), 55°C (30 seconds) and 72°C (2 
minutes). Subsequently, PCR product (DNA) concentration was checked using the 
NanoDrop 1000 spectrophotometer before submission to Glasgow Polyomics. 
A 2% agarose gel electrophoresis was also run with 5µl of PCR product at 125 
Volts, until the dye reach approximately three quarter across the gel to confirm 
the correct product size following PCR. Then the remaining 25µl of PCR product 
underwent purification with 20µl of elution buffer PE to elute the samples using 
Qiagen QIAquick® PCR Purification Kit as described in Chapter 2. 
For NGS, libraries were prepared using the NEBNext Ultra II DNA Library Prep kit 
for Illumina (New England BioLabs), single index with no size selection, and then 
libraries were sequenced on the Illumina HiSeq 4000 sequencer with a maximum 
read length of 2x75bp, and coverage of approximately 50,000 reads per sample 
(Glasgow Polyomics, University of Glasgow). Sequencing data were visualised 
using Integrative Genomics Viewer (IGV, version 2.4.14) and a summary table 
was prepared by the bioinformatician Dr. Hamilton from Glasgow Polyomics 
using the FreeBayes 
(https://github.com/ekg/freebayes/blob/master/README.md; (Garrison and 
Marth, 2012) program to call the variants. Prior to alignment, the reads were 
trimmed to remove any sequencing adapters and any low quality bases, where 
the average quality PHRED score 
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(https://www.illumina.com/documents/products/technotes/technote_Q-
Scores.pdf) over four bases was lower than 20. In addition, reads that were 
trimmed to less than 54 bases were discarded. Nucleotide variants occurring at a 
frequency from 10% in the reads from one sample were considered relevant, 
with the REFerence and ALTernative nucleotide listed in the summary table. 
 
Figure 6-2: The nucleotide sequence of Equine FOXL2 (EF202823.1), with the position of 
forward and reverse primers shown and the expected site of the mutation highlighted in 
yellow and primer in blue. 
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Table 6-1: PCR products for GCTs and for controls 
PCR 
Product 
Mare ID Sample Name  Tissues Buffer Concentration 
(ng/L) 
G
C
T 
1 GCT1 Fixed solid AE buffer 53.50 
2 
 
GCT 2A Fixed solid AE buffer 34.62 
GCT 2B Frozen cystic  AE buffer 32.77 
GCT 2C Frozen solid AE buffer 35.02 
3 GCT 3 
Fixed solid AE buffer 
45.45 
4 GCT4 
Fixed solid AE buffer 
14.82 
5 GCT5 Fixed solid AE buffer 108.82 
6 GCT6 
Fixed solid AE buffer 
35.69 
7 
GCT 10A Fresh solid AE buffer 87.74 
GCT 10B Fresh cystic AE buffer 84.40 
N
O
N
 G
C
T 
1 NON GCT 1 Fixed stroma Tris-HCI PH 8 15.36 
2 NON GCT5 Fixed stroma Tris-HCI PH 8 6.25 
3 NON GCT 7B Fresh L. Follicle wall AE buffer 49.08 
4 
NON GCT 8A 
Fixed stroma  
L. Ovary Tris-HCI PH 8 15.76 
NON GCT 8B 
Fixed 
 L. Follicle wall Tris-HCI PH 8 13.91 
NON GCT 8C 
Fixed stroma  
R. Ovary Tris-HCI PH 8 12.39 
NON GCT 8D 
Fixed  
R. Follicle wall Tris-HCI PH 8 10.99 
5 NON GCT 9A Fixed stroma AE buffer 134.06 
NON GCT 9B Fixed follicle wall AE buffer 42.92 
NON GCT 9C Fixed stroma Tris-HCI PH 8 17.64 
 
6.2.2 Immunohistochemistry (IHC) procedures 
6.2.2.1 Tissue samples  
Existing wax blocks were used from 40 antral follicle walls (40x Control FW 
samples) (average size of follicles was 21.4mm) dissected from the ovaries of 16 
mares (age range from 1.5 to 20 years old), which had previously been 
categorised using H&E sections as Very Healthy (VH, n=10), Healthy (H, n=10), 
Early Atretic (EA, n=10) and Late Atretic (LA, n=10) (Chapter 4). Existing wax 
blocks were also used from the cystic and solid tissue sample dissected from the 
GCT of five mares (10x GCT samples) where cystic and solid areas were also 
previously categorised using H&E sections as GCT1-4 as described in Chapter 5. 
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6.2.2.2 IHC technique 
The IHC was performed as described in detail in Chapter 2. Following embedding 
of the tissue samples in a wax block (Thermo Histostar embedding centre), 
sectioning at a thickness of 2.5 µm (Thermo Finesse NE+ Microtome) and 
rehydrating, sections underwent Heat-Induced Epitope Retrieval (HIER) followed 
by incubation at room temperature using the Dako Autostainer (Agilent, Dako, 
USA) with the anti-FOXL2 goat polyclonal antibody (Abcam, Cat. No. ab5096) 
diluted at 1:600. Subsequently, the ImmPRESS HRP anti-goat IgG (peroxidase) 
secondary antibody raised in horses was used according to the suppliers’ 
instructions (Vector Laboratories, Cat. No. MP-7405). 
6.2.2.3 IHC Measurements 
Images for immunohistochemistry were captured using a Leica DM4000B 
microscope (Leica Microsystems, Switzerland) and Leica Application Suite 
software (version 4.3.0; Leica Microsystems, Switzerland) as described previously 
in Chapter 5. The magnification of the microscope binocular was 10X and the 20x 
objective was used, therefore, each section was evaluated at 200X 
magnification. Stain intensity, distribution and percentage area were estimated 
over the whole view. The measurements were based on a previous study in 
ovarian human samples (Hes et al., 2011). They classified the nuclear 
immunoreactivity intensity as negative (coded as 0 for analysis), weak (coded as 
1), moderate (coded as 2) or strong (coded as 3) intensity. Their evaluation of 
the distribution was scored as focal (<50% of positive neoplastic cells) or diffuse 
(>50% of positive neoplastic cells), while our distribution categories included 
continuous (coded as 1) vs. individual (coded as 2) vs. cluster like (coded as 3) 
distribution as presented in Figure 6-13 and also in chapter 5 (Figure 5-6, 5-12, 
5-18 and 5-26). 
6.2.3 Statistical analysis 
The Null Hypotheses tested using statistical analyses were: 
I) For NGS results: no difference exists between FW and GCT samples in the 
percentage of alternate = T reads (mutated from the reference = C read) at 
position 117 of the reference sequence NCBI EF202823.1. 
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II) For IHC results: no differences exist in FOXL2 stain intensity classified as 0 
(=no stain) or 1 (=weak) to 3 (=strong); stain distribution classified as 1 
(=continuous), 2 (=individual) or 3 (clusters); and percentage area stained 
(percentage area) estimated subjectively by the same operator, between: 
d) Follicle health categories of control FW, 
e) GCT categories of GCT samples, and 
f) FW combined (VH, H, EA, LA for theca only) and GCT combined (GCT1, 
GCT2, GCT3, GCT4). 
III) For IHC results: in control FW no correlation exists between follicle diameter 
or follicular fluid (FF) oestradiol (E2) and %area FOXL2 immunoreactivity 
estimated by the same operator. 
Data were analysed using the descriptive statistic function and the normality 
tests in Minitab 18. Because data were not all normally distributed, statistical 
comparisons were carried out using Kruskal-Wallis and Mann-Whitney tests, to 
detect the effect of GCT on alternate read percentage (mare being the 
statistical unit so multiple samples from the same mare were averaged), and 
associations between a) follicle health category in control follicle walls (VH, H, 
EA, and LA for Theca), and b) GCT area category (category 1, 2, 3, 4) and FOXL2 
histological measurements. Associations between stain intensity and distribution 
of FOXL2 expression and the follicular diameter and follicular fluid oestradiol of 
control FW were also tested using the Kruskal-Wallis and Mann-Whitney tests. 
The correlation between estimated percentage area of FOXL2 immunoreactivity 
and follicular diameter as well as follicular fluid oestradiol concentrations of 
control FW was determined using the Spearman Rho function (Minitab 18). 
6.3 Results  
6.3.1 Next generation sequencing of PCR products 
The reads sequenced from the PCR samples were aligned to the equine FOXL2 
cDNA sequence available on NCBI (EF202823.1, (Bugno et al., 2008)) and 
visualized in Integrative Genomics Viewer (IGV, 
http://software.broadinstitute.org/software/igv/home) as in Figure 6-3. 
226 
 
a) Human mutation SNP CG 
The SNP (C402G) was not identified in GCT or control samples at a frequency of 
more than 5% reads 
b) Different mutation CT identified in variable proportion of reads. 
 
Figure 6-3: This screenshot shows multiple reads sequenced from one control sample with 
the mutation from C  T shown in position 117 bp of the reference sequence EF202823.1. 
Please note that the alternate base is in red when it differs from the reference base. 
Although the target number of reads for the sequences was 1000, the coverage 
initially ranged from 52,000-90,000. Following processing of sequencing data the 
number of reads analysed ranged from 24,855-64,897 total reads. An interesting 
point mutation CT was identified in 18 out of 20 samples, at bp117 of the 
reference sequence (Figure 6-4). In sample number 10 the mutation was called 
in 9.4% of reads, but the bioinformatician considered this low frequency <10% as 
not conclusive (Table 6-3). On average %Ref reads in GCT and control samples 
were 67.31% and 76.53%; respectively, and %Alt reads in GCT and control 
samples were 32.68% and 23.46%, respectively. Bearing in mind, the average 
calculation was done on 17 samples excluding the 0/0 GT and also sample 
number 10 (Table 6-3) because the %Alt was less than 10% (which the 
bioinformatician considered as the GT 0/0). The wild type and mutated read 
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sequences were aligned to the FOXL2 gene sequences to show the mutation as 
presented in Figure 6-5 using 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi). 
Also shown (Figure 6-4) are examples of random sequencing errors indicated by 
the individual red lines distal to the frequent mutation identified, which occur 
when a large number of reads are sequenced. However, because they occur only 
in a small number of reads it is not identified as a variant genotype. This likely 
happened in the two GCT samples number 3 and 4 (Table 6-2). 
 
Figure 6-4: The number and percentages of mutation localisation 
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Figure 6-5: Mutated sequences aligned with original FOXL2 gene sequence. The yellow 
highlighted is the new identified SNP and the green highlighted would be the original human 
SNP 
This C117T mutation (based on the reference sequence) was found in almost all 
samples except two, and it was the only single nucleotide polymorphism (SNP) 
identified (based on showing in 10% or more of the sequenced reads) for all of 
the PCR products. All samples showing the mutation were heterozygous. The 
detailed percentage results for the REFerence base and the ALTernate base are 
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presented for the GCT samples in Table 6-2 and for the control samples in Table 
6-3. 
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Table 6-2: GCT samples: GT is Genotype, DP is Depth, RO is Reference allele count, QR is Reference allele quality, AO is Alternate count, QA is Alternate 
quality and GL is Genotype likelihood (0/0 is Ref and 1/1 is Alt and both are Homozygous, 0/1 is Heterozygous). * Please note that Freebayes identified ‘no 
mutation’ in samples 3 and 4 because %Alt is less than 10%, thus we consider the genotype of the sample as 0/0. 
 
NO. GCT samples EF202823.1             
  POSITION 117             
  
Reference allele count 
(Ref) 
C 
            
  
Alternate allele count 
(Alt) 
T 
            
  
FORMAT GT:DP:RO:QR:AO:QA:GL GT Depth Ref 
count 
Alt 
count 
% Ref % Alt 
1 GCT 6  0/1:32648:22416:911927:10229:414743:-36312.3,0,-81058.8 0/1 32,648 22,416 10,229 68.66% 31.33% 
2 GCT 3  0/1:28052:21004:855242:7047:284122:-23991.7,0,-75392.5 0/1 28,052 21,004 7,047 74.88% 25.12% 
3* GCT 2B  0/0:45954:44292:1801022:1659:67183:0,-4687.52,-156046 0/0 45,954 44,292 1,659 96.38% 3.61% 
4* GCT 2C  0/0:37286:34937:1421096:2346:95129:-1140.41,0,-120477 0/0 37,286 34,937 2,346 93.70% 6.29% 
5 GCT 2A  0/1:25817:19536:793847:6277:254514:-21352.2,0,-69892.1 0/1 25,817 19,536 6,277 75.67% 24.31% 
6 GCT 10A  0/1:29372:15217:618145:14154:574050:-51653.8,0,-55622.4 0/1 29,372 15,217 14,154 51.81% 48.19% 
7 GCT 10B  0/1:32974:16876:686541:16097:652908:-58755.4,0,-61782.3 0/1 32,974 16,876 16,097 51.18% 48.82% 
8 GCT 1  0/1:31678:22730:924471:8945:362293:-31256.8,0,-81852.9 0/1 31,678 22,730 8,945 71.75% 28.24% 
9 GCT 4  0/1:35591:23824:968738:11767:477050:-42027.8,0,-86279.7 0/1 35,591 23,824 11,767 66.94% 33.06% 
10 GCT 5  0/1:24924:19342:785530:5581:226339:-18622.6,0,-68949.8 0/1 24,924 19,342 5,581 77.60% 22.39% 
  
Average of %Ref and 
%Alt without samples 
3 and 4           72.86% 27.14% 
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Table 6-3: Control samples. * Please note that Freebayes identified the mutation in sample 10 but as %Alt is less than 10% we consider the genotype of the 
sample as 0/0. 
NO. CONTROL samples EF202823.1             
  POSITION 117             
  
Reference allele count 
(Ref) 
C 
            
  
Alternate allele count 
(Alt) 
T 
            
  
FORMAT GT:DP:RO:QR:AO:QA:GL GT Depth Ref 
count 
Alt 
count 
% Ref % Alt 
1 NON GCT 1  0/1:24855:19117:777978:5736:231604:-19191.7,0,-68365.4 0/1 24,855 19,117 5,736 76.91% 23.08% 
2 NON GCT 9A  0/1:34451:27270:1108023:7180:291167:-23490.3,0,-97007.4 0/1 34,451 27,270 7,180 79.16% 20.84% 
3 NON GCT 9B 0/1:24233:18072:735967:6161:248844:-21066,0,-64907 0/1 24,233 18,072 6,161 74.58% 25.42% 
4 NON GCT 9C  0/1:29034:21846:889043:7185:290043:-24417.4,0,-78327.4 0/1 29,034 21,846 7,185 75.24% 24.75% 
5 NON GCT 5 0/1:31712:24248:987350:7460:301173:-25071.1,0,-86827 0/1 31,712 24,248 7,460 76.46% 23.52% 
6 NON GCT 7B  0/1:36636:23069:938356:13566:550071:-48962.6,0,-83908.2 0/1 36,636 23,069 13,566 62.97% 37.03% 
7 NON GCT 8A  0/1:26566:21309:868048:5253:211952:-16814.1,0,-75862.7 0/1 26,566 21,309 5,253 80.21% 19.77% 
8 NON GCT 8B  0/1:35036:25288:1029935:9723:393263:-33834.9,0,-91135.3 0/1 35,036 25,288 9,723 72.18% 27.75% 
9 NON GCT 8C  0/1:28162:21682:883582:6480:262164:-21712.4,0,-77640 0/1 28,162 21,682 6,480 76.99% 23.01% 
10* NON GCT 8D  0/1:64897:58783:2386158:6109:247386:-11521.4,0,-204011 0/0 64,897 58,783 6,109 90.58% 9.41% 
  
Average of %Ref and 
%Alt without sample 
10           76.53% 23.46% 
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6.3.1.1 PCR sequence analysis 
There was no significant difference between GCT (n=7 mares) and control 
samples (n=5 mares; P= 0.4) in the average ± SE Mean reference nucleotide 
percentage (Ref%), (specifically, 72.8±4.3% for GCT (eight samples in total from 
seven mares, after excluding the two samples no.3&4), and 74.5±3.0% for 
controls (nine samples in total from five mares, after excluding sample no.10)). 
Conversely, the average ± SE Mean Alternative nucleotide percentage (Alt%) was 
27.2±4.3% for GCT and 25.5±3.0% for controls (P= 0.4). 
The mutation was identified in almost all GCT and control samples, with GCT 
samples ranging from 5 to 48.5 Alt%, and control samples ranging from 20 to 37 
Alt%. While the range appeared to be greater in GCT compared with control 
samples, a two-variance test showed no difference (P> 0.3). In addition, this 
mutation does not lead to a change in amino acid (phenylalanine is encoded by 
both TTC and TTT) within the protein as presented in Figure 6-6 using 
(https://www.ebi.ac.uk/Tools/msa/). Moreover, there is no difference between 
the equine FOXL2 protein compared with the human reference protein spanning 
and including the site of the mutation (Figure 6-7). 
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Figure 6-6: Original FOXL2 gene sequences and mutated sequences aligned with amino acids 
code showing no alternative changes within protein. 
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Figure 6-7: Human vs. Equine FOXL2 gene with known sites of mutation highlighted.  
 
6.3.2 Immunohistochemical findings 
For each follicle wall (FW) health category there were ten follicles analysed 
from between five and eight mares (eight VH mares, seven H and EA mares, and 
five LA mares). For each GCT category there were 10 sections analysed obtained 
from five mares (one apparently solid and one apparently cystic tissue sample 
per mare).  
The expression of FOXL2 protein in GC and THC in FW categorised as very 
healthy (VH), healthy (H), early atretic (EA) and late atretic (EA) is shown below 
in Figure 6-8 and Figure 6-9. The expression of FOXL2 protein in GCT cysts 
categorised as GCT1 (which resemble long stretches of healthy follicular walls), 
GCT2 (circular cystic like structures where antral, intermediate and basal GC are 
clearly discernible enclosing the fluid-filled cyst), GCT3 (circular cysts but with 
only very few antral GC lining the cyst), and GCT4 (solid variably sized nests of 
GC embedded in the stroma) is shown in Figure 6-10 and Figure 6-11.  
Examples of different stain intensity, distribution and %area detected in FW and 
GCT sections can be seen in Figure 6-12 and Figure 6-13.  
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Figure 6-8:FOXL2 expression in GC and THC in VH and H FW categories; A1 shows VH with 
200x and A2 with 400x magnification; B1 shows H with 200x and B2 with 400x magnification. 
Black arrow shows positive nuclear stain, Blue arrow shows negative nuclear stain. 
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Figure 6-9: FOXL2 expression in GC and THC in EA and LA FW; A1 shows EA with 200X and 
A2 with 400x magnification. B1 shows LA with 200x and B2 with 400x magnification. Black 
arrow shows positive nuclear stain, Blue arrow shows negative nuclear stain. 
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Figure 6-10: FOXL2 expression in GC and few interstitial cells (Stromal cells) of GCT1 and 
GCT2 categories; A1 shows GCT1 with 200x and A2 with 400x magnification, B1 shows 
GCT2 with 200x and B2 with 400x magnification. Black arrow shows positive mesenchymal 
nuclear stain, Blue arrow shows negative mesenchymal irregular nuclear stain. 
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Figure 6-11: FOXL2 expression in GC and few interstitial cells (Stromal cells) of GCT3 and 
GCT4 categories; A1 shows GCT3 with 200x and A2 with 400x magnification, B1 shows 
GCT4 with 200x and B2 with 400x magnification. Black arrow shows positive mesenchymal 
nuclear stain, Blue arrow shows negative mesenchymal irregular nuclear stain. 
  
GC 
B2 B1 
A2 
Stroma 
GC GC 
Stroma 
A1 
GC 
Stroma 
239 
 
 
Figure 6-12: FOXL2 expression in GC and THC showing different stain intensity with 200x 
(ABCD1) and 400x magnification (ABCD2); A1 & A2 from VH FW with high expression, 
B1&B2 with medium expression from EA FW, C1 &C2 with Low expression from LA FW, 
D1&D2 from GCT1 with high expression. Black arrow shows positive mesenchymal irregular 
nuclear stain, Blue arrow shows negative mesenchymal irregular nuclear stain. 
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Figure 6-13: FOXL2 expression in GC and THC showing different stain distribution and 
%area with 200x (ABC1) and 400x magnification (ABC2); A1&A2 show continuous 
distribution and almost 90% GC and THC area covered from VH FW, B1&B2 show individual 
distribution and almost 50% area covered from LA FW; C1&C2 show continuous distribution 
and almost 100% area covered from a GCT2. There are no images for clustered distribution 
as FOXL2 always stained continuously or in a few occasions individually. Black arrow 
shows positive mesenchymal irregular nuclear stain, Blue arrow shows negative 
mesenchymal irregular nuclear stain. 
 
6.3.2.1 The association between FW and GCT categories and FOXL2 GC and 
THC stain intensity, distribution and percentage area covered  
As shown in Table 6-4 there was no effect of FW category on FOXL2 GC stain 
intensity and distribution estimates. However, a significant difference was 
detected between FW categories with respect to FOXL2 GC percentage area (P< 
0.05), with EA follicles showing a reduction in percentage area. In FW THC layer 
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the stain intensity and percentage area decreased (P< 0.01) in EA and further in 
LA follicles, and the stain distribution changed from continuous to individual 
cells (P< 0.05). In GCTs there were no differences in stain intensity, distribution 
or percentage area between the different categories (P> 0.7).
242 
 
 
Table 6-4: Association between FW and GCT categories and FOXL2 GC and THC stain intensity, distribution and percentage area covered 
Outcome 
variable 
FW categories  
Mean ± SE Mean (median) 
No. = each group has 10 distributed follicles  
P-value GCT categories 
Mean ± SE Mean (median) 
No. = each group has 10 tissue samples from 
5 mares (1 mare=2 samples) 
P-value 
VH  H EA LA GCT1 GCT2 GCT3 GCT4 
FOXL2 GC stain 
intensity 
2.8±0.1 
(3) 
2.8±0.1 
(3) 
2.2±0.3 
(2.5) 
- 0.285 3.0±0.0 
(3) 
3.0±0.0 
(3) 
3.0±0.0 
(3) 
3.0±0.0 
(3) 
1.000 
FOXL2 GC stain 
distribution 
1.0±0.0 
(1) 
1.0±0.0 
(1) 
1.3±0.2 
(1) 
- 0.419 1.0±0.0 
(1) 
1.0±0.0 
(1) 
1.0±0.0 
(1) 
1.0±0.0 
(1) 
1.000 
FOXL2 GC %area  92.5±1.3a 97.5±1.1a 78.5±6.1b - 0.005 99.0±0.7 100.0±0.0 100.0±0.0 98.0±1.5 0.760 
FOXL2 TH stain 
intensity 
2.8±0.1 
(3)a 
2.8±0.1 
(3)a 
1.9±0.2 
(2)b 
1.5±0.2 
(1.5)b 
<0.001 1.0±0.0 
(1) 
1.0±0.0 
(1) 
1.0±0.0 
(1) 
1.0±0.0 
(1) 
1.000 
FOXL2 TH stain 
distribution 
1.0±0.0 
(1)a 
1.0±0.0 
(1)a 
1.0±0.0 
(1)a 
1.6±0.2 
(2)b 
0.048 2.0±0.0 
(2) 
2.0±0.0 
(2) 
2.0±0.0 
(2) 
2.0±0.0 
(2) 
1.000 
FOXL2 TH %area  90.0±1.5a 93.5±1.3a 76.0±1.3b 44.5±4.4c <0.001 12.5±3.7 10.5±1.4 11.5±0.8 11.0±1.8 0.754 
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6.3.2.2 FW and GCT categories comparison 
In the comparison of health status (FW vs. GCT categories combined) and FOXL2 
GC measurements, significant differences were found in FOXL2 granulosa stain 
intensity and percentage area covered (P< 0.01) with means lower in FW 
categories compared to GCT categories (2.6±0.1, 89.5±2.5; respectively) and 
(3.0±0.0, 99.3±0.4; respectively) as presented in Table 6-5. In addition, 
significant differences were seen in theca stain intensity, stain distribution and 
percentage area covered (P< 0.01) with means higher in theca stain intensity 
and percentage area in FW categories compared to GCT categories (2.3±0.1, 
76.0±3.3; respectively) and (1.0±0.0, 11.4±1.1; respectively) but the THC stain 
was more individual in the GCT categories (1.2±0.1, 2.0±0.0; respectively; P< 
0.01). Exactly the same results were obtained when GCT3 was excluded from 
GCT categories in the GC comparisons (GCT3 cysts resemble atretic follicle 
walls, with severe loss of GC, thus almost resemble LA FW with no GC).  
Table 6-5: Comparing the difference in combined health status of GC and THC in FW and 
GCT categories on FOXL2 stain measurements  
Outcome variable FW categories 
Mean ± SE Mean 
No.=30 without LA 
GCT categories 
Mean ± SE Mean 
No.=40 all GCT 
0verall  
P-value 
 FW categories GCT categories  
FOXL2 GC stain 
intensity 
2.6±0.1 3.0±0.0 0.033 
FOXL2 GC stain 
distribution 
1.1±0.1 1.0±0.0 0.476 
FOXL2 GC %area  89.5±2.5 99.3±0.4 0.000 
 No.=40 all FW No.=40 all GCT  
FOXL2 TH stain 
intensity 
2.3±0.1 1.0±0.0 0.000 
FOXL2 TH stain 
distribution 
1.2±0.1 2.0±0.0 0.000 
FOXL2 TH % area  76.0±3.3 11.4±1.1 0.000 
 
 
6.3.2.3 The association between FOXL2 stain categories and control FW 
diameter (FWD)  
To determine whether the different FOXL2 protein expression measurements 
were only found in specific follicle size classes, the effects of stain intensity or 
distribution categories on the control FWD were tested. Interestingly, a 
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tendency (P≤0.1)) was found with three smaller (<20mm) follicles showing lower 
GC stain intensity category and more individual distribution (Table 6-6). When 
follicles in the low and medium category (19.5±2.4 mm FWD) were combined 
and compared with follicles in the high GC stain intensity category (22.2±1.3 mm 
FWD), no significant differences were revealed (P=0.1). 
Table 6-6: Effect of FOXL2 GC and THC stain intensity and distribution on FWD 
 
 
6.3.2.4 The association between FOXL2 stain categories and control 
Follicular fluid oestradiol (FFE2) concentration  
The association between different FOXL2 protein expression (stain) 
measurements and control FFE2 concentration was tested and there were 
significant differences in FFE2 concentrations between the different FOXL2 GC 
stain intensity and distribution categories (P< 0.05) and the FOXL2 THC stain 
intensity and distribution categories (P-value 0.01, < 0.05; respectively) as 
presented in Table 6-7. Follicles showing increasing GC and THC FOXL2 stain 
intensity and continuous distribution had higher median FFE2 concentrations. A 
Mann Whitney test was followed between GCs stain intensity after combining low 
FOXL2 expression P-value No=30 FWD (mm) Mean 
±SE Mean 
FWD (mm) 
Median 
Stain intensity GC 0.143    
0 (No stain)     
1 (Low)  3 15.4±2.5 17.5 
2 (Medium)  6 21.5±3.1 20.5 
3 (High)  21 22.2±1.3 21.9 
Stain distribution GC 0.053    
1 (Continuous)  27 22.0±1.2 21.3 
2 (Individual)  3 15.4±2.5 17.5 
3 (Clusters)      
FOXL2 expression P-value No=40 FWD (mm) Mean 
±SE Mean 
FWD (mm) 
Median 
Stain intensity THC 0.770    
0 (No stain)     
1 (Low)  7 20.1±3.3 18.2 
2 (Medium)  16 22.5±1.9 21.1 
3 (High)  17 20.2±1.4 20.7 
Stain distribution THC 0.705    
0 (No stain)     
1 (Continuous)  34 21.3±1.1 20.8 
2 (Individual)  6 20.2±3.9 19.0 
3 (Clusters)      
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and medium (19.5±2.4) and compared them to high (22.2±1.3) and revealed no 
significant difference but there was a significant difference when stain intensity 
low (3.9±2.1) and high were compared (P< 0.05). 
Table 6-7: Effect of FOXL2 GC and THC stain intensity and distribution on FFE2 
concentration   
FOXL2 expression P-value No=25 FFE2 (ng/ml) 
Mean ±SE Mean 
FFE2 
(ng/ml) 
Median 
Stain intensity 
GC 
0.021    
0 (No stain)     
1 (Low)  3 4.0±2.1 2.5 
2 (Medium)  6 223±109 62 
3 (High)  16 164.8±47.7 119.5 
Stain distribution 
GC 
0.006    
1 (Continuous)  22 180.7±44.6 97.4 
2 (Individual)  3 4.0±2.1 2.5 
3 (Clusters)      
FOXL2 expression P-value No=34 FFE2 Mean ±SE 
Mean 
FFE2         
Median 
Stain intensity 
TH 
0.003    
0 (No stain)     
1 (Low)  7 7.5±3.9 2.5 
2 (Medium)  11 191.6±89.7 46.0 
3 (High)  16 118.0±22.7 97.4 
Stain distribution 
TH 
0.006    
1 (Continuous)  28 142.8±37.5 74.7 
2 (Individual)  6 8.3±4.5 3.7 
3 (Clusters)      
 
6.3.2.5 Correlation of FOXL2 protein stain percentage area covered with 
control FWD and FFE2. 
Following a normality test, indicating evidence of a lack of normality Spearman 
Rho tests were applied for the correlation analyses as presented in Table 6-8. 
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Table 6-8: Correlation of GC and THC percentage area covered and FWD and FFE2 
concentration. FWD (NO.=30 follicles) and FFE2 concentration (NO.=25 follicles) 
 FOXL2 percentage area 
covered GC 
FOXL2 percentage area 
covered THC 
Outcome 
variables  
Spearman 
Rho 
correlation 
coefficient  
P-value Spearman 
Rho 
correlation 
coefficient 
P-value 
FWD 0.371 0.043 0.028 0.862 
FFE2  0.530 0.006 0.632 0.000 
 
There were significant correlations between FFE2 concentrations and FOXL2 GC 
and THC percentages area stained (P< 0.01). The follicles appearing on the left 
hand side of the scattered plots for GC percentage area stained in Figure 6-14 
are EA or small with low E2 in follicular fluid. All follicles showing 100% of GC 
expressing FOXL2 are healthy.  
The follicles appearing on the left hand side of the scattered plots for THC 
percentage area stained in Figure 6-15 are LA with low E2 in follicular fluid. All 
follicles showing 85% or more of THC expressing FOXL2 are VH or H.  
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Figure 6-14: Correlation of FOXL2 GC percentage area covered with FWD (A&B) and FFE2 
(C&D) concentration. A &C follicles are characterised by health status categories (VH blue, H 
red and EA green), B & D follicles are characterised by follicle size categories (Large follicle 
(LF) blue, small follicle (sF) red).  
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Figure 6-15: Correlation of FOXL2 THC percentage area covered in FWD (A&B) and FFE2 
concentration (C&D). A &C follicle are characterised by health status categories (VH blue, H 
red and EA green, LA purple), B & D follicle are characterised by follicle size categories (Large 
follicle (LF) blue, small follicle (sF) red). 
 
 
6.4 Discussion  
To our knowledge there is only one equine FOXL2 sequence currently available 
on NCBI and this came from whole blood DNA of an intersex horse with a male 
body conformation and stallion-like behaviour (Bugno et al., 2008). Our study 
firstly identified for the first time partial FOXL2 gene sequence in DNA extracted 
from equine ovarian stroma and follicle walls, and (based on almost all of the 
protein being expressed in GC) most likely from the somatic tumour granulosa 
cells of GCT; secondly characterised FOXL2 protein expression in equine antral 
follicles of different health status, and in different GCT cysts and solid tumour 
tissue; and thirdly identified a frequently occurring point mutation in the coding 
sequence of the FOXL2 gene. However, in our study of seven different GCT 
cases, which were different in age profile of mares, the human SNP sequence 
(C402G) was not identified sufficiently frequently to call it a mutation. 
Therefore, it is unlikely in equine GCT, in contrast to human GCT, that the 
existence of this specific human FOXL2 mutation, which alters the protein 
amino-acid sequence, plays a role in mare GCT development. However, it would 
 A 
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B 
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be worthwhile confirming this finding with a much larger number of GCT cases 
and fresh or directly frozen rather than formalin-fixed materials.  
Another SNP (C->T) was found at a different location upstream (closer to the 5’ 
end of the cds) and was detected frequently enough (23-27%) to be called a 
mutation. However, there was no difference between GCT and control FW allele 
percentage, and it would not have changed the amino acid sequence unlike the 
human 402 C-G mutation. Based on the fact that our study identified a new 
FOXL2 SNP in a very small amplified gene region and the potential importance of 
FOXL2 in GCT development, we conclude that the whole equine FOXL2 gene 
needs to be sequenced and compared between GCT and control FW samples. 
The FOXL2 protein was abundantly expressed in VH and H antral follicle GC and 
THC compartments, with a decline in protein expression (%area, intensity and 
also distribution) when atresia is initiated (EA follicles) or has progressed (LA 
follicles). In fact murine studies have shown FOXL2 expression in earlier stages 
of follicle development, where FOXL2 expression was detected in primordial, 
primary and larger secondary follicles, but also in cumulus cells of preovulatory 
follicles, therefore, it proposed to play a critical role in separate stages of 
follicle development (Pisarska et al., 2011). Our study has extended such 
information and shown a general relationship with health and atresia in equine 
follicles. Our study also characterised FOXL2 expression in growing antral cohort 
and dominant follicles, and, for the first time, also identified a positive 
relationship between FOXL2 protein expression in GC and THC and intrafollicular 
oestradiol, which is a known marker for differentiated follicle function. The 
wildtype FOXL2 protein has been shown to stimulate the aromatase promotor in 
vitro, while repressing CYP17 expression in steroidogenic cells, so here we 
present new functional data to support this same relationship for equine antral 
follicles, and their GC and THC compartments. Thus FOXL2 may be an important 
physiological regulator of differentiated and controlled follicle growth. 
Interestingly, follicle diameter per se was not related to FOXL2 expression. 
The antibody used will bind to both wildtype and mutant protein, but in our 
study we only saw nuclear localization of FOXL2 in both follicle wall cells and 
GCT tumour cells, no cytoplasmic aggregates. This is similar to previously 
published human studies, where independent of whether the 402C-G SNP was 
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found in adult GCT of women, the mutation did not change the nuclear 
localisation of the FOXL2 protein (Shah et al., 2009) (Jamieson et al., 2010). 
Very high expression of FOXL2 in tumour GC was seen (it must be assumed that it 
is the wildtype protein) independent of (cyst or solid) GCT category, which went 
beyond that of healthy antral follicles. In contrast the interstitial or stromal 
tissue in GCT only contained very few stained theca cells, compared to the theca 
layer of healthy FW. Interestingly, a severe reduction in GC numbers in GCT3 
which resembles what happens in LA follicles, did not lead to a reduction in 
FOXL2 staining of GC, indicating dysregulated FOXL2 expression in tumours 
compared with control follicles. 
Another fundamental difference to the differentiated FW from control mares is 
the complete absence of aromatase expression in GCT, confirmed by a lack of 
increased circulating oestradiol in affected mares. Yet the proliferating GC 
appear very healthy and show very high FOXL2 expression. Thus, FOXL2 appears 
to be a marker of health or proliferation in tumour GC independent of GCT 
category and size of the GC compartment, as the expression did not appear to 
be affected by the reduction of GC numbers in GCT3, for example. But FOXL2 
expression in GCT is clearly disconnected from steroid (oestradiol) production in 
contrast to FW. At this stage it is not clear where the fundamental switch or 
transformation occurs, but the following questions need to be addressed: Does 
oestradiol in differentiating follicles of dominant follicle size regulate FOXL2 
expression, and does FOXL2 then act to limit GC proliferation? Is FOXL2 
(wildtype or mutant) expression directly regulating GC survival or proliferation 
as shown in GCT1-4 and itself disconnected from hormone control when GC 
transformation to tumour cells occurs? 
Interestingly, while GC in GCT show very high FOXL2 expression compared to FW 
GC, the interstitial or stromal area in GCT was characterised by very low FOXL2 
expression independent of GCT category. This may be due to the fact that there 
were very few theca like cells in GCT leading to such a reduced expression 
pattern in the surrounding interstitial or stromal tissue compared with a 
relatively higher THC expression in control FW. 
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Finally, it may now be possible to use FOXL2 as an immunomarker for specific 
GCT diagnosis when equine ovarian tumour samples are submitted to pathology. 
In women, all cases of GCT patients positively expressed nuclear FOXL2 protein 
(Hes et al., 2011, Takahashi et al., 2013, Yanagida et al., 2017, Jamieson et al., 
2010) and FOXL2 has been found a successful immunomarker for sex cord 
stromal tumours but not other ovarian tumours, due to its high sensitivity and 
specificity (80% and 90%, respectively) independent of the presence of the 
specific point mutation (Al-Agha et al., 2011, Geiersbach et al., 2011, 
McCluggage et al., 2013, Kommoss et al., 2013).  
6.5 Conclusion 
The specific human SNP (C402G) did not occur in equine GCT in our samples but 
we did identify another frequent mutation in the small region amplified in both 
FW and GCT. Further comparative studies of SNPs within the full equine FOXL2 
gene may thus reveal mutations with functional significance in GCT formation. 
The nuclear transcription factor FOXL2 is expressed in both granulosa and theca 
FW compartments even at the onset of histological atresia, but expression is 
highly upregulated in healthy follicles producing most estradiol. In GCT FOXL2 is 
abundantly expressed in the granulosa compartment only independent of GCT 
category.  
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Chapter 7 General Discussion  
The main objectives of the work presented in this thesis were to: 
 Determine the prevalence of mare ovarian pathology and GCT in 
electronic veterinary records collected in the UK from seven practices and 
investigate whether any predictive factors might leads to those diseases  
 Determine the histomorphological changes in ovarian follicle wall health 
categories by measuring the GC and THC counts, thickness and the 
intrafollicular FFE2 concentration. 
 Determine the effect of FW health and GCT categories on the expression 
of different marker proteins using IHC, and comparing the GC nuclear 
circumference between FW and GCT categories.  
 Determine whether FOXL2 gene mutation exist in mares as it does in 
humans using molecular techniques, and investigate its protein 
localization in FW and GCT categories.  
Ovarian tumours in the Western World are considered as the most fatal 
malignant disease in human gynaecology (Cheng et al., 2013). Approximately 5% 
of those cancers are GCT, which occur normally at the age of 50-60 years old. 
The percentage of GCT incidence in equine is considered to be the same, 
however, it is not a fatal disease and most mares recover after unilateral or 
bilateral ovariectomy. If it is unilateral they recover fertility and can still 
produce offspring (Watson, 1994, Troedsson et al., 2003).  
The first study in chapter 3 looked at the data collected from seven practices 
around the UK to investigate through a text mining approach using 
WordStat/Simstat software the estimation of the prevalence of ovarian tumours 
particularly GCT, and ovarian pathology in general. Three dictionaries were 
created with different words and phrases to assist the searching in data mining 
(see Appendices). Those dictionaries allow recovering large text data on ovarian 
pathology and GCT, however, very few cases were relevant and considered as a 
true positive result. The reason of that was the software pulled out all words 
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entered by the clinicians, which may not relate to the main specific targeted 
word. Examples of that are: writing a suggested GCT diagnosis or it might be 
ovarian cyst or samples sent to lab for GCT examination and so on. Another 
reasons include the spelling mistakes or the software retrieved a disease from 
different parts of the body such as eosinophilic granuloma.  
The sensitivity and specificity of measurement of the ovarian pathology and GCT 
that were retrieved from electronic veterinary medical records were high (100%, 
99.7% and 100%, 99.6%, respectively). We could not identify a previous estimate 
of the true prevalence of either ovarian pathology or GCT derived from a large 
population of horses. Anecdotal reports, and clinical experience, would suggest 
that these conditions are indeed rare, and it is possible that the estimates 
derived here of 0.25% for ovarian pathology and up to 0.1% for GCT are realistic. 
They would represent 1 in 400 mares suffering some form of ovarian pathology 
and 1 in 1000 mares sustaining a GCT. However, it is also possible that due to 
the nature of the data recorded these estimates are underestimates of the true 
population prevalence.  
The scoring analysis and univariable and multivariable logistic regression created 
in this chapter for ovarian pathology and GCT allows for predictive factors to be 
identified for development of both diseases. Those factors included some that 
were a common veterinary routine investigation such as previous respiratory and 
orthopaedic examinations, which could easily be detected in a randomly 
selected control population but appeared to be less likely in mares that are 
prone to ovarian pathology. An eye treatment category had an unexplained 
positive relationship with ovarian pathology but this may be an accidental 
finding due to the high possibility for most control and ovarian pathology mares 
to previously have had an eye treatment. In comparison, logistic regression 
analysis identified previous reproduction and sedation categories particularly 
reproductive investigation that was related to a subsequent GCT diagnosis. 
However, none of those factors listed were found highly associated with GCT and 
considered as good predictive factors. 
It is likely that the variation in the age of mares when they are diagnosed with 
GCT were similar in our study and the previous literature, which confirmed that 
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most ages were susceptible to GCT (Watson, 1994, Charman and McKinnon, 
2007).  
Although data were retrieved successfully, we did not identify predictive factors 
that could indicate that GCT development was to be expected.   
The second study, detailed in chapter 4, examined the histology of the normal 
follicular wall in terms of health status and aimed to confirm this by measuring 
the GC and THC cell counts and GC and THC thickness layer, plus examine the 
association between those measurements and different follicle and mare 
parameters. There was a significant association between FWD and disease 
categories with non-diseased follicles having a larger diameter than diseased 
ones. Additionally, larger follicles from the VH and H categories had higher E2 
production compared to smaller sized follicles from the EA and LA categories. 
This is in agreement with a previous study by Sessions et al. (2009) which 
categorised the health status of follicles based on the intrafollicular 
concentration of E2, with the healthier follicles having high FF E2 
concentrations. 
While investigating the effect of breeding season on GC layer, it was found that 
the thickness of the basal GC increased gradually from the transitional period to 
the winter season, which may indicate changes in differentiation and follicle 
type as follicles fail to complete development. We also know that the E2 
concentrations increase dramatically from small follicles to reach a peak in 
preovulatory follicles (Mlodawska et al., 2018), and indeed our study found 
highest intrafollicular concentration in a large follicle. We also detected an 
effect of age on the GC layer, specifically the percentage of basal GC and 
intermediate GC counts which were significantly higher in prepubertal than in 
young adult mares. This, however, may be more related to the fact that there 
were differences in the proportions of healthy and atretic follicles recovered 
from the different age groups of mares. 
Significant differences were found between health categories in terms of THC 
thickness and counts. The number of small THC in LA was increased compared to 
VH, H and EA whereas the large THC counts decreased in number in LA 
compared to VH, H and EA. This finding appears to support a previous study by 
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Watson and Al-zi'abi (2002) where they stated that there was difference in THC 
interna layer thickness between preovulatory follicle which had a thick layer of 
polyhedral thecal cells and transitional anovulatory follicles which had a thin 
and undeveloped THC. 
The number of large THC counts was increased during winter compared to 
summer and transition, whereas the small THC counts decreased in winter 
compared to summer and transition. The THC thickness was significantly 
different between winter and summer as follicles showed increased THC 
thickness when recovered in winter than in summer. 
The percentages of small and large THC counts were also significantly associated 
with age, as prepubertal follicles had reduced small THC counts compared to 
adults but with increased large THC counts. The THC thickness also differed 
between prepubertal age and adults over 10 years in which the THC layer was 
thickest. 
When examining the effect of disease on THC thickness a significant difference 
was seen between diseased and non-diseased groups, with a thicker layer in 
follicles from diseased mares. However, all these mare factors need to be 
examined in multivariate analyses for independent effects, as it appears that 
more healthy and estrogenic follicles were, for example, recovered from 
prepubertal animals late in the year. 
The third study described in chapter 5 focused on immunohistochemistry of very 
relevant hormone, enzyme and receptor protein expression in control FW and 
GCT categories. The expression of inhibin immunostaining as a percentage of GC 
area in the VH and H groups and GCT1 and GCT2 was higher than in EA and 
GCT3, which is due to the low number of GC in EA and GCT3; and this also 
reduced the immunostaining area covered. This has also been reported in 
previous studies (Davis et al., 2005, Evkuran Dal et al., 2013). This GC stain 
reduction was also detected in aromatase expression in FW categories when they 
become atretic, and similar to previous studies where no aromatase expression 
was seen in advanced atresia, the GC layer and therefore inhibin and aromatase 
expression disappeared completely in our study when follicles become 
LA,(Watson and Thomson (1996). This is also an agreement with another former 
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study addressing the presence of aromatase expression in GC recovered from 
dominant follicles (Belin et al., 2000), and as in our images, it was confirmed 
that the only place of aromatase expression in the mare’s ovary is the GC layer 
(Mlodawska et al., 2018). In our study aromatase was not expressed in THC 
similar to (Mlodawska and Slomczynska, 2010) but in contrast to a previous 
report (Almadhidi et al. (1995) where it was observed that aromatase was 
expressed in the theca interna. Aromatase was also not expressed in any GC of 
GCT categories in our study. In contrast, research showed that aromatase was 
expressed slightly in three mares with GCT disease (Watson and Thomson, 1996) 
but this is could be due to the presence of high amount of testosterone possibly 
inducing the enzyme. None of the mares from which GCT samples were collected 
reported a sign of stallion like behaviour, itself an indication of high circulating 
concentrations of testosterone, and in this case the thecal cell androgen 
production would be involved (Rodger et al., 1998). In our study the expression 
of CYP17 was detected in clusters of THC within GCT, and only in the THC 
compartment of FW, and this finding is similar to what was stated by Albrecht 
and Daels (1997). We also found that aromatase stain intensity and percentage 
area covered reduced with atresia. 
In comparison between combined FW and GCT categories, the FW categories of 
inhibin and AMHR2 have higher GC stain intensity and percentage area covered. 
The FW CYP17 and AMHR2 IHC images show higher THC percentage area covered 
than within the GCT categories, while the THC distribution of both CYP17 and 
AMHR2 is more in clusters in GCT than in FW categories.   
Measuring the association between inhibin and aromatase expression, and FW 
diameter and E2 concentration in control FW revealed that follicles with large 
diameter and high amount of E2 production had higher GC stain intensity as well 
as a continuous distribution. In contrast, no associations were found between 
CYP17 and AMHR2 expression and FW diameter but there was an association with 
E2 concentration, which revealed that the THC stain intensity expression and 
continuous distribution increased with a high level of E2 production.  
The follicles with large diameter and a high level of intrafollicular E2 
concentration expressed more GC stain percentage area covered by inhibin and 
aromatase protein, and the follicles with large diameter are highly correlated 
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with THC CYP17 percentage area covered. This is in agreement with a previous 
study by Bashir et al. (2016) which found the intrafollicular steroid hormone 
concentrations were elevated with an expansion of follicular diameter. 
However, this correlation does not exist for AMHR2 GC and THC expression.  
When investigating GC nuclear circumferences, a potential marker for DNA 
content and proliferation, in FW health categories, it was found that basal GC in 
EA are smaller than those in healthy follicles. None of the following different 
follicle and mare parameters; follicle size, breeding season, breed and disease 
status had an effect on GC nuclear circumferences. In addition, location played 
a role as the basal GC were found to be larger than intermediate and antral GC, 
and this applied to both FW and GCT categories. In comparison of combined GCT 
and FW samples, it was found that GC nuclei were larger in GCT, particularly in 
GCT4 and the basal location. 
The final study in this thesis illustrated in chapter 6, investigated a partial 
sequence of the Equine FOXL2 gene, which had only once before been extracted 
from whole blood DNA of an intersex horse with a male body confirmation and 
stallion like behavior (Bugno et al., 2008). To the best of our knowledge, this 
equine FOXL2 gene sequence and the mutation found is the only one 
documented from ovarian samples, and there are no previous published reports 
of FOXL2 protein expression in equine ovarian follicles and GCT tissues. 
The FOXL2 gene sequence was amplified from fixed, frozen and fresh ovarian 
stroma, control FW and GCT cysts and solid areas. However, the human SNP 
sequence (C402G) was not detected adequately repeatedly to call it a mutation. 
However, another SNP upstream (closer to the 5’end) of the human SNP was 
found (C>T, with T found in 23%-27%of reads) and frequently enough to be called 
a mutation. There was no difference between FW and GCT allele proportions, 
and with no predicted amino acid sequence change, this point mutation was 
considered to have the same significance as the human 402 C-G mutation. 
The FOXL2 expression was localized to the nuclei of GC and THC of FW and GCT. 
The findings of our study are in agreement with a previous human study that 
detected the nuclear localization of FOXL2 staining (Jamieson et al., 2010). It 
was found that there was a variation of GC %area and THC stain intensity as well 
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as % area between follicle health categories, with a decrease seen with atresia. 
This was probably due to the low concentration of E2 produced in atretic 
follicles. On the other hand, and in contrast to the regulated expression of 
FOXL2 in antral follicles, there was no association between the different GCT 
categories and FOXL2 tumour expression. When combined GCT and FW data 
were compared, the GCT categories appeared to have an extra level of GC stain 
intensity and % area covered. Knowing that in our study GCT had no distinct 
large THC compartment, the FOXL2 stain intensity and %area covered in the 
interstitial/ stromal tissue definitely declined. 
A strong correlation was found with follicular E2 production and FW health 
categories in which the healthier follicles with high intrafollicular E2 
concentrations showed more FOXL2 stain intensity and %area. In contrast, GCT 
had also a very strong GC stain intensity and %area covered but without 
concomitant E2 production. This suggests that proliferation in GC in GCT is 
independent of E2 production. It is possible that this important difference in the 
regulation of FOXL2 expression leads to tumour transformation in GC. 
Diagnosis of GCT regularly occurs in adult humans before the menopausal stage, 
however, it might occur earlier (Verdin and De Baere, 2012). Normal expression 
of FOXL2 in the adult ovary is really significant to avoid somatic trans-
differentiation of GC and Theca cells from their usual characteristic features to 
testis specific Sertoli and Leydig like cells, respectively. Despite patients hetero- 
or homozygous for the FOXL2 mutation having a significant GCT incidence, a 
previous study by Rosario et al. (2013) reported that there was no significant 
correlation between tumour size and stage and the FOXL2 mutation (Leung et 
al., 2016).  
Detection of FOXL2 mutation in mares might help us in early diagnosis and 
perhaps even future therapy of GCT. The FOXL2 mutation C134W has been found 
in Japanese patients but not very commonly, thus the authors suggested that 
further experiments should be conducted on a large number of patients to 
illustrate the exact prevalence (Oseto et al., 2014). Therefore, further study 
with many fresh equine GCT cases is recommended as well as examining the 
complete FOXL2 gene to identify any further significant mutations.  
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Overall Conclusion 
Text mining could facilitate predicting future GCT by providing further 
predictive factors in a larger data set. The result of the text mining also 
revealed the possibility of performing prevalence estimation of different disease 
conditions despite the limitations that were found. Studying different functional 
proteins immunohistochemically in control follicle walls and GCT tissue can 
effectively detect variations that could potentially identify biomarkers for GCT. 
The result of the GC nuclear circumference comparison between FW and GCT 
revealed location differences, but also that GC nuclei in GCT were larger than 
the one in FW. This might be due to the GC having transformed to tumours 
showing enhanced proliferation. The FOXL2 SNP (C402G) mutation was not 
detected in our GCT samples but another upstream mutation was detected in 
both FW and GCT, therefore, this study is a basis for future analyses of the 
FOXL2 gene in control ovaries and equine GCT. 
Limitations 
Few limitations were associated with this study: we only had seven ovaries 
diagnosed with GCT available for this study, with two obtained before the study 
started and five collected during three years. It would be helpful if they were 
collected all at one time, as well as having larger numbers of GCT samples. In 
addition, a single operator performed the cell counts and thickness 
measurements, as well as IHC analyses described in this thesis, and it may be 
advisable to validate a second operator for future analyses.  
In text mining, the data were not recorded for research purposes for instance, 
therefore, some horse records confusingly had the same ID number and there 
was missing information, as the clinician did not always record the subsequent 
laboratory results. 
During hormonal assay of oestradiol in follicular fluid the only Gamma counter 
available for reading the samples became dysfunctional, and the RIA assay used 
for more than 20 years became unavailable. This resulted in choosing an 
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alternative assay approach, i.e. the human ELISA kit. When designing the 
immunohistochemical analyses and choosing relevant marker proteins, some 
antibodies for protein expression were not available such as HSD3B1, which 
would have been very useful to investigate follicle function, and might have 
assisted us in finding the function of the large theca cells. Furthermore, the 
CYP17 antibody that was used in this study was in fact manufactured for 
immunoblot assay and had never been used in IHC. 
In the final study, there was no previous research found reporting the function 
and regulation of the equine FOXL2 gene in granulosa and theca cells of follicles, 
and in GCT, which could assist the investigation of the human C402G or any 
other SNP mutation. 
Future Work 
The results of this study suggest further work including: 
Presence of amorphous eosinophilic band of deposit in LA follicles is indicative of 
atresia, and in some studies this layer is described as hyaline (Pedersen et al., 
2003). However, as tests for collagen (eg. Masson’s Trichrome stain) were not 
carried out in our experiment, it was not possible to determine definitively that 
this band is made of collagen. These assays could be done in future experiments 
so as to confirm the development and composition of this membrane.  
As GCTs were discovered within the testis of human males showing the 
characteristic FOXL2 gene mutation in at least one case (Lima et al., 2012) this 
would also be of interest for future study in the equine industry, as testicular 
primary neoplasms are rare with no reports of granulosa/sex cord tumours so 
far; in such a study abdominal cryptorchid testicular tumours would very much 
need to be considered. Further equine studies can also be done in the future to 
investigate the regulation of gene expression that FOXL2 targets as a 
transcription factor, such as StAR and CYP19A (Rosario et al., 2012), as well as  
some further candidates among FSH-responsive genes (Benayoun et al., 2013), 
and also other intraovarian regulators of apoptosis (Cheng et al., 2013). 
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The expression of follistatin requires FOXL2 gene activity controlling activin A, 
and this may have significance for granulosa cells. Therefore, overexpression of 
the wild-type FOXL2 might operate as a cancer inhibitor by reducing activin A-
stimulated cell proliferation (Cheng et al., 2014). This kind of experiment could 
be a future study in horses. It has been documented that plasma from human 
cases of GCT might support GCT diagnosis by examining the FOXL2 mutation 
(McConechy et al., 2014). Thus, in future, DNA can be extracted from plasma of 
mares with and without GCT to detect any significant FOXL2 mutations and assist 
in the diagnosis of GCT. 
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Appendices 
Appendix 1 Method of using the software 
SimStat/WordStat 
The data file should be downloaded and saved in the computer then Simstat 
should be clicked. If the data can not be opened in Simstat then it needs to be 
imported by clicking file, data and then import, however if the data already 
exist in Simstat just click open. After that, search for where the data has been 
stored and before opening the data make sure that in the box where the file 
type should be written is in provalis project ppj. Thus the file imported in the 
“supported file box” should be ppj, and then can be opened easily. Always in 
Simstat and Wordstat enough time should be given either for importing data or 
loading because it seems that it not loading or this also during searching. Click 
the statistic on the tool bar and choose X-Y as presented in Figure 7-1, then put 
ID in independent and Text in dependent after that click ok as presented in 
Figure 7-2. Again go to statistic and click on content analysis at the bottom of 
choices. This will shift the screen from Simstat to Wordstat where the 
dictionaries that have been prepared by the researcher appear, so the software 
can search for particular words as presented in Figure 7-3. 
 
Figure 7-1: Choosing X_Y 
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Figure 7-2: Adding ID to independent column and Text to dependent column 
 
 
Figure 7-3: Shifting from Simstat to Wordstat by clicking on content analysis 
 
When Wordstat appears on screen click the file open to choose the particular 
dictionary that has been made as presented in Figure 7-4 then tick box that near 
categorisation to check the level as presented in Figure 7-5.  
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Figure 7-4: Choosing dictionary 
 
 
Figure 7-5: Put tick in the box near categories 
 
After running dictionary on Wordstat by clicking on Keyword-In-Context and 
leave it for a while to search bearing in mind this might take a couple of minutes 
depending on the data size the Keyword box should be filtered and chose one 
category, after that the text will appear on screen. See examples of these steps 
as presented below on Figure 7-6, Figure 7-7 and Figure 7-8. 
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Figure 7-6: Clicking on Keyword-In-Content  
 
 
Figure 7-7: Choosing a category or subcategory from the box near keyword  
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Figure 7-8: Case no., Keyword and Text appeared on the screen with highlighted keyword  
 
Click on Frequency to check if any words have been leftover which can be useful 
to the dictionary, bearing in mind that always give plenty of time to the program 
to think. In order to check those words in alphabetical order click on the top of 
these words underneath the box of leftover words beside Frequency then words 
can be checked. If any useful word has been detected click on it and keep 
pressing then drag it to the dictionary at the left of the screen where the 
exclusion list is and chose the preferable file. See examples of these steps below 
as presented on Figure 7-9, Figure 7-10, Figure 7-11 and Figure 7-12. 
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Figure 7-9: Clicking on Frequency showed the frequency and percentages of cases on 
categories  
 
 
Figure 7-10: Clicking on Leftover words showed words with no alphabetical order 
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Figure 7-11: Tabbing on top of the first word from the list of leftover words arranged them 
alphabetically    
 
 
Figure 7-12: Choosing the required or useful word and drag it to the dictionary 
 
Exporting data can be achieved by clicking the red arrow as presented Figure 
7-13 then export data matrix as shown in Figure 7-14.  
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Figure 7-13: Clicking the Red arrow to export data matrix 
 
 
Figure 7-14: A box for exporting data to file appeared  
 
After the button ok has been pressed it will transfer to Save Word Frequency list 
as presented in Figure 7-15, so the searcher should choose a name and save it in 
a particular place but be aware of changing the file type. It is recommended to 
be save as comma separated files (CSV) as presented in Figure 7-16 then the file 
can be examine by searching for word, ID, or any things. 
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Figure 7-15: Saving the word frequency list 
 
 
Figure 7-16: Choosing the comma separated files (CSV) type to save 
 
Once the file saved as CSV, clicking on data then filter will assist on filtering the 
columns for particular search either by filtering number or sort from largest to 
smallest or vice versa as presented in Figure 7-17, Figure 7-18 and Figure 7-19. 
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Figure 7-17: Tabbing filter  
 
 
Figure 7-18: Filtering numbers for particular column  
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Figure 7-19: Sorting from largest to smallest or vice versa 
 
The numbers of ID should be written down or extracted in new sheet to help 
searching in the original data that been saved in computer and search for 
individual cases. Bearing in mind that some repetition of ID numbers might be 
found.  
Sometimes filtering is not always helpful because when the information seeker 
wants to choose the specific gender such as female having ovarian granulosa cell 
tumour the filtering will come out with all female not the one that have GCT 
which is according to ID numbers. Therefore, the best way is using pivot table. 
Clicking on it to highlight all cells can use pivot table and the box will appear on 
the screen. Examples of creating pivot table are as shown below and presented 
in Figure 7-20, Figure 7-21, Figure 7-22, and Figure 7-23. 
  Create pivot table by clicking on 
 Select a table or range 
 New work sheet 
 Then press ok button 
  Drag the ID number to Raw labels then drag the breed to Report 
filter 
 Then from the sheet click (All) this will delete all ticks which besides 
All, F, M, Mnx, Unknown then click on select Multiple items 
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 Click on F then click ok 
 
 
Figure 7-20: creating pivot table by selecting table/range and choose new wroksheet 
 
 
Figure 7-21: Dragging ID number to raw labels 
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Figure 7-22: Choosing the gender for example by clicking all to delete the ticks from all boxes 
 
 
Figure 7-23: Choose the required gender e.g female then tab select multiple items then ok 
 
Moreover, ID numbers can be arranged from smallest to largest or vice versa by 
filtering and clicking on Row Labels where the ID numbers based then choose 
through the options appears as presented in Figure 7-24 and when it is done it 
can be by clicking on the icon undo. In order to know how many females, the 
female column should be highlighted by drag the column from top to bottom, 
however it is time consuming. Therefore, the easiest way is by clicking on the 
top cell and go to the bottom one then press shift and click on it. The count will 
be found at the bottom on the right hand side of the screen. 
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Figure 7-24: Filtering ID number from smallest to largest or vice versa by clicking the Row 
labels 
 
Searching for particular ID to find how many entries for this animal go to main 
data then open home and click on find and select after that click on find then 
option as presented in Figure 7-25.  
 
Figure 7-25: Clicking on find and select to search for particular D number 
 
Put the of the ID number in (Find what) and click the box (options >>) then make 
sure you click the tick in the box near Match entire cell contents. Then click 
(Find next) as presented in Figure 7-26, Figure 7-27 and Figure 7-28.  This will 
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identified the rows of ID numbers, so those entries can be read through or copy 
and paste somewhere save. 
 
Figure 7-26: clicking on Find 
 
 
Figure 7-27: The box of Find and replace appeared 
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Figure 7-28: Write the ID number required on the box of find what then tick the box close to 
Match entire cell contents  
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Appendix 2 Dictionary used in Text mining 
2.1 Ovarian Tumour dictionary 
TERATOMA 
 TERATOM* (1) 
 TERATOC* (1) 
CYSTADENOMA 
 BENIN_CYST (1) 
 CYCTIC (1) 
 CYSTAD* (1) 
 CYST_LIKE_STRUCTURE (1) 
 CYSTIC (1) 
DYSGERMINOMA 
 DYSCARCINOMA (1) 
 DYSGERM* (1) 
 MALIGNANT_OVAR* (1) 
GRANULOSA CELL TUMOUR 
 GRANULOS (1) 
 GRANULOSAL (1) 
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 GRANULOSE (1) 
 GRANULOSIS (1) 
 GRANULOUSA (1) 
 OVARY (1) 
 HONEYCOMB_STRUCTURE (1) 
 HONEYCB (1) 
 OVARIECTOMY (1) 
 OVARIATOMY (1) 
 OVARIES (1) 
 OVARIAN (1) 
 LARGE_OVAR* (1) 
 OVARIE (1) 
 ENLARGED_OVAR* (1) 
 BIG_OVAR* (1) 
 THECA_CELL_TUMOR* (1) 
 STALLION_LIKE_BEHAVIOUR (1) 
 STALLION_LIKE_BEHAVIOR (1) 
 INHIBIN_CONC* (1) 
 GTCT (1) 
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 GCT (1) 
 GRANULOSA (1) 
 GRANNULOSA (1) 
 GRANLOSA (1) 
 ANTI_MULLARIAN_HORMON* (1) 
 AMH (1) 
2.2 Ovarian pathology dictionary 
FOLLICULAR_DEVELOPMENT_ABNORMALITIES 
 CHROMOSOMAL_ABNORMALITIES 
  ABNORMAL_GONAD* (1) 
  CHROMOSOM*_ABNORMALITIES (1) 
  ABNORMAL_CHROMOSOM* (1) 
  GONADAL_DYSGENESIS (1) 
  GONADAL_ABNORMALIT* (1) 
 OVARIAN_DYSFUNCTION 
  INFERTILE (1) 
  INFERTILITY (1) 
  SUBFERTILE_MARE (1) 
  INFERTILE_MARE (1) 
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 EXOGENOUS_HORMONE_TREATMENT 
  ANABOLIC_STEROID (1) 
  P4 (1) 
  PROGESTIN (1) 
  PROGESTERONE (1) 
 EQUINE_CUSHING'S_DISEASE 
  ANDROGEN_PRODUCTION (1) 
  DECREASE_GONADOTROPIN (1) 
  HYPOTHALAMUS_COMPRESSION (1) 
  ANTERIOR_PITUTATRY_COMPRESSION (1) 
OVULATION_ABNORMALITIES 
 ANOVULATORY_FOLLICLE 
  CYSTIC_OVAR* (1) 
  HAEMORRHAGIC_FOLLICLE (1) 
  HEMORRHAGIC_FOLLICLE (1) 
  OVARIAN_BIOPSY (1) 
  OVULATION_FAILURE (1) 
  PERSISTENT_ANOVULATORY_FOLLICLE (1) 
  PAF (1) 
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 OVARIAN_HAEMATOMA 
  BIG_CH (1) 
  ENLARGED_CH (1) 
  ENLARGED_CORPORA_HAEMORRHAGICA (1) 
  OVARIAN_HAEMOATOMA (1) 
  OVARIAN_HEMATOMA (1) 
LUTEAL_DYSFUNCTION 
 PERSISTENT_CORPUS_LUTEUM 
  PERSISETENT_CL (1) 
  DESTRUCTED_CL (1) 
  FAILED_REGRESSION_CL (1) 
 SHORTENED_LUTEAL_PHASE 
  PREMATURE_LUTEOLYSIS (1) 
  SHORT_LUTEAL_PHASE (1) 
 LUTEAL_INSUFFICIENCY 
  LUTEAL_DYSFUNCTION (1) 
  LUTEAL_INSUFFICIENCY (1) 
OVARIAN_TUMORS 
 GRANULOSA_CELL_TUMOR 
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  GRANULOSA (1) 
  GRANULOSA_CELL_TUMOR* (1) 
  GRANULOSA_TUMOR (1) 
  GCT (1) 
  GTCT (1) 
  MULTICYSTIC (1) 
  HONEYCOMB*_STRUCTURE (1) 
  HONEYCOMBED_STRUCTURE (1) 
  HONEYCOMBED_APPEARENCE (1) 
  SOLID_MASS (1) 
  POLYCYSTIC (1) 
  LARGE_CYST* (1) 
  INACTIVE_OVAR* (1) 
  ATROPHIED_OVAR* (1) 
  AFFECTED_OVAR* (1) 
  TRANSITIONAL_OVAR* (1) 
  SMALL_OVAR* (1) 
  OVARIAN_ENLARGEMENT (1) 
  LARGE_OVAR* (1) 
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  BIG_OVAR* (1) 
  ENLARGED_OVAR* (1) 
  NYMPHOMANIA (1) 
  MARE_NYMPHOMANIA (1) 
  CONTRALATERAL_OVAR* (1) 
  OVARIECTOMY (1) 
  REMOVE_OVAR* (1) 
  OVARICTOMY (1) 
  CLOPTOMY (1) 
  OVARIAN_NEOPLASMA (1) 
  OVARIAN_TUMOR* (1) 
  OESTROGEN_PRODUCING_TUMOR* (1) 
 CYSTADENOMA 
  CYSTADENOMA* (1) 
  CYST_LIKE_STRUCTURE (1) 
  BENIGN_CYST (1) 
 TERATOMA 
  TERATOM* (1) 
  TERATOC* (1) 
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  TERATOMAS (1) 
 DYSEGERMINOMA 
  MALIGNANT_OVAR* (1) 
  DYSGERMINOMA (1) 
MISCELLANEOUS_ABNORMALITIES 
 FIMBRIAL_CYST* (1) 
 FOSSA_CYST* (1) 
 IRREGULAR_ESTRUS (1) 
 IRREGULAR_HEAT (1) 
 IRREGULAR_OESTRUS (1) 
 MULLERIAN_CYST* (1) 
 OVARIAN_ABSCESS* (1) 
 PAROVARIAN_CYST* (1) 
 PREPUBERTY (1) 
 ABNORMAL_ESTRUS (1) 
 ABNORMAL_OESTRUS (1) 
 ABNORMAL_HEAT (1) 
 ABNORMAL_CYCLICITY (1) 
 POSTPARTUM_HEAT (1) 
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 POSTPARTUM_ANOESTRUS (1) 
 REDUCED_FERTILITY (1) 
 SEASONAL_ANESTRUS (1) 
 SEASONAL_HEAT (1) 
 SEASONAL_ANOESTRUS (1) 
 WOLFFIAN_DUCT_CYST* (1) 
2.3 GCT dictionary  
OVARIAN_PATHOLOGY 
 BIG_OVAR* (1) 
 MARE_SCAN (1) 
 @SCAN [SCAN AND MARE /A /S] (1) 
 *LARGE*_OVAR* (1) 
 FIRM_OVAR* (1) 
 CYST 
  @CYSTS [CYST* NEAR OVAR* /A /S5] (1) 
  @POLY [POLYCYST* NEAR OVAR* /A /S5] (1) 
  @MULTICYST [MULTICYST* NEAR OVAR* /A /S5] (1) 
 TUMOUR 
287 
 
  @TUMOUR 
[OVAR* NEAR TUMO*R NEAR MASS NEAR NEOPLAS* NEAR CANSER /A /S5/D5/D5/D
5] (1) 
  @TUMOUR [TUMO*R AND OVAR* /A /S] (1) 
  SOLID_MASS (1) 
  GCT 
   GCT (1) 
   GRANCULOSA (1) 
   GRANLOSA (1) 
   GRANULOS (1) 
   GRANULOSA (1) 
   GRANNULOSA (1) 
   GRANULOSAL (1) 
   GRANULOSE (1) 
   GRANULOSIS (1) 
   GRANULOUSA (1) 
   GTCT (1) 
   TUMORS (1) 
   TUMOURS (1) 
  BEHAVIOUR 
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   NEIGHING (1) 
   STIKING (1) 
   STALLION_LIKE (1) 
   UNRULY (1) 
 
  
289 
 
List of References 
AGRESTI, A. & COULL, B. 2000. Agresti, A., and Coull, B. A. (1998), "Approximate 
is better than 'exact' for interval estimation of binomial proportions," The 
American Statistician, 52, 119-126: Comment by Rindskopf and reply - 
Response. American Statistician, 54, 88-88. 
 
AL-AGHA, O. M., HUWAIT, H. F., CHOW, C., YANG, W., SENZ, J., KALLOGER, S. 
E., HUNTSMAN, D. G., YOUNG, R. H. & GILKS, C. B. 2011. FOXL2 Is a 
Sensitive and Specific Marker for Sex Cord-Stromal Tumors of the Ovary. 
American Journal of Surgical Pathology, 35, 484-494. 
 
ALBRECHT, B. A. & DAELS, P. F. 1997. Immunolocalization of 3 beta-
hydroxysteroid dehydrogenase, cytochrome P450 17 alpha-
hydroxylase/17,20-lyase and cytochrome P450 aromatase in the equine 
corpus luteum of dioestrus and early pregnancy. Journal of Reproduction 
and Fertility, 111, 127-133. 
 
ALMADHIDI, J., SERALINI, G. E., FRESNEL, J., SILBERZAHN, P. & GAILLARD, J. L. 
1995. IMMUNOHISTOCHEMICAL LOCALIZATION OF CYTOCHROME-P450 
AROMATASE IN EQUINE GONADS. Journal of Histochemistry & 
Cytochemistry, 43, 571-577. 
 
ALMEIDA, J., BALL, B. A., CONLEY, A. J., PLACE, N. J., LIU, I. K. M., SCHOLTZ, E. 
L., MATHEWSON, L., STANLEY, S. D. & MOELLER, B. C. 2011a. Biological 
and clinical significance of anti-Mullerian hormone determination in blood 
serum of the mare. Theriogenology, 76, 1393-1403. 
 
ALMEIDA, J., CONLEY, A. J., MATHEWSON, L. & BALL, B. A. 2011b. Expression of 
steroidogenic enzymes during equine testicular development. 
Reproduction, 141, 841-848. 
 
ANHOLT, R. M., BEREZOWSKI, J., JAMAL, I., RIBBLE, C. & STEPHEN, C. 2014a. 
Mining free-text medical records for companion animal enteric syndrome 
surveillance. Preventive Veterinary Medicine, 113, 417-422. 
 
ANHOLT, R. M., BEREZOWSKI, J., RIBBLE, C. S., RUSSELL, M. L. & STEPHEN, C. 
2014b. Using Informatics and the Electronic Medical Record to Describe 
Antimicrobial Use in the Clinical Management of Diarrhea Cases at 12 
Companion Animal Practices. Plos One, 9. 
 
ASSIS NETO, A. C., BALL, B. A., BROWNE, P. & CONLEY, A. J. 2010. Cellular 
localization of androgen synthesis in equine granulosa-theca cell tumors: 
Immunohistochemical expression of 17 alpha-hydroxylase/17,20-lyase 
cytochrome P450. Theriogenology, 74, 393-401. 
 
AURICH, C. 2011. Reproductive cycles of horses. Animal Reproduction Science, 
124, 220-228. 
 
BAILEY, M. T., CHRISTMAN, S. A., WHEATON, J. E., TROEDSSON, M. H., O'BRIEN, 
T. D., ABABNEH, M. M. & SANTSCHI, E. 2000. Inhibin localization in equine 
290 
 
granulosa-theca cell tumours and inhibin forms in tumour fluid. Journal of 
reproduction and fertility. Supplement, 247-55. 
 
BAILEY, M. T., TROEDSSON, M. H. T. & WHEATON, J. E. 2002. Inhibin 
concentrations in mares with granulosa cell tumors. Theriogenology, 57, 
1885-1895. 
 
BALL, B. A., ALMEIDA, J. & CONLEY, A. J. 2013. Determination of serum anti-
Mullerian hormone concentrations for the diagnosis of granulosa-cell 
tumours in mares. Equine Veterinary Journal, 45, 199-203. 
 
BALL, B. A., CONLEY, A. J., ALMEIDA, J., ESTELLER-VICO, A., CRABTREE, J., 
MUNRO, C. & LIU, I. K. M. 2014. A Retrospective Analysis of 2,253 Cases 
Submitted for Endocrine Diagnosis of Possible Granulosa Cell Tumors in 
Mares. Journal of Equine Veterinary Science, 34, 307-313. 
 
BALL, B. A., CONLEY, A. J. & LIU, I. K. M. 2008a. Expression of anti-Mullerian 
hormone in equine granulosa cell tumors. Proceedings of the 54th Annual 
Convention of the American Association of Equine Practitioners, San 
Diego, California, USA, 6-10 December 2008, 272-273. 
 
BALL, B. A., CONLEY, A. J., MACLAUGHLIN, D. T., GRUNDY, S. A., SABEUR, K. & 
LIU, I. K. M. 2008b. Expression of anti-Mullerian hormone (AMH) in equine 
granulosa-cell tumors and in normal equine ovaries. Theriogenology, 70, 
968-977. 
 
BASHIR, S. T., ISHAK, G. M., GASTAL, M. O., ROSER, J. F. & GASTAL, E. L. 2016. 
Changes in intrafollicular concentrations of free IGF-1, activin A, inhibin 
A, VEGF, estradiol, and prolactin before ovulation in mares. 
Theriogenology, 85, 1491-1498. 
 
BEACHLER, T. M., BAILEY, C. S., MCKELVEY, K. A., DAVIS, J. L., EDWARDS, A., 
DIAW, M., VASGAARD, J. M. & WHITACRE, M. D. 2016. Haemoperitoneum 
in a pregnant mare with an ovarian haematoma. Equine Veterinary 
Education, 28, 359-363. 
 
BELIN, F., GOUDET, G., DUCHAMP, G. & GERARD, N. 2000. Intrafollicular 
concentrations of steroids and steroidogenic enzymes in relation to 
follicular development in the mare. Biology of Reproduction, 62, 1335-
1343. 
 
BENAYOUN, B. A., ANTTONEN, M., L'HOTE, D., BAILLY-BECHET, M., ANDERSSON, 
N., HEIKINHEIMO, M. & VEITIA, R. A. 2013. Adult ovarian granulosa cell 
tumor transcriptomics: prevalence of FOXL2 target genes misregulation 
gives insights into the pathogenic mechanism of the p.Cys134Trp somatic 
mutation. Oncogene, 32, 2739-2746. 
 
BENAYOUN, B. A., BATISTA, F., AUER, J., DIPIETROMARIA, A., L'HOTE, D., DE 
BAERE, E. & VEITIA, R. A. 2009. Positive and negative feedback regulates 
the transcription factor FOXL2 in response to cell stress: evidence for a 
regulatory imbalance induced by disease-causing mutations. Human 
Molecular Genetics, 18, 632-644. 
291 
 
BENAYOUN, B. A., GEORGES, A. B., L'HOTE, D., ANDERSSON, N., DIPIETROMARIA, 
A., TODESCHINI, A.-L., CABURET, S., BAZIN, C., ANTTONEN, M. & VEITIA, 
R. A. 2011. Transcription factor FOXL2 protects granulosa cells from stress 
and delays cell cycle: role of its regulation by the SIRT1 deacetylase. 
Human Molecular Genetics, 20, 1673-1686. 
 
BIOSYSTEMS, A. 2016. Applied_Biosystems. BigDye® Terminator v3.1 Cycle 
Sequencing Kit User Guide. Carlsbad, CA:. 
 
BIOSYSTEMS., A. 2010. AmpliTaq Gold® DNA Polymerase, LD. Foster City, CA: 
Applied Biosystems. 
 
BRADLEY, C. A., ROLKA, H., WALKER, D. & LOONSK, J. 2005. BioSense: 
implementation of a National Early Event Detection and Situational 
Awareness System. MMWR supplements, 54, 11-9. 
 
BROWN, L. D., CAI, T. T., DASGUPTA, A., AGRESTI, A., COULL, B. A., CASELLA, 
G., CORCORAN, C., MEHTA, C., GHOSH, M. & SANTNER, T. J. 2001. 
Interval estimation for a binomial proportion - Comment - Rejoinder. 
Statistical Science, 16, 101-133. 
 
BUGNO, M., ZABEK, T., GOLONKA, P., PIENKOWSKA-SCHELLING, A., SCHELLING, 
C. & SLOTA, E. 2008. A case of an intersex horse with 
63,X/64,XX/65,XX,del(Y)(q?) karyotype. Cytogenetic and Genome 
Research, 120, 123-126. 
 
BUSTAMANTE, R. M. I. 1998. Granulosa theca cell tumors in 93 mares. Revista 
Cientifica-Facultad De Ciencias Veterinarias, 8, 222-228. 
 
CABURET, S., GEORGES, A., L'HOTE, D., TODESCHINI, A.-L., BENAYOUN, B. A. & 
VEITIA, R. A. 2012. The transcription factor FOXL2: At the crossroads of 
ovarian physiology and pathology. Molecular and Cellular Endocrinology, 
356, 55-64. 
 
CARNEVALE, E. M., MCKINNON, A. O. & SQUIRES, E. L. 1988. ULTRASONIC 
CHARACTERISTICS OF THE PREOVULATORY FOLLICLE DIRECTLY 
PROCEEDING AND DURING OVULATION IN THE MARE. Theriogenology, 29, 
232-232. 
 
CATONE, G., MARINO, G., MANCUSO, R. & ZANGHI, A. 2004. Clinicopathological 
features of an equine ovarian teratoma. Reproduction in Domestic 
Animals, 39, 65-69. 
 
CHANDRA, A. M. S., WOODARD, J. C. & MERRITT, A. M. 1998. Dysgerminoma in 
an Arabian filly. Veterinary Pathology, 35, 308-311. 
 
CHAPMAN, W. W., CHRISTENSEN, L. M., WAGNER, M. M., HAUG, P. J., IVANOV, 
O., DOWLING, J. N. & OLSZEWSKI, R. T. 2005. Classifying free-text triage 
chief complaints into syndromic categories with natural language 
processing. Artificial Intelligence in Medicine, 33, 31-40. 
292 
 
CHAPMAN, W. W., DOWLING, J. N. & WAGNER, M. M. 2004. Fever detection from 
free-text clinical records for biosurveillance. Journal of Biomedical 
Informatics, 37, 120-127. 
 
CHARMAN, R. E. & MCKINNON, A. O. 2007. A granulosa-theca cell tumour in a 15-
month-old Thoroughbred filly. Australian Veterinary Journal, 85, 124-125. 
 
CHENG, J.-C., CHANG, H.-M., QIU, X., FANG, L. & LEUNG, P. C. K. 2014. FOXL2-
induced follistatin attenuates activin A-stimulated cell proliferation in 
human granulosa cell tumors. Biochemical and Biophysical Research 
Communications, 443, 537-542. 
 
CHENG, J.-C., KLAUSEN, C. & LEUNG, P. C. K. 2013. Overexpression of Wild-Type 
but Not C134W Mutant FOXL2 Enhances GnRH-Induced Cell Apoptosis by 
Increasing GnRH Receptor Expression in Human Granulosa Cell Tumors. 
Plos One, 8. 
 
CHOPIN, J. B., CHOPIN, L. K., KNOTT, L. M., DE KRETSER, D. M. & DOWSETT, K. 
F. 2002. Unusual ovarian activity in a mare preceding the development of 
an ovarian granulosa cell tumour. Australian Veterinary Journal, 80, 32-
36. 
 
COCQUET, J., PAILHOUX, E., JAUBERT, F., SERVEL, N., XIA, X., PANNETIER, M., 
DE BAERE, E., MESSIAEN, L., COTINOT, C., FELLOUS, M. & VEITIA, R. A. 
2002. Evolution and expression of FOXL2. Journal of Medical Genetics, 39, 
916-921. 
 
CRABTREE, J. 2011. Review of seven cases of granulosa cell tumour of the 
equine ovary. Veterinary Record, 169, 251-U41. 
 
CRABTREE, J. 2013. Review of seven cases of granulosa cell tumour of the 
equine ovary. Veterinary Record Case Reports, 1, ed4635-ed4635. 
 
CRABTREE, J. R., BRENNAN, M. J., FOOTE, A. K. & PYCOCK, J. F. 2013. 
Granulosa cell tumour: An interesting case in a pregnant mare. Equine 
Veterinary Education, 25, 4-10. 
 
CUERVO-ARANGO, J. & NEWCOMBE, J. R. 2010. Risk Factors for the Development 
of Haemorrhagic Anovulatory Follicles in the Mare. Reproduction in 
Domestic Animals, 45, 473-480. 
 
CURTIN, D. J. E. 2003. Ovarian hematoma in an 11-year-old Thoroughbred- 
Hanovarian mare. Canadian Veterinary Journal-Revue Veterinaire 
Canadienne, 44, 589-591. 
 
DA ENCARNACAO FIALA, S. M., AMARAL, M., RICHER, L. M., CRUZ, L. A. & 
RODRIGUES, R. F. 2011. Ovarian Teratoma in a Mare. Journal of Equine 
Veterinary Science, 31, 511-513. 
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